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Abstract 
The collection of microbes and their genomic activity within us, referred to as the human 
microbiome, is crucial in maintaining health, and disruptions in composition and/or 
activity have been associated with various diseases. Considering the importance of breast 
milk in neonatal development and the high rate of breast cancer in women, the objective 
of my thesis was to obtain a comprehensive analysis of the microbiota of the mammary 
glands and to examine the influence of these organisms on health and disease.  
Human milk is an important source of bacteria for the developing infant. While a variety 
of studies over the last 20 years have provided a greater appreciation for how diverse and 
variable the milk microbiota is, little is known about these bacterial communities. Many 
studies have emphasized the adverse effects of antibiotics on the infant microbiota, 
however the impact of drugs on the lactating mother has not been studied. In Chapter 2 
we report the changes caused by chemotherapy (over a 4 month period) on the milk 
microbiota and metabolome of a woman undergoing treatment for Hodgkin’s lymphoma. 
In Chapter 3, we show from a study of 39 Canadian women that neither gestation, mode 
of delivery nor gender of the child explains the diversity of the milk microbiota.   
As milk is not sterile and given the nutrient-rich fatty composition of the breast and its 
exposure to the external environment via the nipple, we hypothesized that breast tissue 
has its own indigenous microbiota. In Chapter 4, we confirmed this in a study of breast 
tissue from 81 Canadian and Irish women, with the discovery of diverse bacterial 
communities dominated by the phylum Proteobacteria. To determine whether this tissue 
microbiota could play a role in breast cancer development, we compared, in Chapter 5, 
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bacterial profiles in tissue between women with breast cancer and those who were 
disease free. We show that differences do exist and that women with cancer have higher 
numbers of bacteria with the ability to induce host DNA damage. 
This work forms the platform for further studies that examine how breast milk and tissue 
are first colonized and how these microbiotas can be manipulated to promote optimal 
maternal and infant health.  
Keywords 
Human microbiome, breast milk microbiome, breast tissue microbiome, 16S rRNA gene 
sequencing, breast cancer, DNA damage 
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Chapter 1  
1 General introduction  
 Functional anatomy of the female breast 1.1
The mammary gland, as the “mammary” part implies, is an organ unique to mammals, 
with the main purpose of delivering nutrients and protective immunity to the baby in the 
form of milk. But before milk can be produced and secreted, a complex and coordinated 
process of gland morphogenesis occurs during three stages of human development; 
embryogenesis, puberty and reproduction.  
1.1.1 Embryogenesis  
Human mammary gland morphogenesis starts with the formation of the milk line (lateral 
thickening of the ectoderm) which then gives rise to a single pair of placodes (Robinson, 
2007). These placodes later transform into bulbs of epithelial cells, which invaginate into 
the underlying mesenchyme becoming “mammary buds” (Gjorevski and Nelson, 2011). 
During the later stages of embryogenesis, the mammary buds start to proliferate and 
elongate, forming sprouts that push down and out of the mesenchyme and into the 
stromal fat pad, located within the dermis (Hens and Wysolmerski, 2005). These sprouts 
concomitantly develop a lumen with an opening to the skin via the nipple (Macias and 
Hinck, 2012). Once the sprouts have reached the fat pad, ductal branching occurs, 
regulated by the stromal environment (Pavlovich et al., 2010; Tan et al., 2014; Wiesen et 
al., 1999). This branched network gives rise to what is known as the “rudimentary ductal 
tree” consisting of a primary duct and 15-20 secondary branches (Hens and Wysolmerski, 
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2005). This structure is what is present at birth and will remain as such until puberty  
(Figure 1-1, top). 
1.1.2 Puberty 
The pubertal stage is characterized by ductal elongation accompanied by secondary 
branching. Unlike the embryonic stage, which is independent of hormone regulation, this 
stage is initiated by elevated levels of estrogen (Silberstein et al., 1994), working in 
concert with estrogen receptor (Feng et al., 2007) and growth hormone (Gallego et al., 
2001). At the tips of these elongating and branching ducts is a structure termed the 
terminal end bud (TEB), which is a highly proliferative cap that “drives” the elongating 
duct into the fat pad (Hinck and Silberstein, 2005). After successive rounds of elongation 
and branching, when the limits of the fat pad have been reached, growth ceases and TEBs 
disappear (Humphreys et al., 1996) (Figure 1-1, bottom) 
1.1.3 Reproduction  
While the hallmark of the pubertal stage is elongation and secondary branching, the 
hallmark of the reproductive stage (pregnancy/lactation) is formation of extensive tertiary 
branches (i.e. side branches) and the differentiation of TEBs into alveoli which produce 
milk during lactogenesis (Robinson et al., 1995) (Figure 1-1, bottom). This process is 
dependent on progesterone, progesterone receptor and prolactin (Atwood et al., 2000; 
Gallego et al., 2001; Lydon et al., 1995). During lactogenesis, the breast is composed of 
mostly glandular tissue with very few adipocytes (Ramsay et al., 2005). While the 
mammary gland has the ability to synthesize milk throughout pregnancy, this does not 
occur due to the high levels of progesterone secreted by the placenta, which acts as a 
negative regulator of milk production (Djiane and Durand, 1977; López-Fontana et al., 
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2012). Once progesterone levels have decreased at parturition, copious amounts of milk 
are produced at approximately 2 days post partum.   
Cessation of lactation is followed by a phase known as involution, characterized by 
apoptosis of milk producing epithelial cells, clearance of these apoptotic cells and milk 
components and repopulation of the stroma with adipocytes (Alexander et al., 2001; 
Clarkson et al., 2004; Lund et al., 1996; O’Brien et al., 2012; Walker et al., 1989). It is 
estimated that about 80% of milk producing cells will undergo regulated apoptosis in 
only a few days (Watson and Khaled, 2008). To prevent inflammation associated with 
cellular debris, involution must be efficient and rapid. While clearance of apoptotic 
bodies is usually associated with professional phagocytes such as macrophages, it has 
been shown that mammary epithelial cells, rather than macrophages, are involved in 
removing cellular debris and milk fat globules during post-lactational involution (Monks 
et al., 2005, 2008). 
Although the mammary gland reverts back to its pre-pregnancy state after involution, the 
ductal network retains a more extensive framework of side branching than nulliparous 
glands (Fendrick et al., 1998).   
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Figure 1-1. Stages of mammary gland development 
Top panel, embryonic; Bottom panel, post embryonic 
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1.1.4 Structure of ducts and alveoli 
The ducts and alveoli are composed of a bi-layered epithelium consisting of (i) an inner 
layer of luminal epithelial cells that surround a hollow lumen, which differentiate into 
milk producing alveoli during pregnancy/lactation and (ii) an outer layer of myoepithelial 
cells, that upon oxytocin-mediated contraction triggers the release of milk through the 
ducts (Gjorevski and Nelson, 2011). In 2006, Shackleton and colleagues isolated 
mammary stem cells from adult mice and demonstrated that a single stem cell could give 
rise to these luminal and myoepithelial cells and could generate a complete functional 
gland when transplanted into gland-free mammary fat pads of C3H mice (Shackleton et 
al., 2006). 
This bi-layered epithelium is surrounded by an extracellular basement membrane 
embedded within the stroma (a.k.a. fat pad) which consists of adipocytes, fibroblasts, 
blood vessels and immune cells which all play a crucial role in optimal mammary 
development (Gjorevski and Nelson, 2011).  For example, macrophages, eosinophils and 
mast cells are recruited from the connective tissue and lymph nodes in the stroma to the 
TEB in the pubertal mammary gland to promote ductal elongation and branching 
(Gouon-Evans et al., 2000; Lilla and Werb, 2010). These leukocytes are essential, as in 
their absence, ductal growth is abrogated and the glands retain a neonatal appearance 
(Gouon-Evans et al., 2000).  
 Human microbiome 1.2
The term “human microbiome”, was coined in 2001 by Joshua Lederberg who defined it 
as the “ecological community of commensal, symbiotic and pathogenic microorganisms 
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that literally share our body space” (Lederberg, 2001). These microorganisms consist of 
viruses, fungi, archaea and eukaryotes, with bacteria making up the majority of 
organisms present (99%) (Qin et al., 2010). While the terms “human microbiome” and 
“human microbiota” are often used interchangeably, the latter refers to the microbial taxa 
associated with humans, while the former refers to the collection of microbial taxa and 
their genes (Ursell et al., 2012).   
The human microbiota consists of trillions of microbial cells. The gastrointestinal tract 
(GIT) alone harbours 100 trillion microbes, 1000 different species, 7000 bacterial strains 
and 3.3 million non-redundant microbial genes (Eckburg et al., 2005; Gill et al., 2006; 
Qin et al., 2010). On the other hand, some sites have more simple bacterial communities, 
like the healthy vagina, which is mainly composed of Lactobacillus (Ravel et al., 2011). 
These differences in community structure are likely a result of evolutionary pressures that 
select for specific organisms able to adapt to a particular niche. This highlights the 
different functional capacities of these microbes across various body sites.   
1.2.1 Influence of the microbiota on health and disease 
The bacterial communities that colonize various parts of our body are important in 
promoting health whether it be by synthesizing vitamins the host cannot make, salvaging 
energy from indigestible compounds, creating a competitive environment to prevent 
pathogen colonization, promoting maturation and regulation of the immune system, 
contributing to vascular development and angiogenesis or enhancing the integrity of the 
epithelial barrier (Hyun et al., 2015; Mazmanian et al., 2005; Ragupathy et al., 2014; 
Rakoff-Nahoum et al., 2004; Stappenbeck et al., 2002).  
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The human microbiota in healthy individuals contains a collection of (i) symbionts, 
which are bacteria that actively promote health, (ii) commensals, which are neither 
advantageous nor detrimental to the host and (iii) pathobionts, which can promote 
pathology when conditions are altered in the host (Round and Mazmanian, 2009). When 
there is microbial disruption, either by reduction of symbionts and/or an overgrowth of 
pathobionts, a breakdown in homeostasis will occur, leading to disease. This has been 
observed in periodontitis (Darveau, 2010; Ximénez-Fyvie et al., 2000), inflammatory 
bowel disease (Frank et al., 2007), psoriasis (Gao et al., 2008), asthma (Hilty et al., 
2010), bacterial vaginosis (Hummelen et al., 2010) and colorectal cancer (Mira-Pascual et 
al., 2014). These changes are not simply a consequence of the diseased state creating an 
environment that selects for certain bacteria, as studies have shown that healthy animals 
transplanted with feces from those with obesity, colitis and colorectal cancer then go on 
to develop disease (Garrett et al., 2007; Turnbaugh et al., 2009; Zackular et al., 2013). 
These shifts in bacterial profiles not only have consequences at the site of origin but can 
have distal site effects as well. For example, alterations in the gut microbiota can have 
effects on the brain (Bercik et al., 2011; Cryan and Dinan, 2012), liver (Boursier and 
Diehl, 2015; Yoshimoto et al., 2013) and pancreas (Larsen et al., 2010), while microbial 
shifts in the oral cavity can be detrimental to cardiovascular health (Ettinger et al., 2014). 
The human microbiota undergoes dramatic changes during the first year of life at which 
time it becomes more stable and reflects what the community structure of the adult will 
be. Thus, the bacteria acquired during infancy, influences the adult microbiota, which in 
turn influences disease risk in adulthood (Guaraldi and Salvatori, 2012). For this reason, 
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early life factors that shape the human microbiota play a critical role in health and 
disease. 
1.2.2 Early life factors that shape our microbiota  
1.2.2.1 Mode of delivery 
As early as 5 min after birth, newborns become colonized with a plethora of bacteria. 
Unlike adults, whose bacterial composition is structured by body habitat, the microbiota 
of the newborn is believed to be somewhat uniform across body sites (Dominguez-Bello 
et al., 2010) until about 3 months of age (Capone et al., 2011).  While traditional dogma 
is that we are all born germfree, the discovery of bacteria in the healthy placenta 
(Aagaard et al., 2014), amniotic fluid (DiGiulio et al., 2008), umbilical cord blood 
(Jiménez et al., 2005) and meconium (Gosalbes et al., 2013) suggests that microbial 
contact could occur in utero. However, a more complex community is acquired during 
the birthing process and is largely influenced by mode of delivery. Vaginally delivered 
babies have microbial profiles similar to that of their mother’s vaginal and fecal 
microbiota, while those born by cesarean section have profiles similar to that of their 
mother’s skin (Bäckhed et al., 2015; Dominguez-Bello et al., 2010). Infants born by C-
section are more often colonized with Clostridium, have lower levels of Bacteroides and 
acquire Bifidobacterium and Lactobacillus later than vaginally delivered infants 
(Biasucci et al., 2008; Grönlund et al., 1999; Penders et al., 2006). These microbial 
differences and the consequential immune responses associated with them can last 
anywhere from 6 months to 7 years of age (Grönlund et al., 1999; Jakobsson et al., 2013; 
Salminen et al., 2004).   
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1.2.2.2 Breast feeding 
In addition to bacteria acquired during the birthing process, the ingestion of fresh human 
milk is a major source of microbes for the newborn (Martín et al., 2003, 2012). A 
characteristic of breast fed infants is a gut microbiota dominated by Bifidobacterium. 
Formula fed infants on the other hand harbour more diverse taxa dominated by 
Enterobacteriaceae, Streptococcus, Bacteroides and Clostridium (Bezirtzoglou et al., 
2011; Favier et al., 2002). While the high abundance of Bifidobacterium in the gut of 
breast fed infants is partly due to its ability to utilize human milk oligosaccharides 
(HMOs) as an energy source (Sela et al., 2008), Bifidobacterium originating from milk 
also contribute to its prevalence, as low levels in milk correlate to low levels in the 
neonate (Grönlund et al., 2007). 
 Human milk microbiota 1.3
Human milk is generally the first food given to newborns and while the average amount 
consumed varies with age, one study has shown that 15 week old infants ingest 
approximately 788 ml of milk per day (Kent et al., 2006). The composition of human 
milk consists of various fats, proteins, minerals, vitamins, sugars, bioactive compounds, 
antibodies, immune cells, chemokines/cytokines, anti-microbials and growth factors 
which all contribute to optimal nutrition, protection and development of the infant 
(Ballard and Morrow, 2013). Bacteria also contribute in a significant way to the overall 
make-up of human milk, with the microbiological content routinely recorded as high as 
1x105 colony-forming units (CFU) per milliliter (Mense et al., 2014).  The earliest studies 
describing bacterial diversity in human milk utilized simple culture methods and reported 
high levels of staphylococci and streptococci, originally believed to be contaminants 
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(Eidelman and Szilagyi, 1979; West et al., 1979). Since then, numerous studies using 
both culture and non-culture methods have detected a plethora of bacterial species in 
human milk, which are no longer considered contaminants, but normal constituents in the 
overall composition. 
The first non-culture analysis of human milk started in the mid-2000s with the use of 
denaturing gradient gel electrophoresis and 16S rRNA gene clone library analysis, 
followed by the first deep sequencing analysis in 2011. These studies confirmed what 
was observed by culture but also showed a greater diversity of bacteria in milk (Hunt et 
al., 2011; Martín et al., 2007). While the milk microbiota varies greatly among women, 
common constituents appear to be Staphylococcus and Streptococcus (in high 
abundance), Corynebacterium and Propionibacterium and at lower levels, Lactobacillus 
and Bifidobacterium. A list of all the bacteria identified in human milk to date, is 
presented in Table 1-1.  
1.3.1 Importance of milk bacteria in neonatal and long term 
health  
It is widely accepted that breast milk is far superior than formula for optimal physical, 
psychological and immunological development of the newborn. The World Health 
Organization recommends exclusive breastfeeding for 6 months, followed by another 2 
years of partial breastfeeding, supplemented with solid foods. Infants fed human milk 
compared to formula have lower incidences of necrotizing enterocolitis and diarrhea in 
infancy and allergies, asthma, inflammatory bowel disease, type 1 and type II diabetes, 
obesity and cardiovascular disease in adulthood (Guaraldi and Salvatori, 2012; Stuebe, 
2009) as well as better cognitive function throughout life (Anderson et al., 1999). This 
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protective effect may be due, in part, to the types of bacteria present in milk, as infants 
fed formula supplemented with probiotics were better protected against some of the 
above diseases than those just fed formula (Chouraqui et al., 2008; Guaraldi and 
Salvatori, 2012; Silvers et al., 2012).  
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Table 1-1. Bacteria identified in human milk by both culture dependent and 
independent techniques. 
Genera Species 
Acinetobacter A. calcoaceticus 
Akkermansia  A. muciniphilia 
Bifidobacterium B. breve, B. adolescentis, B. bifidum, B. longum, B. animalis, 
B. catenulatum 
Enterococcus E. faecalis, E. faecium, E. durans, E. gallinarum, E. mundtii, 
E. hirae 
Escherichia E. coli 
Gemella G. haemolysans 
Klebsiella K. oxytoca 
Kocuria K. kristinae 
Lactobacillus L. animalis, L. brevis, L. crispatus, L. fermentum, L. gasseri, 
L. oris, L. plantarum, L. rhamnosus 
Lactococcus L. lactis 
Leuconostoc L. citreum, L. fallax, L. mesenteroides 
Pediococcus P. pentosaceus 
Propionibacterium P. acnes, P. granulosum 
Pseudomonas P. synxantha, P. fluorescens 
Rothia R. mucilaginosa 
Serratia S. proteomaculans 
Staphylococcus S. aureus, S. epidermidis, S. haemolyticus, S. hominis,  
S. pasteuri, S. warneri 
Streptococcus S. salivarius, S. mitis, S. gallolyticus, S. australis,  
S. vestibularis, S. parasanguis, S. pneumoniae 
Weisella W. cibaria, W. confusa 
Other genera detected but not assigned to species  
Actinomyces, Bacteroides, Blautia, Bradyrhizobium, Brevundimonas, Burkholderia, 
Clostridium, Corynebacterium, Flavobacterium, Granulicatella, Prevotella, Rlastonia, 
Sphingomonas, Stenotrophomonas, Veillonella 
 
Data taken from: (Albesharat et al., 2011; Cabrera-Rubio et al., 2012; Collado et al., 
2009; Grönlund et al., 2007; Heikkila and Saris, 2003; Hunt et al., 2011; Jost et al., 2013; 
Khodayar-Pardo et al., 2014; Martín et al., 2003, 2007; Solís et al., 2010) 
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1.3.2 Where do breast milk bacteria come from? 
Until recently, it was generally believed that bacteria in human milk originated from the 
skin surrounding the nipple or from the oral cavity of the infant as a result of retrograde 
backflow during suckling (Ramsay et al., 2004). However, the presence of obligate 
anaerobes and species associated with the gut, respiratory tract and vagina would suggest 
additional mechanisms.  
This begs the question then, as to what other mechanisms could be responsible for 
bacterial homing to the breast? Mucosal surfaces are defined as areas of the body exposed 
to the external environment with a single layer of epithelial cells protecting the lumen 
from the rest of the body. The mammary glands, along with the GIT, respiratory tract, 
urogenital tract and glandular tissue (salivary, lacrimal) are considered mucosal surfaces 
with their own specialized immune system that maintains homeostasis (McGhee and 
Fujihashi, 2012). It has long been recognized that there is a common mucosal system that 
allows for trafficking and homing of immune cells between mucosal sites. This has been 
established through studies showing that (i) immunization at one mucosal site confers 
protection at another mucosal site (Weisz-Carrington et al., 1979; Wilson and Obradovic, 
2014) and that (ii) adoptive transfer of lymphoblasts from the mesenteric lymph nodes 
(MLN) or bronchial lymph nodes (BLN) into syngeneic recipients home to other mucosal 
surfaces such as the breast, bronchus, cervix and gut (McDermott and Bienenstock, 
1979). It was also shown in the 1970s that cells isolated from the MLN would 
preferentially home to the breast during lactation (Roux et al., 1977) which is probably 
due the increased expression of CCL28 during this time (Meurens et al., 2006; Wilson 
and Butcher, 2004). CCL28 is a chemokine expressed on mammary epithelial cells, 
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responsible for the recruitment of IgA plasmoblasts and T cells to the mammary glands 
from the gut or the airways (Lazarus et al., 2003; Wang et al., 2000). This migration and 
homing of cells from the GIT and the respiratory tract to the breast has been termed the 
entero-mammary and bronchial-mammary pathway respectively.  
While these entero-mammary and bronchial-mammary pathways are important in 
delivering antigen specific immune cells to the immunologically immature infant in order 
to provide passive immunity against gastrointestinal and respiratory infections, it could 
also be a mode by which bacteria migrate to the mammary glands. Indeed, during 
pregnancy and lactation, increased numbers of bacteria have been detected in the 
mammary glands compared to virgin mice with these bacteria co-localizing with 
dendritic cells (Donnet-Hughes et al., 2010). This transfer of bacteria from the GIT to the 
breast would explain the commonality of strains between a mother’s faeces and her breast 
milk (Albesharat et al., 2011; Jost et al., 2014) and the detection of probiotic strains in 
human milk after oral ingestion (Arroyo et al., 2010; Jiménez et al., 2008) (Figure 1-2). 
1.3.2.1 Does trafficking occur in the “resting” breast? 
Trafficking of bacteria via dendritic cells to the mammary glands has only been proposed 
in the context of pregnancy and lactation but the fact that immune cells still migrate to the 
mammary glands in non-gravid and non-lactating women suggests that bacterial 
translocation to the breast could be happening continuously throughout a woman’s life. 
VCAM-1, expressed on mammary epithelial cells, is responsible for B cell migration to 
the breast during pregnancy (Low et al., 2010). However it is also expressed at high 
levels irrespective of pregnancy and lactation and it is the main mechanism by which 
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mouse mammary tumour virus infected lymphocytes reach the non-lactating/non-gravid 
gland from the gastrointestinal tract (Finke and Acha-Orbea, 2001). High proportions of 
intralobular B cells and luminal deposits of IgA have also been observed in breast tissue 
of non-gravid/non-lactating women (Brandtzaeg, 1983; Drife et al., 1976). Most 
importantly, dendritic cells, which have been the proposed vehicle for bacterial transfer 
from the GIT to the mammary gland, are present in high numbers in breast lobules of 
non-lactating/non-pregnant women (Degnim et al., 2014). 
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Figure 1-2. Possible mechanism of bacterial translocation from the gut to the breast 
The lumen of the gut is inhabited by trillions of bacteria and is separated from the interior 
by a thin layer of cells called the epithelium. DCs can sample bacteria directly from the 
lumen by the extension of dendrites or can capture bacteria that have translocated across 
specialized epithelial cells called ‘M cells.’ DCs laden with bacteria can either prime T 
cells in the Peyer’s patches or migrate to the MLN to prime T-cell reactions there. Unlike 
primed T cells, DCs do not normally move past the MLN. However, during pregnancy 
and lactation, it is believed that bacteria-laden DCs migrate out of the MLN and into the 
mammary glands. These glands are composed of approximately 15–20 lobes that circle 
around the nipple, albeit not as definitively visible during surgery as depicted in this 
diagram. Inside these lobes are lobules and at the end of each lobule are tiny alveoli that 
produce milk. The milk is carried via the ducts into the nipple.  DC: Dendritic cell; MLN: 
Mesenteric lymph node.  Figure taken from (Urbaniak et al., 2012) 
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 Human microbiome and breast cancer  1.4
While the breast (via milk) is so vital to the health of the offspring, ironically, it is the 
cause of one of the deadliest cancers in women. In Canada alone, it is estimated that by 
the end of this year, 25,400 women will be diagnosed with breast cancer with 5,000 of 
them dying from the disease (Canadian Cancer Society, 2016). To put into perspective, 
this equates to 68 women being diagnosed and 14 women dying each day. Based on 
current trends, it is predicted that these numbers will increase rather than decrease over 
the next 20 years.  
The etiology of breast cancer is still unknown but thought to be due to a combination of 
both genetic and environmental factors. Support for environmental factors comes from 
migration studies showing an increased incidence of breast cancer amongst migrants and 
their descendants, after they move from a region of low breast cancer risk to a region of 
high risk (Le et al., 2002; Shimizu et al., 1991). While many environmental predictors 
have been proposed, such as smoking and diet, one factor not considered at the time of 
entrance into my PhD program, was the potential of microbes, specifically in the breast, 
to influence the risk of breast cancer development. The rationale for this idea is presented 
below.  
1.4.1 Causative role of bacteria in breast cancer 
development 
Almost 40 years ago, it was reported that the spontaneous rate of various tumour 
formations, over a 10 -year period, was higher in conventional rats compared to germ-
free ones, with mammary tumours being the second most common tumour recorded 
(Sacksteder, 1976). The role of bacteria in mammary carcinoma was again delineated a 
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few years later, when it was shown that conventional rats had an increased risk of 
mammary tumours compared to germ free ones after sub-cutaneous injection with the 
carcinogen, 3,2'-dimethyl-4-aminobiphenyl (DMAB) (Reddy and Watanabe, 1978). 
One mechanism by which bacteria may contribute to disease onset is through production 
of carcinogenic compounds from dietary components. Numerous studies using germ-free 
and conventional animals have shown that risk-related components of the human diet 
interact with the gut microbiota to induce DNA adducts and colon cancer (Hambly et al., 
1997; Reddy et al., 1975; Rumney et al., 1993). One of these risk-related dietary 
components, PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), has been 
detected in the milk of lactating rats and human milk (DeBruin and Josephy, 2002; Scott 
et al., 2007).  
Another mechanism by which bacteria may promote breast cancer is through chronic 
inflammation, which is now widely accepted to be associated with the development of 
cancer (Mantovani et al., 2008). The effect of pathogen-induced inflammation is however 
not limited to the site of infection. It has been shown that C57BL/6 ApcMin/+ mice, which 
are genetically predisposed to develop mammary carcinomas, fail to develop disease 
when housed under specific pathogen free conditions (Moser et al., 1993) but upon 
gastric administration of Helicobacter hepaticus they develop mammary adenosquamous 
carcinoma as a result of innate immune induction of inflammation (Rao et al., 2006a, 
2006b). 
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1.4.2 Protective role of bacteria in breast cancer 
development 
Certain bacteria have properties that may reduce the risk of breast cancer development.  
An epidemiological study conducted in The Netherlands involved 323 women showed 
that the incidence of breast cancer decreased in women who drank fermented milk 
products, irrespective of multivariable risk factors such as smoking, obesity, age of first 
pregnancy, parity and alcohol consumption (van’t Veer et al., 1989).  In vivo and in vitro 
studies further support the protective role of lactic acid bacteria in breast cancer 
development. An in vitro study showed that milk fermented with separate strains of lactic 
acid bacteria (Bifidobacterium infantis, B. bifidum, B.animalis, Lactobacillus acidophilus, 
L.paracasei) had an anti-proliferative effect on the MCF7 breast cancer cell line (Biffi et 
al., 1997).  In vivo, it has been shown that mice fed milk fermented with Lactobacillus 
helveticus R389, display delayed or absent tumour growth compared to those that did not 
receive the probiotic (de Moreno de LeBlanc et al., 2005). These protective effects were 
proposed to be due to immune modulation by Lactobacillus, specifically a reduction in 
IL-6 and an increase in IL-10 cytokine levels. Lactobacillus and Bifidobacterium have 
also been shown to increase the percentage of activated natural killer (NK) cells in 
peripheral blood mononuclear cells (PBMC) (Chiang et al., 2000; Takeda and Okumura, 
2007). This could be beneficial, as women with breast cancer have impaired NK cell 
function compared to healthy controls (Piroozmand and Hassan, 2010), which is 
associated with an increased risk of breast cancer development (Imai et al., 2000; Strayer 
et al., 1984).  
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1.4.3 Bacteria in the breast and their role in breast cancer 
development  
The studies described above present a rationale for how distally located bacteria may 
contribute to disease progression or prevention. Below I discuss the possible role of 
bacteria within the breast in modulating this risk.  
In a large scale analysis of 140,000 women in 47 studies from 30 different countries it 
was shown that for every 12 months of breast-feeding the risk of breast cancer decreased 
by 4.3% (Collaborative Group on Hormonal Factors in Breast Cancer, 2002). This study 
did not account for the different molecular subtypes of breast cancer, but another 
international study, conducted to assess the role of breast feeding in hereditary cancer, 
showed that women with BRCA1 mutations who breast fed for 1 year or longer had a 
45% reduced risk of breast cancer, though these protective effects were not seen in 
patients with BRCA2 mutations (Jernström et al., 2004; Tryggvadottir et al., 2003).  
Interestingly, an in vivo model with Caveolin-3-/- mice, which have constitutive milk 
production, showed that mutants were substantially more protected against mammary 
tumour development than their wild-type counterparts, after tumour injection (Sotgia et 
al., 2009).   
There are many theories as to why lactation could be protective, such as reduction of 
estrogen levels (Jernström et al., 2004; Lyons et al., 2009), excretion of carcinogens from 
the breast and differentiation of mammary epithelial cells (Lipworth et al., 2000).  
Hormone modulation, however, may not be a significant contributor, as breast-feeding is 
protective in estrogen receptor negative, progesterone receptor negative (ER-PR-) and 
triple negative tumours (Gaudet et al., 2011; Ursin et al., 2005).  
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We raise the possibility that bacteria present in the mammary glands during lactation 
could act independently or in concert with other factors to afford protection. In a study 
comparing the immunomodulatory potential of two species of Lactobacillus isolated from 
breast milk  (L. fermentum CECT5716 and L. salivarius CECT5713) with two non-milk 
derived species (L. fermentum NCIMB7017511 and L. salivarius NCIMB11795) it was 
shown that the milk-derived strains induced higher levels of IL-10 and activated NK cells 
from PBMC (Pérez-Cano et al., 2010), two factors that are protective against breast 
cancer. Possibly, the strains of bacteria growing in breast milk have been selected to 
provide an evolutionary advantage to women to help control and/or prevent the 
progression of breast cancer. This will be a difficult hypothesis to prove but one worthy 
of consideration.  
 High-throughput sequencing to analyze the human 1.5
microbiota 
The first description of microbes was reported in 1673 by the Dutch scientist Antonie van 
Leeuwenhoek, with his work considered to be the start of the field of Microbiology. 
Another pivotal landmark was the development of solid media by Robert Koch in 1881, 
which allowed him to isolate disease-causing organisms thereby determining the agents 
responsible for tuberculosis, cholera and anthrax. While culture analysis is routinely used 
in labs across the world and has been indispensable to microbiologists over the last 130 
years, culture methods have limited our understanding of the composition and function of 
complex microbial communities, as most organisms cannot be grown in the lab (Amann 
et al., 1995; Stewart, 2012).  It is for this reason, that culture-independent methods, most 
notably high throughput sequencing (HTS), has revolutionized the field of microbial 
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ecology, allowing us to study the human microbiota and its function at various body sites, 
in healthy and diseased patients and at different stages of human development (Coburn et 
al., 2015; Costello et al., 2013; Gill et al., 2006; Grice et al., 2009; Human Microbiome 
Project Consortium, 2012; Hummelen et al., 2010; Hunt et al., 2011; Koenig et al., 2011; 
Macklaim et al., 2013; Turnbaugh et al., 2009; Wolfe et al., 2012).  
1.5.1 16S rRNA gene targeted sequencing  
The 16S rRNA gene is part of the small ribosomal subunit of bacteria, an evolutionary 
conserved, ubiquitous molecule, that makes it useful for phylogenetic studies (Woese and 
Fox, 1977). While 16S rRNA gene amplicon sequencing is the most popular method to 
identify and compare bacteria within samples, some groups have opted to utilize other 
targets, such as cpn60 (Links et al., 2012).  
HTS has allowed for the unprecedented ability to process 100-1000s of samples at a time, 
generating millions of reads at a reasonable cost, however, it is limited by the length of 
sequence it can produce and the resolution of the phylogenetic assignment. The current 
version of the Illumina MiSeq platform generates a maximum read length of 600bp, up 
from 100bp when it was first developed. Because of this, HTS studies do not sequence 
the full 16S rRNA gene (1.5kb) but specific regions of it, called hypervariable regions. 
These hypervariable regions (V1-V9), flanked by conserved regions from which 
amplification primers are designed, are as effective as the full length version at assigning 
taxonomy and estimating community richness (Andersson et al., 2008; Gloor et al., 2010; 
Liu et al., 2007). 
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Currently there is no consensus in the field as to which hypervariable region should be 
sequenced, because the “best one” will depend on the sequencing platform, databases 
used for assigning taxonomy and the type of samples used (Soergel et al., 2012). Stool 
microbiota studies typically use V4 or V3-V5 (which span the V4 region). V3, V4 and 
V4/V5 have been shown to be more accurate in determining taxonomy compared to V2, 
V5 alone and V6, regardless of sequencing platform (454 and Illumina MiSeq) or 
database used to assign taxonomy (i.e. RDP, Greengenes, NCBI) (Claesson et al., 2010; 
Huse et al., 2008; Liu et al., 2008; Mizrahi-Man et al., 2013). However, in terms of 
estimating diversity (in the stool), all regions tested performed equally well (Liu et al., 
2008). Since V4 can detect a broad range of bacteria and archaea it has been chosen as 
the target for the Earth Microbiome Project (www.earthmicrobiome.org). V6 is commonly 
used in vaginal microbiota studies as it can differentiate Lactobacillus species, which 
dominate the healthy vagina, as well as picking up the various organisms found in 
women with bacterial vaginosis (Gloor et al., 2010). 
V6 was the region of choice for the milk and tissue studies described herein, because 
unlike primers for the V4 region, it does not cross-react with eukaryotic mitochondrial 
DNA (personal observations and also noted in (Huys et al., 2008)). In stool samples, 
where there is a higher proportion of bacterial vs eukaryotic DNA this is not a problem. 
But in tissue, where eukaryotic DNA predominates, amplification needs to be as specific 
as possible so as to not saturate the reads with eukaryotic sequences. In addition, V6 but 
not V4 directed primers, detect Propionibacterium (Kuczynski et al., 2012) a common 
skin organism that we expected to be present in our samples.  
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In order to more readily interpret the massive amount of data generated with HTS, 16S 
rRNA gene sequences that are similar to each other are clustered together into operational 
taxonomic units (OTUs) which can then be used to estimate microbial diversity (Chen et 
al., 2013; Schloss and Westcott, 2011). This is based on the assumption that sequences 
that are similar to each other represent organisms that are more phylogentically related 
(He et al., 2015). Sequences are typically clustered into OTUs with 97% similarity 
(considered the threshold for separating species)(Schloss and Handelsman, 2005), with 
the most abundant sequence in that group being the representative one used for 
taxonomy. A table of OTUs and counts for each sample is then used for downstream 
analysis such as beta diversity (diversity between samples), alpha diversity (diversity 
within a sample) and comparing relative abundances between groups.  
 Scope and objectives 1.6
The Human Microbiome Project (HMP), funded by the National Institutes of Health, was 
developed in order to comprehensively characterize the presence and function of bacteria 
colonizing different body sites, under different conditions. This initiative, and a similar 
one in Europe, was undertaken because of the overwhelming evidence showing how 
important microbes can be in maintaining health and how significant aberrations can lead 
to detrimental outcomes (Peterson et al., 2009). Phase 1 of the project was published in 
2012 and reported the diversity of bacterial communities from 242 healthy American 
adults (males and females) from 15-18 body sites (Human Microbiome Project 
Consortium, 2012).  Unfortunately and surprisingly, this large-scale study did not include 
analysis of human milk.  
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While there were milk microbiota studies prior to the HMP and others conducted after its 
2012 publication, most of these utilized culture, denaturing gradient gel electrophoresis 
and/or PCR specific amplification.  At the start of this thesis there had only been 1 human 
milk microbiota study utilizing HTS to characterize its composition (Hunt et al., 2011) 
and none to determine what factor(s) could shape this bacterial community.  
My first objective was thus to characterize the human milk microbiota in Canadian 
women and to determine what factors shape its composition. In Chapter 2, I present a 
case report following a woman over 4 months for Hodgkins lymphoma to determine how 
drugs given distally could affect the milk microbiota- in this case we looked at the effects 
of the ABVD chemotherapeutic regime (adriamycin, bleomycin, vinblastine, 
dacarbazine).  In Chapter 3, I look at the effects of common pregnancy related factors 
and its impact on the milk microbiota- specifically gestation (pre-term vs term birth), 
mode of delivery (cesarean vs vaginal) and gender of the child (male vs female vs twins).  
Considering that milk is not sterile, that there is exposure of the nipple to the external 
environment and that the nutrient rich fatty environment of the breast could support 
bacterial growth, I hypothesized that breast tissue, irrespective of lactation and 
pregnancy, could also have its own indigenous microbiota. My second objective was thus 
to characterize, using HTS and culture, the bacteria in breast tissue. In Chapter 4, I 
present our findings from tissue samples analyzed from women from two distant 
demographics: Canada (n=43) and Ireland (n=39).   
After showing that a breast microbiome exists, my third objective was to examine 
whether this microbiome could have a role in the development of breast cancer.  The first 
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aim within this objective was to determine whether bacterial profiles differ between 
women with breast cancer and those who are disease free (Chapter 5). The rationale for 
this comes from studies showing differences in microbial profiles between healthy 
individuals and those with colorectal cancer, with these differences driving disease 
development. The second aim within this objective was to explore how the breast 
microbiota could promote disease progression. I did this by looking at the ability of 
bacteria isolated from breast cancer patients to induce DNA damage using the γH2AX 
assay (Chapter 5) and by sequencing the genome of a Bacillus cereus strain isolated 
from a women with stage III invasive breast cancer (Chapter 6). Bacillus cereus was 
chosen for this analysis as Bacillus species were higher in cancer patients compared to 
controls and they were the most abundant organism cultured from breast cancer patients.  
In a series of Appendices, I describe my work showing (i) the optimization of DNA 
extraction protocols for low biomass samples, (ii) histological work to try and identify 
where in the breast bacteria were located and lastly (iii) the properties of Lactobacillus 
rhamnosus GR-1 (a probiotic) when grown in bovine milk, with an emphasis on a 
pathway involving breakdown of lactosylceramide to ceramide, a pro-apoptotic signaling 
molecule involved in controlling aberrant cell growth. 
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Chapter 2  
2 Effect of chemotherapy on the microbiota and 
metabolome of human milk, a case report 
This chapter has been reproduced with permission (Appendix 8.6) from: 
Urbaniak, C., McMillan, A., Angelini, M., Gloor, G.B., Sumarah, M., Burton, J.P., and 
Reid, G. (2014). Effect of chemotherapy on the microbiota and metabolome of human 
milk, a case report. Microbiome 2, 24. 
 
A summary of clinical data (Dataset 2-1) and metabolites detected in human milk 
(Dataset 2-2) is available for download online.  
 
 Introduction 2.1
Colonization of the neonatal gut plays a pivotal role in gastrointestinal, immunological 
and neurological development with one of the initial sources of bacteria coming from the 
mother’s milk (Martín et al., 2003, 2012). Breast fed infants have been shown to have 
lower incidences of asthma, diarrhea, and necrotizing enterocolitis (NEC) compared to 
formula fed infants (Stuebe, 2009). This protective effect may be due, in part, to the types 
of bacteria present in milk, as infants fed formula supplemented with probiotics were 
better protected against these conditions compared to those just fed formula (Chouraqui 
et al., 2008; Guaraldi and Salvatori, 2012; Silvers et al., 2012). The bacteria acquired 
during infancy can influence disease risk later in life and play a major role in what the 
composition of the adult microbiome will be (Guaraldi and Salvatori, 2012). Thus, 
factors that affect the milk microbiota have important health consequences for the child 
not only during development but also into adulthood. In addition to the microbiota, the 
metabolites of human milk, such as fatty acids, carbohydrates, proteins and vitamins also 
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play an important role in infant development and long term health (Agostoni, 2008; 
Boudry et al., 2010; German et al., 2002; Kunz et al., 2000).  
Post delivery, many women are prescribed pharmaceutical agents for various reasons. 
While most over the counter drugs and antibiotics are not contraindicated during breast 
feeding (Donaldson and Goodchild, 2012; U.S. National Library of Medicine), when it 
comes to chemotherapeutics, the recommendation is that breastfeeding should be avoided 
until the drug has been cleared from the milk (Gartner et al., 2005). In a case report of a 
70mg infusion of cisplatin, no detectable levels were found in milk after 66hr (Hays et 
al., 2013) and in another case study using doxorubicin (trade name Adriamycin), no 
detectable levels were seen after 72hr (Pistilli et al., 2013). In our particular study, the 
subject was advised that breastfeeding could resume 12 days after each chemotherapy 
session. 
Here we present the first report on the effects of chemotherapy on microbial and   
metabolomic profiles in human milk over a 4 month period in a breast feeding woman 
undergoing treatment for Hodgkin’s lymphoma (Figure 2-1).  
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Figure 2-1.  Summary of sample collection 
Milk samples were collected from a lactating woman undergoing chemotherapy for 
Hodgkin’s lymphoma. Milk samples were collected every two weeks over a 4-month 
period. At each session milk was collected 15-30min before (“A”) and after (“B”) 
chemotherapy. Duration of chemotherapy treatment lasted 2hr.  No milk was collected at 
week 8 due to scheduling conflicts. 
 
 
 
 
Figure'1'
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 Methods 2.2
2.2.1 Clinical samples and study design  
Ethical approval was obtained from Western Research Ethics Board and Lawson Health 
Research Institute, London, Ontario, Canada. Subjects provided written consent for 
sample collection and subsequent analyses. 
2.2.2 Milk collection and processing 
Mature milk was collected from a lactating woman undergoing the ABVD chemotherapy 
regime (A=Adriamycin (40mg), B=Bleomycin (16 units), V= Vinblastine (9.6mg), D= 
Dacarbazine (600mg) for Hodgkin’s lymphoma at the London Health Sciences Center, 
London, Ontario. Mature milk was also collected from 8 healthy women recruited from 
London, Ontario and the surrounding area. Wearing sterile gloves the women cleaned 
their nipple and surrounding area with sterile saline swabs to reduce the presence of skin 
bacteria. Milk was collected using a sterile HygieniKit Milk Collection System (Ameda) 
attached to an electric breast pump. Between 5-15mL of milk was pumped into a sterile 
tube and kept on ice until transfer to the laboratory which occurred within 1 hour of 
collection. Samples were aliquoted and stored at -20oC until DNA extraction. 
2.2.3 DNA isolation 
After thawing on ice, 2 mL of milk were spun down at 13,000g for 10min and the 
supernatant discarded. The pellet was then homogenized in 1.4mL of ASL buffer 
(QIAamp® DNA Stool Kit, Qiagen) and 400mg of 0.1mm diameter zirconium-glass 
beads (BioSpec Products). Mechanical and chemical lyses were performed by bead 
beading at 4800rpm for 60s, then 60s on ice (repeated twice) (mini-beadbeater-1, 
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BioSpec Products) and then incubated at 95oC for 5min. Subsequent procedures were 
performed using the Qiagen QIAamp® DNA Stool Kit according to the manufacturer’s 
protocol, with the exception of the last step in which the column was eluted with 120µL 
of elution buffer.  DNA was stored at -20oC until further use. 
2.2.4 Ion Torrent V6 16S rRNA sequencing 
2.2.4.1 PCR amplification 
Genomic DNA isolated from the clinical samples, was amplified using the barcoded 
primers,V6-LT: 
5’CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNCWACGCGARGAACCTTACC3’  
and V6-RT: 5’CCTCTCTATGGGCAGTCGGTGATACRACACGAGCTGACGAC 3’, which 
amplify the V6 hypervariable region of the 16S rRNA gene. The PCR was carried out in 
a 40µL reaction containing 5µL of DNA template (or nuclease free water as a negative 
control), 1.5mM MgCl2, 0.8µM of each primer, 4µL of 10x PCR Buffer (Invitrogen), 
0.2mM dNTPs, 0.05U Taq Polymerase (Invitrogen) and 0.15µg/µL of bovine serum 
albumin. Thermal cycling was carried out in an Eppendorf Mastercyler under the 
following conditions: Initial denaturation at 95oC for 2min followed by 25 cycles of 95oC 
for 1min, 55oC for 1min and 72oC for 1min. After amplification, the DNA concentration 
was measured with the Qubit® 2.0 Fluorometer (Invitrogen) using the broad range assay. 
Equimolar amounts of each PCR product were pooled together and purified using the 
QIAquick PCR purification kit (Qiagen). The PCR purified sample was then sent to the 
London Regional Genomics Center, London, Ontario, Canada for V6 16S rRNA 
sequencing using the Ion Torrent platform as per the Center’s standard operating 
procedure. 
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2.2.4.2 Sequence processing and taxonomic assignment  
Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded 
reads to individual samples. Reads were kept if the sequence included a perfect match to 
the barcode and the V6 16S rRNA gene primers. Reads were clustered by 97% identity 
into Operational Taxonomic Units (OTUs) using UClust v. 3.0.617 (Edgar, 2010). OTUs 
that represented ≥1% of the reads in at least one sample were kept, while those that did 
not meet the cut-off were discarded. Taxonomic assignments for each OTU were made 
by the ribosomal database project (RDP) SeqMatch tool (Cole et al., 2009).  From the top 
20 matches to the RDP named isolates database, the full taxonomy was retained for 
matches with the highest S_ab score. For multiple top matches with equal scores, the 
highest common taxonomy was retained (e.g. genus level if multiple species matched 
equally well). Since the maximum number of matches displayed per sequence is 20, the 
RDP taxonomic assignments were verified by BLAST against the Greengenes named 
isolates database with an output of 100 hits (DeSantis et al., 2006). Taxonomy was 
assigned based on hits with the highest % identities and coverage. If multiple hits 
fulfilled this criterion, classification was re-assigned to a higher common taxonomy. In 
instances where the highest % identity/coverage yielded a single match, if this were less 
than 90% and the S_ab score from RDP was less than 0.7, taxonomy was assigned at the 
Family level instead of at the Genus level. The raw sequencing reads generated in this 
study have been deposited to the NCBI Short Read Archive (SRA) database 
(SRP041626). 
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2.2.4.3 Data analysis 
Weighted UniFrac distances were calculated in QIIME (Caporaso et al., 2010) by using a 
phylogenetic tree of OTU sequences built with FastTree (Price et al., 2009) and based on 
an OTU sequence alignment with MUSCLE (Edgar, 2004). The QIIME pipeline was also 
used to calculate Shannon’s diversity index (logarithms with base 2) and to generate 
principal coordinate analysis (PCoA) plots. Weighted UniFrac distances compare 
microbial profiles (presence/absence and abundance) between samples (i.e. beta-
diversity) (Lozupone and Knight, 2005) while Shannon’s diversity index evaluates the 
microbial diversity within a sample (i.e. alpha diversity). The higher the Shannon’s 
diversity index, the more diverse a sample is and a value of zero indicates the presence of 
only one species (Hill et al., 2003). PCoA plots allows one to visualize the UniFrac 
distance matrix and plots the values on a set of orthogonal axes which capture the 
greatest amount of variation between all samples tested. For beta-diversity analyses, the 
data set was rarified to the lowest read count/sample, which was 734 reads. A summary 
of clinical data, including total number of sequence reads per sample is shown in Dataset 
2-1. Barplots, boxplots and stripcharts were all generated in R (https://www.r-
project.org). 
2.2.4.4 Statistical analysis 
The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera 
between the non-treatment and chemotherapy treatment groups (as portrayed in the 
boxplots). Microbiome data represents proportional distributions and are thus not 
independent of each other. This means that a decrease in one organism will inevitably 
lead to a concomitant increase in another organism. For example, if a sample has two 
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organisms A (50%) and B (50%) and A is completely killed by an antibiotic, the 
proportion of B in that sample will now be 100% even if its actual abundance has not 
changed. The ALDEx R package estimates the technical variation inherent in high-
throughput sequencing by Monte-Carlo sampling from a Dirichlet distribution (Jaynes, 
2003). The Monte-Carlo replicates are transformed using the centered log-ratio 
transformation that takes the logarithm of the Monte-Carlo estimates of organism 
abundances in each sample divided by the per-sample geometric mean organism 
abundance (Aitchison and Egozcue, 2005). This transformation has several desirable 
properties that do not exist in proportional data, notably, subcomposition coherence and 
linear sample independence. Data transformed in this way permit the use of standard 
statistical tests to determine significance. Values reported in this manuscript represent the 
expected values of 128 Dirichlet Monte-Carlo instances. A value of zero indicates that 
organism abundance is equal to the geometric mean abundance. Thus organisms more 
abundant than the mean will have positive values and those less abundant than the mean 
will have negative values. Base 2 was used for the logarithm, thus differences between 
values represent fold changes. Statistical significance for these comparisons was 
determined by a Mann Whitney U test with p<0.05 and a false discovery rate of <0.1 
using the q values output by the fdrtool R package. The unpaired student’s t-test was used 
to compare Shannon’s diversity index (p<0.05). 
2.2.5 GC-MS sample preparation 
To extract metabolites 100µL of milk were mixed with 400µL pure methanol. Samples 
were vortexed for 15s and centrifuged for 10 min at 9000g. Supernatants (200µL) were 
transferred to GC-MS vials and 2.5µL of ribitol solution (2mg/ml) was added to each vial 
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as an internal standard. Samples were dried to completeness using a SpeedVac. After 
drying, 100µL of 2% methoxyamine•HCl in pyridine (MOX) was added to each sample 
for derivitization and samples were incubated at 50oC for 90 min. N-Methyl-N-
(trimethylsilyl) trifluoroacetamide (MSTFA) (100µL ) was then added to each vial and 
incubated at 50oC for 30 min. Samples were transferred to microinserts before running on 
GC-MS (Agilent 7890A GC, 5975 inert MSD with triple axis detector, 30m DB5-MS 
column with 10m duraguard column). Samples were run using 1µL injections on scan 
mode and a solvent delay of 10 min. Run time was 60 min per sample. Each sample was 
run twice non-consecutively to ensure consistency throughout the sequence.  
2.2.5.1 Data analysis for GC-MS 
Chromatogram files were converted to ELU format using the AMDIS Mass Spectrometry 
software (Stein, 1999). Chromatograms were aligned and abundance of metabolites 
calculated using the Spectconnect software (Styczynski et al., 2007) with the support 
threshold set to low. In order to determine if differences between week 0 and 
chemotherapy (weeks 2-16) existed, principle component analysis (PCA) was conducted 
in SIMCA (Umetrics) using the relative abundance matrix (RA) output from 
Spectconnect. Data were mean centered and pareto scaled prior to PCA. Independent 
unpaired t-tests with Bonferroni correction were calculated in Excel to determine 
metabolites that were significantly altered by chemotherapy (p < 0.05.). Compounds that 
also contributed to the separation of week 0 from chemotherapy samples according to the 
PCA loadings plot (compounds in bottom left quadrant) were chosen for further 
investigation.  
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 Results 2.3
Chemotherapy affected both bacterial diversity and bacterial profiles in human milk.  
Bacterial diversity within samples was lower in milk collected throughout chemotherapy 
compared to milk samples collected at week 0 and from healthy lactating women (Figure 
2-2). Bacterial profiles at week 0 were similar to those from healthy women, however this 
changed within 2 weeks of treatment (Figure 2-3A). Samples collected at weeks 4-16 
shared similar profiles and differed from week 2 and from week 0/healthy samples 
(Figure 2-3A). These differences were not due to natural changes over time, as the 
bacterial community in two milk samples analyzed from a healthy subject did not change 
over a four-month period (Figure 2-3A, green samples). The bar plot in Figure 2-3B 
shows the bacterial communities present in these samples with a striking increase in 
abundances of Acinetobacter and Xanthomonadaceae in milk collected during 
chemotherapy. A comparison of relative abundances of Acinetobacter, 
Xanthomonadaceae and Stenotrophomonas (a genus part of the Xanthomonadaceae 
family) between the chemotherapy (week 4-week 16) and non-treatment (week 0 and 
healthy samples) groups are displayed in Figure 2-4 and were shown to be significantly 
higher during chemotherapy. We also examined the differences between three bacteria 
believed to confer beneficial health effects to the infant, Bifidobacterium, Eubacterium 
and Lactobacillus. The first two were significantly decreased during chemotherapy 
whereas no differences were observed for Lactobacillus (Figure 2-4).  Overall, a total of 
22 out of the 49 genera identified were differentially abundant between the two groups 
(Table 2-1). 
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Figure 2-2.  Changes in bacterial diversity as a result of chemotherapy  
Bacterial diversity within a sample (i.e alpha diversity) was measured by calculating 
Shannon’s diversity index. Each point on the graph represents a subject with the line 
representing the mean for all samples within a group. The higher the index the greater the 
bacterial diversity found within a sample. The mean of the “Wk0/H” group (week0 and 
healthy samples) was 4.3, and that of the “Chemotherapy” group (week 4-16) was 2.8. 
Groups were statistically different from each other as measured by unpaired student’s t- 
test (p <0.05). 
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Figure 2-3. 16S rRNA sequencing analysis of bacteria in human milk 
Milk samples were collected from a lactating woman undergoing chemotherapy as 
described in Figure 2-1 as well as from 8 healthy lactating women. (A) Weighted 
UniFrac principal coordinates analysis (PCoA) plot.  Each milk sample, represented by a 
coloured circle, is plotted on this 3D, 3 axis plane representing 84% of the variation 
observed between all samples. Samples that cluster together are similar in biota 
composition and abundance. Orange circles represent samples collected from weeks 4-16 
of chemotherapy, blue circles represent samples collected at week 2 of chemotherapy, 
purple circles represent samples collected at week 0, red circles represent milk samples 
from healthy lactating women (only one time point) and green circles represent milk 
samples collected from a healthy lactating women collected 4 months apart. As shown by 
the plot, there were 3 distinct groups: (i) week 0 samples and healthy milk samples; (ii) 
week 2 of chemotherapy and  (iii) weeks 4-16 of chemotherapy. Data were rarified to 735 
reads/sample. (B) Barplot showing the relative abundance of different genera in each 
sample. Each bar represents a subject and each coloured box a different genus. The height 
of the coloured boxes represents the relative abundance of that genus within the sample. 
Genera that were less than 2% abundant in a given sample were placed in the “Remaining 
fraction” at the top of the graph (grey boxes).  
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Figure 2-4.  Comparison of relative proportions of bacterial taxa between groups 
Boxplots comparing 6 bacterial taxa between samples collected during chemotherapy 
(week 4-16) and those without treatment (week 0 and healthy samples, “Wk0/H”). The 
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of 
the samples lie. The black line inside the box represents the median. The whiskers 
represent the lowest datum still within 1.5 IQR of the lower quartile and the highest 
datum still within 1.5 IQR of the upper quartile (IQR= interquartile range). Outliers are 
shown with open circles. The value “0” represents the geometric mean abundance, thus 
values above 0 are more abundant and values less than 0 are less abundant than the 
geometric mean. Significant differences were observed between the two groups for all 
taxa graphed (Mann Whitney U test p<0.05, FDR <0.1). 
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Table 2-1.  Comparison of relative abundances of different genera detected in milk 
between the chemotherapy and non-treatment groups  
Values in the second and third columns represent the base 2 logarithm of the median 
abundance in all samples within a group (that is, Wk0/H samples (non-treatment group) 
or Chemo (treatment group)) relative to the geometric mean abundance, which has a 
value of 0. Thus, positive values are higher than the geometric mean and are thus more 
abundant than negative values, which are lower than the geometric mean. Significant 
differences were based on FDR values of <0.1. Out of the 49 genera identified, 22 were 
significantly different between the two groups 
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Taxa Wk0/H Chemo p-value FDR value Higher in 
Acinetobacter 5.542 10.88 0 0 Chemo 
Gammaproteobacteria 4.372 7.901 0 0.001 Chemo 
Stenotrophomonas -3.181 5.751 0 0.002 Chemo 
Xanthomonadaceae 0.605 8.547 0.001 0.003 Chemo 
Cloacibacterium 5.301 1.981 0.001 0.003 Wk0/H 
Rhizobiales -1.947 2.541 0.001 0.003 Chemo 
Porphyrobacter 2.763 0.259 0.001 0.005 Wk0/H 
Thermus -2.361 1.733 0.002 0.006 Chemo 
Streptococcus 2.313 4.696 0.001 0.007 Chemo 
Flavobacterium/Cytophaga 0.169 3.062 0.002 0.007 Chemo 
Bifidobacterium 0.74 -3.51 0.002 0.008 Wk0/H 
Eubacterium 0.224 -3.607 0.003 0.01 Wk0/H 
Rothia -1.221 2.325 0.002 0.011 Chemo 
Brevundimonas/Caulobacter 3.105 -0.117 0.003 0.013 Wk0/H 
Microbacteriaceae -1.449 1.322 0.006 0.022 Chemo 
Staphylococcus 4.445 2.306 0.008 0.028 Wk0/H 
Anoxybacillus/Bacillus 1.616 3.53 0.007 0.029 Chemo 
Bacillus 0.243 2.623 0.008 0.03 Chemo 
Gammaproteobacteria OTU11 3.729 0.3 0.017 0.052 Wk0/H 
Petrobacter 0.184 -2.054 0.025 0.076 Wk0/H 
Truepera 2.9 -0.271 0.026 0.081 Wk0/H 
Betaproteobacteria 2.579 -0.119 0.026 0.093 Wk0/H 
Enterobacteriaceae 3.204 5.026 0.036 0.123 N/A 
Sphingomonas 0.939 2.103 0.047 0.139 N/A 
Faecalibacterium -0.361 -2.055 0.055 0.156 N/A 
Tepidimonas 0.662 -2.512 0.048 0.159 N/A 
Comamonadaceae 1.21 2.257 0.064 0.195 N/A 
Schlegelella 1.058 -1.364 0.067 0.251 N/A 
Pseudomonas 3.494 4.771 0.098 0.359 N/A 
Finegoldia -2.234 -4.213 0.186 0.42 N/A 
Bacteroidetes -3.188 -5.058 0.248 0.463 N/A 
Prevotella -3.061 -5.022 0.227 0.467 N/A 
Legionella -2.686 -4.538 0.271 0.554 N/A 
Corynebacterium -1.075 -2.789 0.235 0.569 N/A 
Sphingobium/Sphingomonas 1.136 -1.244 0.21 0.584 N/A 
Porphyromonas -3.614 -5.246 0.306 0.611 N/A 
Rhizobium/Agrobacterium 1.212 -0.374 0.23 0.632 N/A 
Ruminococcus -3.541 -4.725 0.36 0.642 N/A 
Flavobacteriaceae -3.811 -5.116 0.346 0.642 N/A 
Gemella -2.353 -0.957 0.375 0.766 N/A 
Peredibacter -2.9 -4.141 0.423 0.768 N/A 
Sphingobacterium -2.283 -3.517 0.476 0.781 N/A 
Atopobium -3.526 -3.942 0.552 0.867 N/A 
Methylophilus -3.242 -1.833 0.517 0.879 N/A 
Brevundimonas 1.479 0.797 0.483 0.918 N/A 
Gardnerella -2.188 -2.203 0.637 0.933 N/A 
Propionibacterium 2.103 2.182 0.721 0.954 N/A 
Lactobacillus 0.891 1.273 0.837 0.993 N/A 
unclassified Bacteria 5.004 4.489 0.874 1 N/A 
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The metabolic profile also changed as a result of chemotherapy (Figure 2-5) and was 
similar between week 2-16, but different to that observed at week 0. A total of 226 
metabolites were detected by our GC-MS method, 12 of which were significantly 
different between the week 0 and chemotherapy (week 2-16) groups (Table 2-2). Dataset 
2-2 shows the relative abundance of all metabolites detected in milk. 
 
Table 2-2.  Metabolites significantly altered by chemotherapy 
(*) metabolite identity confirmed by authentic standards. Chemotherapy refers to samples 
collected from week 2-16. Significant differences were determined using the unpaired 
student’s t-test, p < 0.05. 
Metabolite Elevated in Bonferroni corrected  
p value 
unknown PUFA week 0 1.81E-07 
DHA * week 0 0.000304 
arabinose chemotherapy 0.000456 
threitol chemotherapy 0.001342 
unknown chemotherapy 0.002685 
unknown chemotherapy 0.002768 
decanoic acid chemotherapy 0.008458 
myristic acid chemotherapy 0.008727 
1-monopalmitin chemotherapy 0.009143 
butanal chemotherapy 0.012356 
unknown chemotherapy 0.017961 
Inositol * week 0 0.037225 
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Figure 2-5.  Principal component analysis of metabolites in breast milk at week 0 
and during chemotherapy 
(A) Scoreplot displaying the distribution of samples based on metabolites alone, where 
the distance between samples represents how similar the metabolome of those samples 
are. Each point represents the average of 2 technical replicates. (B) Loadings plot. Each 
point represents a metabolite. Metabolites present in a given quadrant of the loadings plot 
are present in highest abundance in samples present in the same quadrant of the scoreplot 
(A). 
A"
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 Discussion 2.4
This study has shown that a course of chemotherapy has significant effects on bacterial 
and metabolic profiles in human milk, moving away from those of healthy lactating 
women. Of note, the subject did not report any additional drug use, antibiotics, illness or 
major changes in diet over the course of the study. 
The consequences of decreased bacterial diversity in human milk and the implications on 
the child are still unknown however the decreased milk diversity could impact intestinal 
diversity and it has been shown that low intestinal diversity in the first weeks of life has 
been associated with necrotizing enterocolitis (Mshvildadze et al., 2010) and an increased 
risk of allergy and atopy in school age children (Madan et al., 2012). Lower intestinal 
diversity has also been observed in children with type 1 diabetes compared to age 
matched controls (Giongo et al., 2011).    
In addition to overall changes in microbial profiles, we observed a significant decrease in 
the relative abundance of Bifidobacterium in the chemotherapy group compared to the 
non-treatment group. Bifidobacterium is the predominant organism in the gut of breast 
fed infants, attributed to its ability to metabolize the human milk oligosaccharides (HMO) 
present in large amounts in milk (Sela et al., 2008; Asakuma et al., 2011). Maternal levels 
have also been shown to impact gut Bifidobacterium abundance, with low levels in milk 
correlating with low levels in the neonatal gut (Grönlund et al., 2007). The potential 
consequences of decreased numbers of Bifidobacterium being passed on from the mother 
to the neonate could be an increased risk of asthma or obesity later in life. High levels of 
Bacteroides have been reported in the gut of infants with low levels of Bifidobacterium 
(Jost et al., 2012) and early colonization with high Bacteroides counts has been attributed 
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to an increased risk of developing asthma and obesity (Vael et al., 2008, 2011a, 2011b). 
In addition, depleted levels of Bifidobacterium have been shown to promote colonization 
of opportunistic pathogens such as Klebsiella and Citrobacter (Jost et al., 2012).   
Staphylococcus, including coagulase negative species, are one of the predominant 
organisms in human milk (Hunt et al., 2011; Jost et al., 2013; Ward et al., 2013) and were 
also significantly reduced as a result of chemotherapy. It has been shown that numerous 
human milk isolates of Staphylococcus epidermidis can inhibit the growth of 
Staphylococcus aureus (Heikkila and Saris, 2003), the main causative agent of mastitis, a 
painful inflammatory condition of the breast, that often leads to pre-mature cessation of 
breastfeeding in many women. While we were not able to identify the Staphylococcus in 
our samples down to the species level with 16S rRNA gene sequencing, culture analysis 
on mannitol salt agar plates did show that the Staphylococcus isolates were not S.aureus 
and the select few that were tested were coagulase negative. This reduction of 
Staphylococcus (likely coagulase negative species) as a result of chemotherapy could 
make lactating women more prone to infections, affecting both themselves and their 
infants. Like Bifidobacterium, Staphylococcus is passed from the milk to the neonate, 
with higher numbers in the intestine of breastfed compared to formula fed infants (Martín 
et al., 2012). Interestingly, a metagenome analysis revealed the presence of 
immunosuppressive motifs in bacterial DNA from human milk, with the majority of these 
belonging to Staphylococcus (Ward et al., 2013). The exposure of the neonate to this 
DNA, either ingested from the milk or through live bacteria that have released their DNA 
once in the gut, could help to regulate the immune response against a variety of 
innocuous bacterial, environmental and food antigens. 
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The utilization of bacterial products by other bacteria is termed metabolic cross-feeding 
and plays an important role in bacterial selection. For example, the byproducts of 
bacterial metabolism such as lactate and acetate production are utilized as an energy 
source by many butyrate producing bacteria (Barcenilla et al., 2000; Belenguer et al., 
2006; Duncan et al., 2004a, 2004b) such as Eubacterium, which was decreased in our 
chemotherapy group. Butyrate is important for health, as it reduces inflammation and 
metabolic diseases, promotes colonic repair and protects against colon cancer (Hamer et 
al., 2008; Lin et al., 2012). On the other hand some pathogens persist and cause disease 
only in the presence of certain commensal bacteria (Ramsey et al., 2011), likely due to 
the metabolites produced. Thus changes in bacterial communities in human milk will 
inevitably alter the metabolic milieu, selecting for bacteria able to utilize those 
metabolites. As a result, potential shifts from a healthy and balanced intestinal microbiota 
can occur, having important consequences on health. 
Docosahexaenoic acid (DHA), inositol and an unknown poly-unsaturated fatty acid 
(PUFA) were among the 12 metabolites that differed between week 0 and weeks 2-16, 
with reduced levels detected during chemotherapy (weeks 2-16). DHA is the most 
abundant long chain PUFA in the brain, retina and nerve cells and is supplied mainly 
through breast milk (Morse, 2012). DHA deficiencies lead to reduced brain, eye and 
neuronal development (Morse, 2012) and it has been observed that breastfed infants have 
better visual acuity and neuronal development compared to those fed formula (Hoffman 
et al., 2009). Reduced levels of DHA and alpha-linolenic acid (a precursor of DHA) have 
been reported in milk of mothers with atopic children compared to milk from mothers 
with non-atopic children (Duchén et al., 2000; Yu et al., 1998). Another principal 
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metabolite in the neonatal brain is inositol and is important for osmoregulation, cellular 
nutrition and detoxification (Kok et al., 2001). Palmitic acid levels were also reduced 
during chemotherapy, though the results were not significant. Palmitic acid is the most 
abundant lipid in human milk and has been shown to increase bone strength in infants 
(Litmanovitz et al., 2013) and limit intestinal damage and pro-inflammatory immune 
responses in mice (Lu et al., 2013). While changes in metabolite concentrations do occur 
over the course of lactation, especially between colostrum and mature milk, no changes 
in the above metabolites over the course of the first year of life have been detected in 
mature milk (Jóźwik et al.; López-López et al., 2002; Marangoni et al., 2000; Ribeiro et 
al., 2008). Due to the high variability in milk metabolites between individuals, we did not 
have enough samples from healthy women to make substantive claims as to how the 
Hodgkin’s patient compared, however, there were no obvious differences in the 
metabolic profiles of control samples taken at early compared to later stages of lactation. 
We recognize that the main limitation of the study is its single case study content of a 
patient undergoing chemotherapy. However, the findings were revealing and warrant 
further investigation into how more commonly prescribed drugs, such as antibiotics, may 
effect the milk microbiota and if changes do occur, how long do these changes last.  
 Conclusion 2.5
The bacterial and metabolic composition in human milk, so critical for infant 
development, can change significantly by maternal exposure to chemotherapeutic agents. 
This study emphasizes the importance of conducting further studies to examine changes 
in the microbiota and metabolomic as a result of drug intake in lactating mothers, and the 
consequences of these changes to the long term health of the infant.  
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Chapter 3  
3 Human milk microbiota profiles in relation to birthing 
method, gestation and infant gender 
This chapter is reproduced with permission (Appendix 8.6) from: 
Urbaniak, C., Angelini, M., Gloor, G.B., and Reid, G. (2016). Human milk microbiota 
profiles in relation to birthing method, gestation and infant gender. Microbiome 4, 1.  
 
Supporting Datasets 3-1 (clinical metadata), 3-2 (OTU annotations) and 3-3 (ALDEx2 
summary) are available for download online as additional excel files 
 
 Background 3.1
With the incidence of various non-infectious diseases on the rise, there is much interest in 
the developmental origins of health and disease and the potential role of early life feeding 
practices in modulating these outcomes. Breast fed infants have been shown to be better 
protected than formula fed infants against necrotizing enterocolitis and diarrhea, allergy 
and asthma, inflammatory bowel disease, type 1 and type II diabetes, obesity and 
cardiovascular disease (Guaraldi and Salvatori, 2012; Stuebe, 2009). In addition to 
immune protection and bioactive compounds being conveyed through maternal milk, a 
possible protective role of bacteria has been suggested. Lower than average levels of 
Bifidobacterium in human milk correlate with low levels of Bifidobacterium in the 
neonatal gut (Grönlund et al., 2007), allowing for higher than normal levels of 
Bacteroides to be established (Jost et al., 2012). These high levels of Bacteroides early in 
life have been associated with an increased risk of asthma and obesity later in life (Vael 
et al., 2008, 2011a, 2011b). Indeed, efforts to manipulate the microbiota of formula fed 
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infants through probiotic supplementation have resulted in protection against some of the 
above diseases, comparable to that observed for breast fed infants (Chouraqui et al., 
2008; Dilli et al., 2015; Kankaanpää et al., 2002). 
Differences exist in bioactive components, macronutrients, cytokines, enzymes, proteins 
and immunological factors between Pre-term vs Term milk and milk from mothers giving 
birth by vaginal vs cesarean deliveries (Dizdar et al., 2014; Koenig et al., 2005; Mehta 
and Petrova, 2011a, 2011b; Wang et al., 2014; Zanardo et al., 2001). As well, the energy 
content differs in milk depending on gender of the newborn, with breast milk from 
mothers who give birth to sons having more fat content than that of daughters (Fujita et 
al., 2012; Powe et al., 2010). 
We hypothesized that physiological or hormonal triggers that influence milk composition 
might also support different bacterial genera. Thus, we studied human milk samples from 
women giving birth at different stages of gestation, by vaginal or caesarian delivery, and 
examined whether gender of the newborn also affected the microbiota profiles. 
 Methods 3.2
3.2.1 Milk collection and processing  
A single milk sample (Day 6 and onwards post partum) was collected from 39 Caucasian 
Canadian women recruited from London, Ontario and the surrounding area, representing 
a homogenous community (Dataset 3-1, metadata). Even though the samples collected 
were from different days after birth, with some considered “transitional” and others 
“mature,” a Kendall’s Tau correlation test showed no statistically significant correlation 
between OTU relative abundances over time after a Benjamini-Hochberg correction for 
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multiple hypothesis tests. This shows that it is acceptable to use all milk samples, 
regardless of when it was collected, in our analyses. 
Ethical approval was obtained from Western Research Ethics Board and Lawson Health 
Research Institute, London, Ontario, Canada. Subjects provided written consent for 
sample collection and subsequent analyses. Participants were excluded if they were 
suffering from mastitis and were/had been on antibiotics during lactation. Cesarean 
deliveries were classified as either (i) “non-elective”; if there were complications during 
labour or (ii) “elective”; if they were planned in advance or if the health of the fetus 
and/or mother was at risk prior to labour. 
Wearing sterile gloves the women cleaned their nipple and surrounding area with sterile 
saline swabs to reduce the presence of skin bacteria. Milk was collected using a sterile 
HygieniKit Milk Collection System (Ameda, Buffalo Grove, IL, USA) attached to an 
electric breast pump. Between 5 and 15 ml of milk was pumped into a sterile tube and 
kept on ice until transfer to the laboratory, which occurred within 1 hour of collection. 
Samples were aliquoted and stored at -20°C until DNA extraction. 
3.2.2 DNA isolation 
After thawing on ice, 2 ml of milk were spun down at 20,000  g for 10 minutes and the 
supernatant discarded. The pellet was then homogenized in 1.4 ml of ASL buffer 
(QIAamp® DNA Stool Kit, QIAGEN: Valencia, CA, USA) and 400 mg of 0.1 mm 
diameter zirconium-glass beads (BioSpec Products, Bartlesville, OK, USA). Mechanical 
and chemical lyses were performed by bead beading at 4,800 rpm for 60 s, then 60 s on 
ice (repeated twice) using a mini-beadbeater-1 (BioSpec Products) and then incubated at 
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95°C for 5 minutes. Subsequent procedures were performed using the QIAGEN 
QIAamp® DNA Stool Kit according to the manufacturer’s protocol, with the exception 
of the last step in which the column was eluted with 120 µl of elution buffer. DNA was 
stored at -20°C until further use. 
A no template PCR control and a DNA extraction kit reagent control were sequenced 
alongside the samples. We observed that the taxon abundances in the controls were 
uncorrelated with the abundances in the experimental samples, and the distance between 
the controls and samples was large. Thus, we conclude that the controls had different 
profiles than that of the milk samples (Figure 3-1). 
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Figure 3-1. Principal components analysis biplot comparing milk samples with 
controls. 
To verify that the microbiota observed in our milk samples was not due to background 
contamination from reagents in either the DNA extraction kit or from the PCR, a no 
template PCR control (“NTC1”) and a tube of PBS that was extracted alongside the milk 
samples (“reagent_control”) were sequenced.  Data presented in the biplot are from 
centered log ratio transformed values. As observed, the controls have a different 
microbial profile than the milk samples. 
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3.2.3 PCR amplification 
The genomic DNA isolated from the clinical samples was amplified using barcoded 
primers that amplify the V6 hypervariable region of the 16S rRNA gene which is 70 base 
pairs long.   
V6-Forward: 
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACC
TTACC 3’ 
V6-Reverse: 
5’CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTnnnn(8)ACRACACGAGCT
GACGAC 3’ 
nnnn indicates 4 randomly incorporated nucleotides and “8” represents a specific sample 
barcode sequence. The PCR was carried out in a 42 µl reaction containing 2 µl of DNA 
template (or nuclease-free water as a negative control), 0.15 µg/µl bovine serum albumin, 
20µl of 2x GoTaq hot start colorless master mix (Promega) and 10µl of each primer 
(initial concentration: 3.2pmol/µl). Thermal cycling was carried out in an Eppendorf 
Mastercyler under the following conditions: initial denaturation at 95°C for 2 minutes 
followed by 25 cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute. 
After amplification, the DNA concentration was measured with the Qubit® 2.0 
Fluorometer (Invitrogen) using the broad range assay. Equimolar amounts of each PCR 
product were then pooled together and purified using the QIAquick PCR purification kit 
(QIAGEN). The pooled PCR purified sample was then paired-end sequenced on the 
Illumina Mi-Seq platform using a 150 cycle kit with a 2x80 run at the London Regional 
Genomics Center, London, Ontario, Canada following standard operating procedures. 
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3.2.4 Sequence processing and taxonomic assignment 
Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded 
reads to individual samples. Multiple layers of filtering were employed: (i) Paired end 
sequences were overlapped with Pandaseq, allowing 0 mismatches in the overlapped 
reads; (ii) Reads were kept if the sequence included a perfect match to the V6 16S rRNA 
gene primers; (iii) Barcodes were 8mers with an edit distance of >4 and reads were kept 
if the sequence were a perfect match to the barcode; (iv) Reads were clustered by 97% 
identity into operational taxonomic units (OTUs) using the Uclust algorithm of 
USEARCH v7 (Edgar, 2010) which has a de novo chimera filter built into it; (v) All 
singleton OTUs were discarded and those that represented ≥1% of the reads in at least 
one sample were kept. 
Taxonomic assignments for each OTU were made by extracting the best hits from the 
SILVA database (Pruesse et al., 2007) and then manually verified using the Ribosomal 
Database Project (RDP) SeqMatch tool (rdp.cme.msu.edu) and by BLAST against the 
Green genes database (greengenes.lbl.gov) Taxonomy was assigned based on hits with 
the highest percentage identities and coverage. If multiple hits fulfilled this criterion, 
classification was re-assigned to a higher common taxonomy. A summary of each OTU 
classification and its sequence is shown in Dataset 3-2. The raw sequencing reads 
generated in this study have been deposited to the NCBI Short Read Archive (SRA) 
database accession # SRP 064311. 
3.2.5 Data analysis  
Weighted and un-weighted UniFrac distances (Lozupone and Knight, 2005) were 
calculated in QIIME (Caporaso et al., 2010) by using a tree of OTU sequences built with 
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FASTTREE (Price et al., 2009) based on an OTU sequence alignment made with  
MUSCLE (Edgar, 2004). The QIIME pipeline was also used to generate principal 
coordinate analysis (PCoA) plots to visualize the Bray-Curtis dissimilarity. Changes in 
the microbial-community composition were also analyzed by calculating the generalized 
UniFrac distance (alpha= 0.5, rooted phylogenetic tree) using the GUniFrac package in 
R, version 3.1.2 (Chen et al., 2012). PERMANOVA was used to test for statistical 
significance between the groups using 10000 permutations (QIIME package). Barplots, 
boxplots, stripcharts, PCoA plots and k-means clustering analysis were all generated in R 
(http://www.R-project.org/). 
The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera, 
class, family and phyla between preterm vs term milk; cesarean vs vaginal deliveries and 
male vs female child. Values reported in this manuscript represent the expected values of 
128 Dirichlet Monte-Carlo instances. A value of zero indicates that organism abundance 
is equal to the geometric mean abundance. Thus, organisms more abundant than the mean 
will have positive values and those less abundant than the mean will have negative 
values. Base 2 was used for the logarithm so differences between values represent fold 
changes. Significance (p<0.05) was based on the Benjamini-Hochberg corrected p-value 
of the Welch’s t test and the Wilcoxon test. 
 Results 3.3
Characterization of the milk microbiota in 39 Canadian women showed high variability 
amongst women (Figure 3-2). Overall, the top 5 most abundant taxa represented in milk 
were Staphylococcus (31%), Enterobacteriaceae (10%), Pseudomonas (17%), 
Streptococcus (5%) and Lactobacillus (3%) (Figure 3-3). While there was variability 
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amongst samples at the genus level, at higher taxonomic levels, profiles were consistent 
amongst women with Proteobacteria and Firmicutes making up the highest proportion of 
phyla in all samples with Actinobacteria and Bacteroidetes also present, but at lower 
levels (Figure 3-4). 
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Figure 3-2. Breast milk microbiota in 39 Canadian women identified by 16S rRNA 
amplicon sequencing. 
The relative abundances of bacterial genera in different human milk samples were 
visualized by bar plots. Each bar represents a subject and each colored box a bacterial 
taxon. The height of a coloured box represents the relative abundance of that organism 
within the sample. Taxa present in less than 2% abundance in a given sample are 
displayed in the “Remaining fraction” at the top of the graph (gray boxes). As shown by 
the bar plots, a variety of bacteria were detected in breast milk. The legend is read from 
bottom to top, with the bottom organism on the legend corresponding to the bottom 
colored box on the bar plot. 
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Figure 3-3. Five most relatively abundant genera in human milk 
Each point on the graph represents a subject, which indicates the percent relative 
abundance of that genus within the sample.  The line represents the mean for all samples 
within the group. 
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Figure 3-4. Percent abundance of bacterial phyla in breast milk identified by 16S 
rRNA amplicon sequencing 
(A) The relative abundances of different phyla in different breast milk samples were 
visualized by bar plots. (B) Box plots of the four phyla identified in breast milk. The box 
signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of the 
samples lie. The black line inside the box represents the median. The whiskers represent 
the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile and the 
highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with open 
circles.  As shown, 4 phyla are represented in breast milk and present in all samples, with 
Proteobacteria and Firmicutes being the most abundant. 
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No differences were detected in microbial profiles based on gestation, mode of delivery 
or gender of the child, using both weighted (Figure 3-5A) and un-weighted UniFrac 
distances (data not shown). The above two matrices, however, assign a large emphasis on 
either rare or highly abundant taxa, so compositional changes that occur in moderately 
abundant lineages may be overlooked (Chen et al., 2012). For this reason, we also 
analyzed the data using generalized UniFrac at an alpha of 0.5, which overcomes this 
problem (Chen et al., 2012). As with weighted UniFrac, no differences were observed 
based on gestation, mode of delivery or gender of the child (Figure 3-5B), but there was 
separation of 13 samples, forming 2 distinct clusters, which could not be explained by 
any of the other metadata that was collected (Figure 3-6). To further confirm the above 
results, we also utilized the Bray-Curtis dissimilarity metric, which does not take into 
account phylogenetic relatedness of the biological community, as does UniFrac. As 
expected, no differences were observed (data not shown). 
The dataset was also analyzed using ALDEx2 to examine whether specific taxa were 
differentially expressed based on gestation, mode of delivery or gender. Again, no 
differences were detected at the genus (Dataset 3-3), family, class or phyla levels (data 
not shown). 
Of interest, the abundance profiles clearly showed that mothers are transmitting very 
different bacterial profiles to newborns. For example, the milk of subject 40 contained 
over 80% abundance of staphylococci, whereas that of subject 25 comprised mostly 
Gram negative organisms, especially Pseudomonas. 
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Figure 3-5.  Principal coordinate (PCoA) plots comparing bacterial profiles based 
on gestation, mode of delivery and gender 
PCoA plots based on (A) weighted UniFrac distances or (B) generalized UniFrac 
distances at alpha 0.5.  Each sample, represented by a coloured circle, is plotted on this 
two-dimensional, 2 axis plane with the first 2 components plotted. Samples (points) that 
cluster together are more similar in biota composition and abundance.  As shown by the 
plot, the lack of distinct clustering between groups, for Gestation (1st row), mode of 
delivery (2nd row) and gender (3rd row), indicate that no bacterial differences exist 
between pre-term vs term samples, cesarean vs vaginal delivery samples and male vs 
female samples. PERMANOVA (p<0.5). P_ex=extremely pre-mature (gestation <28 
weeks); P_very=very pre-mature (gestation 29-32wks); P_late=late pre-mature (gestation 
33-36wks); T=Term (gestation >37wks). “c_E”= elective cesarean delivery; “c_NE”= 
non-elective c-section; “v”=vaginal delivery. “m”= male child; “f”= female child; 
“m_tw”= twins both male; “f_tw”= twins both female; “Twin”= male and female twins. 
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Figure 3-6.  Principal coordinate analysis based on generalized UniFrac distances. 
Each sample, represented by a coloured circle, is plotted on this two-dimensional, 2 axis 
plane with the first 2 components plotted. Samples (points) that cluster together are more 
similar in biota composition and abundance.  GUniFrac, using an alpha of 0.5 (which is 
more sensitive to changes in moderately abundant taxa), was used to compare microbial 
profiles based on gestation, mode of delivery and gender. While no differences were seen 
based on these conditions, there were 3 distinct groups, which could not be explained by 
any of the metadata collected (Dataset 3-1). The number of clusters was determined using 
the k-means clustering analysis in R. 
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 Discussion 3.4
This study revealed a range of bacterial genera in human milk, consistent with previous 
studies (Hunt et al., 2011; Jost et al., 2013; Urbaniak et al., 2012). Interestingly, even 
when a baby was born extremely prematurely (subject S24), the mother’s milk was 
similar in composition to that of a woman giving birth at full term (subject S30). It can be 
speculated that this might be a failsafe mechanism whereby the mother is 'ready' to pass 
along her bacterial imprint irrespective of when the baby is born. If so, the microbiota 
would appear to be recalcitrant to late pregnancy hormonal and inflammatory changes, 
which could indicate an evolutionary pressure protecting this niche for the baby's benefit. 
Further studies on this concept are warranted, and cases where the milk profiles are very 
different or the outcome for the baby negative, could be particularly insightful. 
It was not surprising that milk from emergency C section deliveries (i.e. non-elective) did 
not differ from women who gave birth vaginally, as this decision is made at the time of 
labour, when the hormones and timing for birth have been initiated. We also did not see 
differences between non-elective C section deliveries and vaginal births which is in 
contrast to a study published by Cabrera-Rubio et al. in which they concluded that the 
human milk microbiome is shaped by mode of delivery (Cabrera-Rubio et al., 2012). 
However, we do not believe that the authors adequately proved this claim. In their 
analysis the milk samples collected were from both obese and normal weight women 
with no indication of the proportion in each group. Since it was shown in that same paper 
that body mass index influences the milk microbiota, the subject’s weight could have 
been a confounding factor responsible for the observed differences. In addition, the 
author’s claim that the milk microbiota is influenced by mode of delivery was based 
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solely on visual observations of barplots (that were not very distinct between the two 
groups), with no PCoA plots or statistical analyses to support this claim. These 
conflicting results between our group and that of Cabrera-Rubio highlights the need for 
future studies with larger sample sizes and inclusion of women from various 
demographics. 
Because of the multivariate nature of the data, differences, if they are present, may have 
been masked by the different variables confounding each other. Thus a larger sample size 
allowing for linear regression analysis would strengthen our claims.  However there is the 
possibility that no matter the sample size, differences will only be apparent when 
examined at the level of the individual. Schwarzberg et al. showed that treatment for 
periodontitis had no effects on microbial profiles when compared to controls.  However, 
when pre and post treatment effects for each individual were compared, significant 
changes in bacterial composition was observed. The authors thus emphasized the 
importance of comparing shifts from a personalized healthy state to a personalized 
disease state in order to truly understand biological changes (Schwarzberg et al., 2014). 
Proteobacteria and Firmicutes were the dominant phyla, consistent with a previous high-
throughput study performed in Switzerland and analyzed with a different sequencing 
platform (454 sequencing) (Jost et al., 2013). The detection of Staphylococcus, as the 
most abundant organism, is likewise consistent with other studies (Hunt et al., 2011; Jost 
et al., 2013; Urbaniak et al., 2012). Staphylococcus is more abundant in the gut of breast 
fed newborns compared to formula fed ones (Balmer and Wharton, 1989; Lundequist et 
al., 1985) but their numbers start to decrease after the first week of life when oxygen has 
been consumed and an environment favourable for anaerobes is created (Adlerberth, 
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2008; Jost et al., 2012). Unlike Staphylococcus, which is present in high abundance in at 
least the first week of life, Proteobacteria are never found in high numbers in the feces of 
newborns, infants or Western adults (Human Microbiome Project Consortium, 2012; Jost 
et al., 2012; Koenig et al., 2011) Thus, an important question arises, as to what the 
evolutionary significance is of having such a diverse population of bacteria in milk, if 
only a select few seem to colonize during the development of the neonate. There are a 
few possibilities; firstly, persistent colonization is not always needed for beneficial 
effects, as transient exposure can be just as effective (Gan et al., 2014; Hapfelmeier et al., 
2010). Secondly, bacteria in milk may not have to be passed on from mother to child to 
exert their beneficial effects. Many of the protective factors in milk such as antibodies, 
immune cells, lactoferrin and beta-defensins originate from the mammary gland and not 
from the blood (Tunzi et al., 2000). With the ability of bacteria to regulate host gene 
expression, such as anti-microbials, and their ability to stimulate the immune system, the 
plethora of bacteria in breast milk could be inducing up regulation of these protective 
factors in the breast that then get passed on in high concentrations to the neonate via 
milk. 
From another perspective, there is the possibility that some of these milk microbes have 
either limited or no effects on the offspring but are present for the benefit of the mother, 
such as in the protection against mastitis. Mastitis is a painful inflammatory condition of 
the breast with the main causative agent being Staphylococcus aureus and it has been 
shown that some milk commensals have the ability to prevent S. aureus growth and 
infection (Heikkila and Saris, 2003). The same is true for a skin derived strain of 
Propionibacterium acnes, which prevents growth of S.aureus via its byproducts of 
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glycerol fermentation (Shu et al., 2013). With the high abundance of glycerol present in 
milk, milk derived strains of Propionibacterium may have similar growth inhibiting 
properties, which would account for its presence in every milk sample collected. 
Lactobacillus was present in high abundance in milk, so for those women who deliver by 
C section and thus do not transfer lactobacilli from the vagina to the infant, the milk 
could provide a means for these beneficial organisms to reach the infant gut. 
 Conclusion 3.5
A diverse population of bacteria is present in breast milk dominated by the phyla 
Proteobacteria and Firmicutes and the taxa Staphylococcus, Pseudomonas, 
Enterobacteriaceae, Streptococcus and Lactobacillus. While no differences in microbial 
profiles were apparent based on gestation, mode of delivery or gender, more studies are 
still needed on what factors do influence bacterial communities in milk and how these 
changes impact neonatal and maternal health. 
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Chapter 4  
4 Microbiota of human breast tissue 
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Supporting Datasets 4-1 (clinical metadata) and 4-2 (taxonomic classification of OTU 
sequences) are available for download online as additional excel files 
 
 Introduction 4.1
The human body is home to a large and diverse population of bacteria with properties 
that are both harmful and beneficial to our health (Bäckhed, 2012; Hooper, 2004; Human 
Microbiome Project Consortium, 2012; Macpherson and Harris, 2004; Serino et al., 
2009; Zhu et al., 2013) and for this reason there has been a strong push in recent years to 
fully characterize the bacteria associated with different parts of the body under different 
health conditions. These studies have been made possible with the use of deep 
sequencing technologies and sites once thought of as sterile, such as the stomach, bladder 
and lungs have now been shown to harbour an indigenous microbiota (Beck et al., 2012; 
Bik et al., 2006; Wolfe et al., 2012). We hypothesized that microbes may also be present 
in breast tissue given the known presence of bacteria in human milk (Urbaniak et al., 
2012). This is not surprising considering that skin and oral bacteria have access to the 
mammary ducts through the nipple (Ramsay et al., 2004) with some recent studies 
suggesting their source to be from the mother’s gastrointestinal tract (Donnet-Hughes et 
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al., 2010). We rationalized that given the nutrient rich fatty composition of the female 
breast, the widespread vasculature and lymphatics, and the diffuse location of the lobules 
and ducts leading from the nipple, bacteria would be widespread within the mammary 
glands, irrespective of lactation. Thus, the objective of the study was to determine, using 
culture and non-culture methods, whether breast tissue contains a microbiome. To ensure 
that the results obtained were not an artifact of a single demographic, tissue was collected 
and processed from two distant countries, Canada and Ireland. 
 Materials and Methods 4.2
4.2.1 Clinical samples and study design (Canadian samples) 
Ethical approval for this study was obtained from Western Research Ethics Board and 
Lawson Health Research Institute, London, Ontario, Canada. Patients provided written 
consent for sample collection and subsequent analyses. 
4.2.1.1 Tissue collection and processing 
Breast tissue was collected from 43 women (aged 18-90) undergoing breast surgery at St. 
Joseph’s Hospital in London, Ontario, Canada. Thirty-eight of those women underwent 
lumpectomies or mastectomies for either benign (n=11) or cancerous (n=27) tumours and 
5 women underwent breast reductions and had no history of breast cancer. For those 
women with tumours, the tissue obtained for analysis was collected outside of the 
marginal zone, approximately 5cm away from the tumour. After excision, the fresh tissue 
was immediately placed in a sterile vial on ice and homogenized within 30 min of 
collection. As an environmental control, a tube filled with sterile phosphate buffered 
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saline (PBS) was left open for the duration of the surgical procedure and then processed 
in parallel with the tissue samples. 
Tissue samples were homogenized in sterile PBS using a PolyTron 2100 homogenizer at 
28000 rpm. The amount of PBS added was based on the weight of the tissue in order to 
obtain a final concentration of 0.4g/ml. Fresh homogenate and the environmental controls 
were then plated on different agar plates for culture analysis and the remaining amount 
aliquoted and stored at -80oC until DNA extraction. 
4.2.1.2 DNA isolation 
After tissue homogenates were thawed on ice, 400µl (equivalent to 160mg of tissue) were 
added to tubes containing 1.2ml of ASL buffer (QIAamp® DNA Stool Kit, Qiagen) and 
400mg of 0.1mm diameter zirconium-glass beads (BioSpec Products). Mechanical and 
chemical lyses were performed by bead beading at 4800rpm for 60s, then 60s on ice 
(repeated twice) (mini-beadbeater-1, BioSpec Products) and then incubated at 95oC for 
5min. Subsequent procedures were performed using the Qiagen QIAamp® DNA Stool 
Kit according to the manufacturer’s protocol, with the exception of the last step in which 
the column was eluted with 120µl of elution buffer. DNA was stored at -20oC until 
further use. 
4.2.2 Clinical samples and study design (Irish samples) 
Ethical approval for this study was obtained from University College Cork Clinical 
Research Committee. Patients provided written consent for sample collection and 
subsequent analyses.  
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4.2.2.1 Tissue collection and DNA isolation 
Breast tissue was collected from 38 women (aged 20-85) undergoing breast surgery at 
Cork University Hospital or South Infirmary Victoria Hospital, Cork, Ireland. Thirty-
three women underwent lumpectomies or mastectomies for cancerous tumours (taken at 
least 5cm away from the primary tumour site) while 5 women underwent breast 
reductions and had no history of breast cancer. Once collected the specimens were placed 
in sterile cryotubes and flash frozen in liquid nitrogen within 45 minutes of collection and 
then stored at -800C until DNA extraction. 
Tissue samples were thawed on ice and the genomic DNA extracted using the Gene-Elute 
Mammalian Genomic DNA miniprep kit (Sigma-Aldrich) as per the manufacturer’s 
protocol with the exception of the elution step, where the column was eluted with 70µl of 
elution buffer. 
4.2.3 Ion Torrent V6 16S rRNA sequencing 
4.2.3.1 PCR amplification 
At the Canadian lab, the genomic DNA isolated from Canadian and Irish clinical samples 
was amplified using the barcoded primers V6-LT and V6-RT (see section 2.2.4.1 for 
primer sequence), which amplify the V6 hypervariable region of the 16S rRNA gene. The 
PCR was carried out in a 40µl reaction containing 5µl of DNA template (or nuclease free 
water as a negative control), 1.5mM MgCl2, 0.8µM of each primer, 4µl of 10x PCR 
Buffer (Invitrogen), 0.2mM dNTPs, 0.05U Taq Polymerase (Invitrogen) and 0.15µg/µl of 
bovine serum albumin. Thermal cycling was carried out in an Eppendorf Mastercyler 
under the following conditions: Initial denaturation at 95oC for 2min followed by 25 
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cycles of 95oC for 1min, 55oC for 1min and 72oC for 1min. After amplification, the DNA 
concentration was measured with the Qubit® 2.0 Fluorometer (Invitrogen) using the 
broad range assay. Equimolar amounts of each PCR product were then pooled together 
and purified using the QIAquick PCR purification kit (Qiagen). The PCR purified sample 
was then sent to the London Regional Genomics Center, London, Ontario, Canada for V6 
16S rRNA sequencing using the Ion Torrent platform as per the Center’s standard 
operating procedure. 
4.2.3.2 Sequence processing and taxonomic assignment  
Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded 
reads to individual samples. Reads were kept if the sequence included a perfect match to 
the barcode and the V6 16S rRNA gene primers and were within the length expected for 
the V6 variable region. Samples with more than 600 reads were kept while those with 
less than 600 were discarded. Reads were then clustered by 97% identity into Operational 
Taxonomic Units (OTUs) using UClust v. 3.0.617 (Edgar, 2010). OTUs that represented 
≥2% of the reads in at least one sample were kept, while those that did not meet the cut-
off were discarded to account for the high error rate intrinsic to Ion Torrent sequencing. 
Taxonomic assignments for each OTU were made by the Ribosomal database project 
(RDP) SeqMatch tool (Cole et al., 2009). From the top 20 matches to the RDP named 
isolates database, the full taxonomy was retained for matches with the highest S_ab 
score. For multiple top matches with equal scores, the highest common taxonomy was 
retained (e.g. genus level if multiple species matched equally well). Since the maximum 
number of matches displayed per sequence is 20, the RDP taxonomic assignments were 
verified by BLAST against the Greengenes named isolates database with an output of 
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100 hits (DeSantis et al., 2006). Taxonomy was assigned based on hits with the highest % 
identities and coverage. If multiple hits fulfilled this criterion, classification was re-
assigned to a higher common taxonomy. In instances where the highest % 
identity/coverage yielded a single match, if this were less than 90% and the S_ab score 
from RDP was less than 0.7, taxonomy was assigned at the Family level instead of at the 
Genus level.  
4.2.3.3 Data analysis 
The QIIME pipeline (Caporaso et al., 2010) was used to (i) calculate weighted UniFrac 
distances and Shannon’s diversity index (logarithms with base 2); (ii) summarize OTUs 
by different taxonomic levels and (iii) generate Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) trees representing hierarchical clustering of samples. The 
UniFrac distances were calculated by using a phylogenetic tree of OTU sequences built 
with FastTree (Price et al., 2009) and based on an OTU sequence alignment with 
MUSCLE (Edgar, 2004). Weighted UniFrac compares microbial profiles 
(presence/absence and abundance) between samples (i.e. beta-diversity) (Lozupone and 
Knight, 2005) while Shannon’s diversity index evaluates the microbial diversity within a 
sample (i.e. alpha diversity). The higher the Shannon’s diversity index, the more diverse 
a sample is and a value of zero indicates the presence of only one species (Hill et al., 
2003). UPGMA trees allows one to visualize the distance matrix and the robustness of 
what was observed was tested with jackknifing and bootstrapping. For beta-diversity 
analyses, the data set was rarified to the lowest read count/sample. Barplots, boxplots and 
stripcharts were all generated in R (http://www.R-project.org/). 
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4.2.4 Culture analysis 
In an effort to prove that bacteria in the breast were viable, 100µl of Canadian tissue 
homogenate from each of the 43 samples and 100µl of each environmental control were 
plated on Columbia blood agar (CBA) plates and incubated aerobically or anaerobically 
at 37oC. Of note, the facilities to perform culture were not available at the Irish site. DNA 
from single colonies was extracted using the InstaGene Matrix (Bio-Rad) and then 
amplified using the eubacterial primers pA/pH, which amplify the 16S rRNA gene: 
pA 5’ AGAGTTTGATCCTGGCTCAG 3’  pH 5’ AAGGAGGTGATCCAGCCGCA 3’ 
The PCR reaction was carried out in 50µl reaction containing 10µl of DNA template (or 
nuclease free water as a negative control), 1.5mM MgCl2, 1.0µM of each primer, 0.2mM 
dNTP, 5µl 10X PCR buffer (Invitrogen), and 0.05 Taq Polymerase (Invitrogen). Thermal 
cycling was carried out in an Eppendorf Mastercycler under the following conditions: 
Initial denaturation step at 95oC for 2min, followed by 30 cycles of 94oC for 30s, 55oC 
for 30s and 72oC for 1min. A final elongation step was performed at 72oC for 10min. 
After running 10µl of the PCR mixture on a 1% agarose gel to verify the presence of 
amplicons, 40µl of the PCR mixture was then purified using the QIAquick PCR 
purification kit (Qiagen). The purified PCR products were then sent for Sanger 
sequencing to the London Regional Genomics Centre, London, Ontario, Canada. 
Sequences were analyzed using the GenBank 16S ribosomal RNA sequences database 
using the BLAST algorithm (Altschul et al., 1990). Taxonomy was assigned based on the 
highest Max score. 
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4.2.5 Statistical analysis 
Statistical analysis was performed in R using the Kruskal-Wallis one-way analysis of 
variance followed by the Mann-Whitney U test with Bonferroni correction. 
 Results 4.3
Tissue was obtained from various locations within the breast, from close to the nipple to 
as far back as the chest wall (Figure 4-1). Regardless of location sampled within the 
breast, presence/absence of breast malignancy, country of origin, age, history of 
pregnancy and method of DNA preparation, a variety of bacteria were detected in breast 
tissue (Figure 4-2, Figure 4-3 and Dataset 4-1). Bacterial diversity within samples varied 
between individuals with Shannon’s diversity indices ranging from 0.8-5.2, with an 
average value of 3.6 (Figure 4-4). To put into perspective, using the same index, oral and 
gut samples, known for their diverse bacterial communities have values between 3.9-6.5 
(Bik et al., 2010; Dethlefsen and Relman, 2011; Dethlefsen et al., 2008; Li et al., 2012), 
while vaginal samples of low bacterial diversity, generate values between 0.46-2.9 (Kim 
et al., 2009; Oakley et al., 2008; Ravel et al., 2011). 
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Figure 4-1.  Location within the breast of tissue samples collected for analysis  
Tissue samples were collected from 43 women from London, Canada and 38 women 
from Cork, Ireland undergoing different breast surgeries. (A) and (B) Location of tissue 
collected from women in Canada undergoing lumpectomies or mastectomies for either 
malignant “LN” (A) or benign “LNb” (B) tumours. (C) Location of tissue collected from 
women in Ireland undergoing lumpectomies or mastectomies for malignant tumours 
“CN”. Blue ovals represent the location of the tumour and purple squares represent the 
location of the specimen obtained for bacterial analysis. The distance between the blue 
ovals and purple squares are approximate estimates of the distance between the tumour 
and the specimen, which was at least 5cm away from the tumour. (D) Location of tissue 
collected from women in both Canada and Ireland undergoing breast reduction surgery, 
“LH” and “CH” respectively.  Asterisks in the purple boxes underneath the subject 
number indicate samples from Ireland. All samples were a minimum of 1cm deep to the 
skin with the surgeons aiming for mid-deep rather than superficial. As shown in the 
diagram, specimens were obtained from a variety of locations within the breast. 
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Figure 4-2. Breast tissue microbiota in 43 Canadian women identified by 16S rRNA 
sequencing 
The relative abundance of bacterial taxa identified in different tissue samples was 
visualized by bar plots. Each bar represents a subject and each coloured box, a bacterial 
taxa.  The height of the coloured boxes represents the relative abundance of that organism 
within the sample. For example, sample L42H is dominated by Acinetobacter whereas 
L19Nb is dominated by Micrococcus. Taxa present in less than 2% abundance in a given 
sample are displayed in the “Remaining fraction” at the top of the graph (grey boxes). As 
shown by the barplots, a variety of bacteria were detected in breast tissue. NB: The 
legend is read from bottom to top, as indicated by the red arrow, with the bottom 
organism on the legend, corresponding to the bottom coloured box on the barplot. “LH”= 
Tissue collected from women undergoing breast reductions; “LN”= Non-malignant tissue 
collected adjacent to cancerous tumours; “LNb”= Non-malignant tissue collected 
adjacent to benign tumours. 
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Figure 4-3.  Breast tissue microbiota in 38 Irish women identified by 16S rRNA 
sequencing  
The relative abundance of bacterial taxa identified in different tissue samples was 
visualized by bar plots. Each bar represents a subject and each coloured box, a bacterial 
taxa. The height of the coloured boxes represents the relative abundance of that organism 
within the sample. For example, sample C40H is dominated by Janibacter whereas C36N 
is dominated by Enterobacteraceae. Taxa present in less than 2% abundance in a given 
sample are displayed in the “Remaining fraction” at the top of the graph (grey boxes). As 
shown by the barplots, a variety of bacteria were detected in breast tissue. NB: The 
legend is read from bottom to top, as indicated by the red arrow, with the bottom 
organism on the legend, corresponding to the bottom coloured box on the barplot. “CH”= 
Tissue collected from women undergoing breast reductions; “CN”= Non-malignant tissue 
collected adjacent to cancerous tumours 
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Figure 4-4. Bacterial diversity of the breast tissue microbiota 
Bacterial diversity within a sample (i.e. alpha diversity) was measured by calculating 
Shannon’s diversity index. Each point on the graph represents a subject with the line 
representing the mean for all samples. The higher the index, the greater the bacterial 
diversity found within a sample. Since Shannon’s diversity index is a logarithmic number 
with a base of 2, a value of “4” is 2x higher than a value of “3”. The mean value for the 
Canadian samples was 3.9 (N=43) and for the Irish samples, 3.3 (N=33).  
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Fig. S1.  Bacterial diversity of the breast microbiota.  Bacterial diversity within a sample (i.e. 
alpha diversity) was measured by calculating Shannon’s diversity index. Each point on the graph 
represents a subject with the line representing the mean for all samples. The higher the index the 
greater the bacterial diversity found within a sample.  Since Shannon’s diversity index is a 
logarithmic number with a base of 2, a value of “4” is 2x higher than a value of “3”.  The mean 
value for the London samples was 3.9 (n=43) and for the Irish samples, 3.3 (n=33).  
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The bacteria identified in tissue were grouped into 121 operational taxonomic units 
(OTUs) based on 97% sequence similarity (Dataset 4-2). These OTUs belonged to 7 
different phyla; Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Deinococcus-
Thermus, Verrucomicrobia and Fusobacteria with Proteobacteria being the most 
abundant phylum followed by Firmicutes (specifically from the class Bacilli) (Figure 4-
5). Of the 121 OTUs identified, 57 could be classified at the genus level and 25 at the 
species level (Dataset 4-2). The most abundant taxa in the Canadian samples were 
Bacillus (11.4%), Acinetobacter (10.0%), unclassified Enterobacteriaceae (8.3%), 
Pseudomonas (6.5%), Staphylococcus (6.5%), Propionibacterium (5.8%), unclassified 
Comamonadaceae (5.7%), unclassified Gammaproteobacteria (5.0%) and Prevotella 
(5.0%). In the Irish samples the most abundant taxa were unclassified Enterobacteriaceae 
(30.8%), Staphylococcus (12.7%), Listeria welshimeri (12.1%), Propionibacterium 
(10.1%) and Pseudomonas (5.3%). 
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Figure 4-5. Percent abundance of different bacterial phyla in breast tissue identified 
by 16S rRNA sequencing  
(A) Boxplots of the seven different phyla identified in breast tissue from the Canadian 
and Irish samples. The box signifies the 75% (upper) and 25% (lower) quartiles and thus 
shows where 50% of the samples lie. The black line inside the box represents the median.  
The whiskers represent the lowest datum still within 1.5 IQR of the lower quartile and the 
highest datum still within 1.5 IQR of the upper quartile (IQR= interquartile range).  
Outliers are shown with open circles. (B) The least abundant phyla shown in (A) were 
plotted on another graph with a smaller scale to allow for better visualization of 
percentage. In samples from both countries Proteobacteria was the most abundant phyla 
followed by Firmicutes (Kruskal-Wallis/Mann-Whitney U with Bonferroni correction, p 
≤ 0.001). 
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Of the 30 environmental controls (i.e. PBS tube processed in parallel with tissue sample) 
sequenced on the Ion Torrent platform, 12 of them were discarded due to low read counts 
(<600 reads). Of the remaining 18 controls that passed quality control filtering, 13 of 
them had lower read counts than their respective tissue samples. Of the 6 with higher read 
counts, weighted UniFrac UPGMA hierarchical clustering showed that microbial profiles 
differed between the control and its respective tissue sample (Figure 4-6).  
Bacteria were able to be cultured from all 43 of the Canadian samples (culture analysis 
was not performed on the Irish samples) with amounts ranging from 75-2000 cfu/gram of 
tissue, depending on the sample. Collectively, eight different strains were identified: 
Bacillus sp, Micrococcus luteus, Propionibacterium acnes, Propionibacterium 
granulosum, Staphylococcus sp, Staphylococcus saprophyticus, Streptococcus oralis, 
Streptococcus agalactiae.  No bacteria were isolated from any of the 43 environmental 
controls. 
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Figure 4-6. UPGMA hierarchical clustering comparing Canadian tissue samples 
with their respective environmental controls  
UPGMA hierarchical clustering translates the UniFrac weighted distances into a rooted 
tree. Samples that cluster together are more similar in bacterial profiles (presence and 
abundance) than those that are farther apart on the tree. Jackknifing and bootstrapping 
were performed to measure the robustness of these observations. The red coloured 
internal nodes provide strong support (75-100%) for similarities or differences between 
samples. The horizontal scale bar at the bottom indicates 1% sample divergence. As 
shown above, there is strong support that the bacterial profile between a tissue sample 
and its respective environmental control is distinct. Reads were rarified to 475 
reads/sample. “E”= environmental control and “N”= tissue sample. 
 
 
 
 
Fig. S2. UPGMA hierarchical clustering comparing Canadian tissue samples with their 
respective environmental controls.  UPGMA hierarchical clustering translates the UniFrac 
weighted distances into a rooted tree.  Samples that cluster together are more similar in bacterial 
profiles (presence and abundance) than those that are farther apart on the tree.  Jackknifing and 
bootstrapping were performed to measure the robustness of these observations.  The red coloured 
internal nodes provide strong support (75-100%) for similarities or differences between samples.  
The horizontal scal  bar at the bottom indicates 1% sa p e divergence.  As shown abov , there 
is strong support that the bacterial profile between a tissue sample and its respective 
environmental control is distinct.   Reads were rarified to 475 reads/sample. “E”= environmental 
control and “N”= tissue sample. 
113 
 
 Discussion 4.4
We first suggested the potential for a breast microbiome in 2012 (Urbaniak et al., 2012), 
and this has now been confirmed in the present study, and recently by Xuan et al who 
examined breast tumor and normal adjacent tissue also using next-generation sequencing 
techniques (Xuan et al., 2014). In our study, none of the 81 women recruited had any 
clinical signs or symptoms of breast infection, yet bacteria were still detected in all 
Canadian samples analyzed, by both culture and molecular techniques and the Irish 
samples which were analyzed by just molecular techniques. While only 8 different strains 
were able to be cultured, we just used Columbia Blood Agar to isolate bacteria, and some 
fastidious bacteria such as Prevotella and Bacteroides, require more nutrient rich 
conditions for growth. Regardless, all those bacteria that were cultured were also detected 
by 16S rRNA sequencing, supporting the argument that the DNA amplimers are from 
viable bacteria and not solely from remnant bacterial DNA. 
Proteobacteria was the most abundant phylum in breast tissue, unlike in the vagina, oral 
cavity, bladder, skin and gastrointestinal tract where they make up only a small 
proportion of the overall bacterial community (Dewhirst et al., 2010; Grice et al., 2009; 
Human Microbiome Project Consortium, 2012; Hummelen et al., 2010; Wade, 2013; 
Wolfe et al., 2012). This finding is similar to what was observed in Xuan et al., and 
suggests that breast tissue may have a unique microbiota, distinct from that found at other 
body sites, which is consistent with published studies showing that bacterial communities 
vary across body habitats (Costello et al., 2009; Human Microbiome Project Consortium, 
2012). The higher abundance of Proteobacteria and Firmicutes (specifically the class 
Bacilli) compared with other taxonomic groups may be a result of host-microbial 
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adaptation to the fatty acid environment in the tissue. A recent study documented a 
positive correlation between Proteobacteria and Bacilli and the metabolic byproducts of 
fatty acid metabolism, as well host derived genes involved in fatty acid biosynthesis (El 
Aidy et al., 2013). It has also been documented that wild-type mice fed a high fat diet 
have a gut microbiota enriched in Firmicutes (Murphy et al., 2010). Of interest, 
Proteobacteria is also the principal phylum in human milk (Ward et al., 2013) with many 
of the same bacteria we detected in tissue, raising the possibility that the tissue 
microbiota could be a source of bacterial inocula for babies. 
Some of the organisms detected in breast tissue have been found at other body sites, such 
as Lactobacillus iners and Prevotella (vagina), Enterobacteriaceae (gastrointestinal 
tract), Fusobacterium and Streptococcus (oral cavity), Propionibacterium and 
Micrococcus (skin) and Pseudomonas (respiratory tract). Species known for their health-
conferring properties, such as Lactobacillus and Bifidobacterium were detected as well as 
taxa known for pathogenesis at other sites, such as Enterobacteriaceae, Pseudomonas 
and Streptococcus agalactiae. We can only speculate why potentially pathogenic bacteria 
do not multiply and induce infections. One concept has been proposed that it is due to a 
host microbial sensory system aligned with antibacterial gene expression (Xuan et al., 
2014). 
Of interest, in the Xuan study, differential abundance was observed with the genera 
Sphingomonas and Methylbacterium between paired normal and tumour tissue, with the 
authors suggesting a potential role in tumour development. While we also detected these 
two genera in our tissue samples, further studies, with a larger sample size of healthy 
women, would be needed to determine whether differential abundance between healthy 
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and normal adjacent tissue also exists. While a comparison between tissue form cancer 
patients and healthy women was not the focus of this paper, we did notice a higher 
abundance of E.coli in women with cancer compared to healthy controls, with this 
species known for its cancer promoting activity (Davis et al., 1991). However, it is 
premature to suggest cause and effect until more work is done in this area. 
One limitation of the study was the inability to make direct comparisons between the two 
countries due to the different collection and DNA extraction techniques used. Thus no 
claims can be made as to whether bacteria detected at one site differ significantly from 
the other. 
This research shows that breast tissue is not sterile but contains a diverse community of 
bacteria, adding to the literature that body sites once believed to be sterile do indeed have 
an endogenous microbiome. It has been proposed that the breast microbiome contributes 
to maintenance of healthy breast tissue by stimulating resident immune cells (Xuan et al., 
2014), but the type of bacteria and their metabolic activity, such as ability to degrade 
carcinogens, may also contribute. Further studies are warranted to determine how this 
breast microbiome is established, why no infections accompanied colonization, what 
impact these organisms have on the host and whether external factors such as diet, 
antibiotics and illness affect this bacterial community and the subsequent consequences 
for the woman. 
 
116 
 
 References 4.5
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local 
alignment search tool. J. Mol. Biol. 215, 403–410. 
 
Bäckhed, F. (2012). Host responses to the human microbiome. Nutr. Rev. 70, S14–S17. 
 
Beck, J.M., Young, V.B., and Huffnagle, G.B. (2012). The microbiome of the lung. 
Transl. Res. 160, 258–266. 
 
Bik, E.M., Eckburg, P.B., Gill, S.R., Nelson, K.E., Purdom, E.A., Francois, F., Perez-
Perez, G., Blaser, M.J., and Relman, D.A. (2006). Molecular analysis of the bacterial 
microbiota in the human stomach. Proc. Natl. Acad. Sci. 103, 732–737. 
 
Bik, E.M., Long, C.D., Armitage, G.C., Loomer, P., Emerson, J., Mongodin, E.F., 
Nelson, K.E., Gill, S.R., Fraser-Liggett, C.M., and Relman, D.A. (2010). Bacterial 
diversity in the oral cavity of 10 healthy individuals. ISME J. 4, 962–974. 
 
Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, 
E.K., Fierer, N., Peña, A.G., Goodrich, J.K., Gordon, J.I., et al. (2010). QIIME allows 
analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336. 
 
Cole, J.R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R.J., Kulam-Syed-
Mohideen, A.S., McGarrell, D.M., Marsh, T., Garrity, G.M., et al. (2009). The 
Ribosomal Database Project: improved alignments and new tools for rRNA analysis. 
Nucleic Acids Res. 37, D141–D145. 
Costello, E.K., Lauber, C.L., Hamady, M., Fierer, N., Gordon, J.I., and Knight, R. (2009). 
Bacterial community variation in human body habitats across space and time. Science 
326, 1694–1697. 
 
Davis, C.P., Cohen, M.S., Hackett, R.L., Anderson, M.D., and Warren, M.M. (1991). 
Urothelial hyperplasia and neoplasia. III. Detection of nitrosamine production with 
different bacterial genera in chronic urinary tract infections of rats. J. Urol. 145, 875–880. 
 
DeSantis, T.Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E.L., Keller, K., Huber, T., 
Dalevi, D., Hu, P., and Andersen, G.L. (2006). Greengenes, a chimera-checked 16S 
rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 
72, 5069–5072. 
 
Dethlefsen, L., and Relman, D.A. (2011). Incomplete recovery and individualized 
responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. 
Natl. Acad. Sci. 108, 4554–4561. 
 
Dethlefsen, L., Huse, S., Sogin, M.L., and Relman, D.A. (2008). The pervasive effects of 
an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. 
PLoS Biol. 6, e280. 
 
117 
 
Dewhirst, F.E., Chen, T., Izard, J., Paster, B.J., Tanner, A.C.R., Yu, W.-H., Lakshmanan, 
A., and Wade, W.G. (2010). The human oral microbiome. J. Bacteriol. 192, 5002–5017. 
Donnet-Hughes, A., Perez, P.F., Doré, J., Leclerc, M., Levenez, F., Benyacoub, J., 
Serrant, P., Segura-Roggero, I., and Schiffrin, E.J. (2010). Potential role of the intestinal 
microbiota of the mother in neonatal immune education. Proc. Nutr. Soc. 69, 407–415. 
 
Edgar, R.C. (2004). MUSCLE: a multiple sequence alignment method with reduced time 
and space complexity. BMC Bioinformatics 5, 113. 
 
Edgar, R.C. (2010). Search and clustering orders of magnitude faster than BLAST. 
Bioinformatics 26, 2460–2461. 
 
El Aidy, S., Derrien, M., Merrifield, C.A., Levenez, F., Doré, J., Boekschoten, M. V, 
Dekker, J., Holmes, E., Zoetendal, E.G., van Baarlen, P., et al. (2013). Gut bacteria-host 
metabolic interplay during conventionalisation of the mouse germfree colon. ISME J. 7, 
743–755. 
 
Grice, E.A., Kong, H.H., Conlan, S., Deming, C.B., Davis, J., Young, A.C., Bouffard, 
G.G., Blakesley, R.W., Murray, P.R., Green, E.D., et al. (2009). Topographical and 
temporal diversity of the human skin microbiome. Science 324, 1190–1192. 
 
Hill, T.C.J., Walsh, K.A., Harris, J.A., and Moffett, B.F. (2003). Using ecological 
diversity measures with bacterial communities. FEMS Microbiol. Ecol. 43, 1–11. 
 
Hooper, L. V (2004). Bacterial contributions to mammalian gut development. Trends 
Microbiol. 12, 129–134. 
 
Human Microbiome Project Consortium (2012). Structure, function and diversity of the 
healthy human microbiome. Nature 486, 207–214. 
 
Hummelen, R., Fernandes, A.D., Macklaim, J.M., Dickson, R.J., Changalucha, J., Gloor, 
G.B., and Reid, G. (2010). Deep sequencing of the vaginal microbiota of women with 
HIV. PLoS One 5, e12078. 
 
Kim, T.K., Thomas, S.M., Ho, M., Sharma, S., Reich, C.I., Frank, J.A., Yeater, K.M., 
Biggs, D.R., Nakamura, N., Stumpf, R., et al. (2009). Heterogeneity of vaginal microbial 
communities within individuals. J. Clin. Microbiol. 47, 1181–1189. 
 
Li, K., Bihan, M., Yooseph, S., and Methé, B.A. (2012). Analyses of the microbial 
diversity across the human microbiome. PLoS One 7, e32118. 
 
Lozupone, C., and Knight, R. (2005). UniFrac: a new phylogenetic method for comparing 
microbial communities. Appl. Environ. Microbiol. 71, 8228–8235. 
 
Macpherson, A.J., and Harris, N.L. (2004). Interactions between commensal intestinal 
bacteria and the immune system. Nat. Rev. Immunol. 4, 478–485. 
118 
 
 
Murphy, E.F., Cotter, P.D., Healy, S., Marques, T.M., O’Sullivan, O., Fouhy, F., Clarke, 
S.F., O’Toole, P.W., Quigley, E.M., Stanton, C., et al. (2010). Composition and energy 
harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse 
models. Gut 59, 1635–1642. 
 
Oakley, B.B., Fiedler, T.L., Marrazzo, J.M., and Fredricks, D.N. (2008). Diversity of 
human vaginal bacterial communities and associations with clinically defined bacterial 
vaginosis. Appl. Environ. Microbiol. 74, 4898–4909. 
 
Price, M.N., Dehal, P.S., and Arkin, A.P. (2009). FastTree: computing large minimum 
evolution trees with profiles instead of a distance matrix. Mol. Biol. Evol. 26, 1641–
1650. 
 
Ramsay, D.T., Kent, J.C., Owens, R.A., and Hartmann, P.E. (2004). Ultrasound imaging 
of milk ejection in the breast of lactating women. Pediatrics 113, 361–367. 
 
Ravel, J., Gajer, P., Abdo, Z., Schneider, G.M., Koenig, S.S.K., McCulle, S.L., 
Karlebach, S., Gorle, R., Russell, J., Tacket, C.O., et al. (2011). Vaginal microbiome of 
reproductive-age women. Proc. Natl. Acad. Sci. 108, 4680–4687. 
 
Serino, M., Luche, E., Chabo, C., Amar, J., and Burcelin, R. (2009). Intestinal microflora 
and metabolic diseases. Diabetes Metab. 35, 262–272. 
 
Urbaniak, C., Burton, J.P., and Reid, G. (2012). Breast, milk and microbes: a complex 
relationship that does not end with lactation. Womens Health 8, 385–398. 
 
Wade, W.G. (2013). The oral microbiome in health and disease. Pharmacol. Res. 69, 
137–143. 
 
Ward, T.L., Hosid, S., Ioshikhes, I., and Altosaar, I. (2013). Human milk metagenome: a 
functional capacity analysis. BMC Microbiol. 13, 116. 
 
Wolfe, A.J., Toh, E., Shibata, N., Rong, R., Kenton, K., Fitzgerald, M., Mueller, E.R., 
Schreckenberger, P., Dong, Q., Nelson, D.E., et al. (2012). Evidence of uncultivated 
bacteria in the adult female bladder. J. Clin. Microbiol. 50, 1376–1383. 
 
Xuan, C., Shamonki, J.M., Chung, A., Dinome, M.L., Chung, M., Sieling, P.A., and Lee, 
D.J. (2014). Microbial dysbiosis is associated with human breast cancer. PLoS One 9, 
e83744. 
 
Zhu, Q., Gao, R., Wu, W., and Qin, H. (2013). The role of gut microbiota in the 
pathogenesis of colorectal cancer. Tumor Biol. 34, 1285–1300.  
 
119 
 
Chapter 5  
5 The microbiota of breast tissue and its association with 
breast cancer 
 
This chapter is based on a manuscript under review for publication at mBio. Supporting 
Datasets 5-1 (clinical metadata) and 5-2 (ALDEx2 summary) are available for download 
online as additional excel files. 
 
 Introduction 5.1
Breast cancer is the leading cause of cancer death in women worldwide and it is expected 
that within the next 15 years the incidence of breast cancer cases in the U.S. will increase 
by 50%, resulting in 440,000 women being diagnosed by 2030 (Rosenberg et al., 2015). 
The etiology of breast cancer is still unknown but is believed to be due to a combination 
of genetic and environmental factors. Support for environmental factors comes from 
migration studies showing increased incidence of breast cancer amongst migrants and 
their descendants after they move from a region of low breast cancer risk to a region of 
high risk (Le et al., 2002; Shimizu et al., 1991). While many environmental factors have 
been proposed, one not yet considered is the role of the host’s local tissue microbiome in 
modulating the risk of breast cancer development. 
Bacteria inhabit numerous body sites and this collection of bacteria, termed the human 
microbiota, plays an integral role in human development. Changes in the composition of 
one’s microbiota could promote disease progression, as individuals with periodontitis 
(Darveau, 2010; Ximénez-Fyvie et al., 2000), inflammatory bowel disease (Frank et al., 
2007), psoriasis (Gao et al., 2008), asthma (Hilty et al., 2010), diabetes (Larsen et al., 
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2010), bacterial vaginosis (Hummelen et al., 2010) and colorectal cancer (Mira-Pascual et 
al., 2014) have different bacterial communities compared with healthy individuals. While 
it is still unclear if microbiota changes are a consequence or a cause of the disease, there 
is evidence in favour of the latter, as healthy animals transplanted with feaces from those 
with obesity, colitis or colorectal cancer then go on to develop disease (Garrett et al., 
2007; Turnbaugh et al., 2009; Zackular et al., 2013). 
The aim of the present study was to assess microbial profiles in breast tissue from women 
with breast cancer and those who were disease free, and to examine the consequences of 
this altered bacterial community in terms of breast cancer development. To investigate 
this, we examined the breast microbiota of 71 women who had either breast cancer, 
benign tumours or were disease free. Bacteria isolated from cancer patients were 
characterized and examined for their ability to induce DNA damage. 
 Methods 5.2
5.2.1 Microbiome analysis 
5.2.1.1 Tissue collection and processing 
Breast tissue was collected from 71 women (aged 19 to 90) undergoing breast surgery at 
St. Joseph's Hospital in London, Ontario, Canada. Ethical approval was obtained from 
Western Research Ethics Board and Lawson Health Research Institute, London, Ontario, 
Canada. Subjects provided written consent for sample collection and subsequent 
analyses.  Fifty-eight women underwent lumpectomies or mastectomies for either benign 
(n=13) or cancerous (n=35) tumours, and 23 underwent either breast reductions or 
enhancements and had no history of breast cancer. For those women with tumours, the 
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tissue obtained for analysis was collected outside the marginal zone, approximately 5 cm 
away from the tumour. 
After excision, fresh tissue was immediately placed in a sterile vial on ice and 
homogenized within 30 min of collection. As an environmental control, a tube filled with 
1ml of sterile phosphate-buffered saline (PBS) was left open for the duration of the 
surgical procedure and then processed in parallel with the tissue samples. As an added 
control, a skin swab was collected of the disinfected breast area prior to surgery. The 
swab was placed in 1ml of sterile PBS and then vortexed at full speed for 5min to pellet 
the contents of the swab. The swab was then removed and the liquid stored at −80°C until 
DNA extraction. 
Tissue samples were homogenized in sterile PBS using a PolyTron 2100 homogenizer at 
28,000 rpm. The amount of PBS added was based on the weight of the tissue in order to 
obtain a final concentration of 0.4 g/ml. The homogenate was then stored at −80°C until 
DNA extraction. 
5.2.1.2 DNA isolation 
After tissue homogenates, in sealed containers, were thawed on ice, 400µl (equivalent to 
160 mg of tissue) was added to tubes containing 1.2 ml of ASL buffer (QIAamp DNA 
stool kit; Qiagen) and 400 mg of 0.1-mm-diameter zirconium-glass beads (BioSpec 
Products). 800µl of the PBS control and 800µl of the skin swab control was also added to 
tubes containing ASL buffer and beads. Mechanical and chemical lyses were performed 
on all samples by bead beating at 4,800 rpm for 60s at room temperature and then 60s on 
ice (repeated twice) (Mini-Beadbeater-1; BioSpec Products), after which the suspension 
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was incubated at 95°C for 5 min. Subsequent procedures were performed using the 
Qiagen QIAamp DNA stool kit according to the manufacturer's protocol, with the 
exception of the last step, in which the column was eluted with 120µl of elution buffer. 
DNA was stored at −20°C until further use. 
5.2.1.3 PCR amplification 
The genomic DNA isolated from the clinical samples was amplified using barcoded 
primers that amplify the V6 hypervariable region of the 16S rRNA gene: 
V6-Forward: 
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACC
TTACC 3’ 
V6-Reverse: 
5’CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTnnnn(8)ACRACACGAGCT
GACGAC 3’ 
nnnn indicates 4 randomly incorporated nucleotides and “8” represents a specific sample 
barcode sequence. The PCR was carried out in a 42µl reaction containing 2µl of DNA 
template (or nuclease-free water as a negative control), 0.15 µg/µl bovine serum albumin, 
20µl of 2x GoTaq hot start colorless master mix (Promega) and 10µl of each primer 
(initial concentration: 3.2pmol/µl). Thermal cycling was carried out in an Eppendorf 
Mastercyler under the following conditions: initial denaturation at 95°C for 2 minutes 
followed by 25 cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute. 
After amplification, the DNA concentration was measured with the Qubit® 2.0 
Fluorometer (Invitrogen) using the broad range assay. Equimolar amounts of each PCR 
product were then pooled together and purified using the QIAquick PCR purification kit 
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(QIAGEN). The pooled PCR purified sample was then paired-end sequenced on the 
Illumina Mi-Seq platform using a 150 cycle kit with a 2x80 run at the London Regional 
Genomics Center, London, Ontario, Canada following standard operating procedures. 
5.2.1.4 Sequence processing and taxonomic assignment 
Custom Perl and Bash scripts were used to de-multiplex the reads and assign barcoded 
reads to individual samples. Multiple layers of filtering were employed: (i) Paired end 
sequences were overlapped with Pandaseq, allowing 0 mismatches in the overlapped 
reads; (ii) Reads were kept if the sequence included a perfect match to the V6 16S rRNA 
gene primers; (iii) Barcodes were 8mers with an edit distance of >4 and reads were kept 
if the sequence were a perfect match to the barcode; (iv) Reads were clustered by 97% 
identity into operational taxonomic units (OTUs) using the Uclust algorithm of 
USEARCH v7 (Edgar, 2010) which has a de novo chimera filter built into it; (v) All 
singleton OTUs were discarded and those that represented ≥2% of the reads in at least 
one sample were kept (a filter for PCR and environmental controls and the skin swabs). 
Taxonomic assignments for each OTU were made by extracting the best hits from the 
SILVA database (Pruesse et al., 2007) and then manually verified using the Ribosomal 
Database Project (RDP) SeqMatch tool (rdp.cme.msu.edu) and by BLAST against the 
Green genes database (greengenes.lbl.gov) Taxonomy was assigned based on hits with 
the highest percentage identities and coverage. If multiple hits fulfilled this criterion, 
classification was re-assigned to a higher common taxonomy. 
5.2.1.5 Data analysis 
PCoA plots of weighted UniFrac distances (Lozupone and Knight, 2005) were generated 
in QIIME (Caporaso et al., 2010) by using a tree of OTU sequences built with 
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FASTTREE (Price et al., 2009) based on an OTU sequence alignment made with  
MUSCLE (Edgar, 2004). PERMANOVA was used to test for statistical significance 
between groups using 10000 permutations (QIIME package). 
Microbiome data is compositional in nature (i.e. proportional distributions that are not 
independent of each other) and thus has several limitations (Fernandes et al., 2014).  A 
simple example is as follows: If a sample has two organisms A (50%) and B (50%) and 
after antibiotic treatment organism A is completely killed, the proportion of B in that 
sample will now be 100% even if its actual abundance has not changed.  Transforming 
the data, using centered log-ratios (CLR) alleviates the constraints inherent with 
compositional data (Aitchison, 1986) by allowing for subcomposition coherence, linear 
sample independence and normalization of read counts. CLR transformed data with a 
uniform prior of 0.5 applied was used when generating the K-means clusterplot and the 
dendogram of Euclidian distances. 
The ALDEx R package version 2 (Fernandes et al., 2014) was used to compare genera 
the relative abundance of genera. Values reported in this manuscript represent the 
expected values of 128 Dirichlet Monte-Carlo instances of CLR transformed data. A 
value of zero indicates that organism abundance is equal to the geometric mean 
abundance. Thus, organisms more abundant than the mean will have positive values and 
those less abundant than the mean will have negative values. Base 2 was used for the 
logarithm so differences between values represent fold changes. Significance was based 
on the Benjamini-Hochberg corrected p-value of the Wilcoxon rank test (significance 
threshold of 0.1). 
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The Microbiome Regression-based Kernel Association Test (MiRKAT) (Zhao et al., 
2015) was performed in R using the MiRKAT package. Differences in microbiota 
profiles were tested using a kernel metric constructed from weighted UniFrac, 
unweighted UniFrac and GUniFrac (Chen et al., 2012) distances and the Bray-Curtis 
dissimilarity metric. “Optimal” MiRKAT allows for the simultaneous examination of 
multiple distance/dissimilarity metrics alleviating the problem of choosing the best one 
and was performed on the aforementioned metrics. The p-values generated were the 
mean of 128 Dirichlet Monte-Carlo instances. 
The R script of “SourceTracker “(version 0.9.1) was used to assess contamination of the 
tissue microbiota. Tissue samples were designated as “sink” and PBS controls as 
“source.”  Barplots, boxplots, K-means clusterplots and dendograms were all generated in 
R (http://www.R-project.org/). 
Full details regarding Irish tissue sample collection, patient demographics, DNA 
extraction protocols and the steps followed to generate the OTU table used for the 
analysis in Figure 5-6, can be found in our previous publications (Lehouritis et al., 2015; 
Urbaniak et al., 2014). 
5.2.2 DNA damage assay 
5.2.2.1 Bacterial strains 
Isolates were obtained by plating 100µl of tissue homogenate on Columbia blood (CBA), 
MacConkey and Beef Heart Infusion (BHI) agar plates and incubating both aerobically or 
anaerobically at 37oC.  DNA from single colonies was extracted using the InstaGene 
Matrix (Bio-Rad) and then amplified using the eubacterial primers pA/pH, which 
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amplifies the complete 16S rRNA gene (see section 4.2.4 for the primer sequences). The 
PCR reaction was carried out in 50µl reaction containing 10µl of DNA template (or 
nuclease free water as a negative control), 1.5mM MgCl2, 1.0µM of each primer, 0.2mM 
dNTP, 5µl 10X PCR buffer (Invitrogen), and 0.05 Taq Polymerase (Invitrogen). Thermal 
cycling was carried out in an Eppendorf Mastercyler under the following conditions: 
Initial denaturation step at 95oC for 2min, followed by 30 cycles of 94oC for 30s, 55oC 
for 30s and 72oC for 1min.  A final elongation step was performed at 72oC for 10min. 
40µl of the PCR mixture was then purified using the QIAquick PCR purification kit 
(Qiagen) and the purified products sent for Sanger sequencing to the London Regional 
Genomics Centre, London, Ontario, Canada. Sequences were analyzed using the 
GenBank 16S ribosomal RNA sequences database and the Greengenes database. 
Taxonomy was assigned based on the highest Max score. Because the 16S rRNA gene 
does not differentiate members of the Enterobacteriaceae family very well, to confirm 
that our isolates were indeed E.coli, we utilized the API® 20E strip to differentiate 
species that are part of the this family. E.coli strain IHE3034 was kindly provided by Jean 
Philippe Nougayrède (INRA, Toulouse, France). 
5.2.2.2 Infection assay 
HeLa cells were maintained and passaged in DMEM/glutamax media (Invitrogen) 
supplemented with 10% FBS (Invitrogen).  On the day of the experiment a 24 well plate 
containing sterile cover slips was seeded with 0.5ml of 1x105 cells/ml, resulting in 5x104 
HeLa cells/well. The plates were then incubated at 37oC with 5% CO2 for 24 hours after 
which times the media was removed and the wells washed with sterile PBS. HeLa cells (2 
wells for each organism) were then infected at a MOI 100 cfu of bacterial cells per HeLa 
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cell for 4 hours with either Staphylococcus epidermidis (subject 31), Micrococcus luteus 
(subject 8), Micrococcus sp (subject 8), E.coli (subject 41 (isolates H and E), subject 34 
and strain IHE3034), Propionibacterium acnes (subject 20) and P. granulosum (subject 
20) or at a MOI 1 for 2 hours with Bacillus cereus (subject 34 & subject 6). The bacterial 
cultures for infection were prepared by inoculating 5ml of BHI with 1 colony and 
incubating aerobically at 37oC for 15 hours, with the exception of Propionibacterium, 
which was incubated anaerobically for 72hr. Bacterial cultures were then spun down at 
3500g for 10min, washed and resuspended in PBS. Bacterial cells were then diluted to 
the appropriate concentration in DMEM media containing 10% FBS and 25mM HEPES. 
40µM etoposide (Sigma) was used as a technical positive control. The pH was checked at 
the end of the experiment to ensure consistency between wells. 
5.2.2.3 Immunofluorescence 
After infection, media was removed and HeLa cells were washed 3x with sterile PBS.   
Cells were then fixed and permeabilized for 12min at room temperature (RT) with a          
-20oC solution of 95% methanol and 5% acetic acid. Cells were then blocked for an hour 
with 0.3% Triton-100/5% goat serum. After blocking, a 1/200 dilution of the primary 
antibody (rabbit anti phospho-H2AX mAb; Cell Signaling technologies) was added and 
incubated over night at 4oC. After washing a 1/1000 dilution of the secondary antibody 
(goat anti-rabbit IgG, Alexa Fluor 647 conjugate; Cell Signaling technologies) was added 
and incubated at RT for 30min. Cells were then counter stained with 1µg/ml of DAPI 
(Life Technologies) for 1min. Cover slips were mounted on microscope slides containing 
a drop of ProLong Gold antifade mountant (Life Technologies). The experiments were 
performed three times. 
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Images were captured using the NIKON eclipse TE2000-S digital microscope. Eight 
fields of view for each replicate were recorded, for a total of 16 fields of view for each 
condition. Using ImageJ software (version 1.48a), the mean fluorescent intensity of each 
γH2AX stained cell was measured from the digital images. The digital images were also 
used to determine the percent of total cells stained positive for γH2AX, which was 
calculated by dividing the number of red cells (i.e. γH2AX positive) by the number of 
blue cells (i.e. DAPI stained) and multiplying by one hundred. 
5.2.2.4 Statistics 
Bar graphs of the mean and standard deviation from the 3 experiments were plotted using 
Prism (version 5.0a).  Significance (p<0.05) was tested by a 1 way ANOVA followed by 
a 2-sided unpaired student’s t-test (Prism v 5.0a) with the false discovery rate (“FDR”) 
multiple test correction performed in R. 
 Results 5.3
5.3.1 Microbiota analysis 
16S rRNA amplicon sequencing of the V6 hypervariable region was performed on 70 
tissue samples and 38 environmental controls. A full summary of patient demographics 
can be found in Dataset 5-1. To assess the contribution of environmental contamination 
towards the overall tissue microbiota, we utilized the contamination predictor tool, 
“SourceTracker”, which compared the microbial population in the tissue samples to that 
of the phosphate buffered saline (PBS) environmental controls. Figure 5-1 shows that 
while there is contamination present, it makes up only a small proportion (average 10%) 
of the overall microbial community in breast tissue.  A dendogram of Euclidian distances 
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of the centered log-ratio (clr) transformed dataset (Aitchison, 1986) was then constructed 
to visualize which tissue samples were similar to the PBS controls and to skin swabs 
collected from the disinfected breast area prior to surgery. As seen in Figure 5-2, skin 
swabs, PBS controls and the no template PCR control (NTC) formed a single cluster, 
which was separate from most of the tissue samples, indicating distinct microbial 
profiles. It is also important to note that no differences were observed within the controls 
and within tissue samples obtained from different surgeons and surgical rooms. To ensure 
stringent quality control, we removed those tissue samples that were part of the 
PBS/skin/NTC cluster from further analysis. In addition, OTUs present in over 2% 
abundance in the NTC and PBS controls were also removed from further analysis. 16S 
rRNA sequencing data of the remaining samples and OTUs, showed a diverse population 
of bacteria consisting of 61 OTUs and 28 taxa (Figure 5-3A) dominated by the phyla 
Proteobacteria and Firmicutes (Figure 5-3B). 
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Figure 5-1. Assessment of DNA contamination towards the breast tissue microbiota 
SourceTracker was used to examine if and in what proportion the tissue microbiota was 
contaminated with environmental DNA by comparing the OTUs detected in the PBS 
environmental controls to that of the OTUs detected in breast tissue.  While there is some 
contamination present, as would be expected in low biomass samples, this contamination 
makes up only 10% of the overall bacterial community in tissue. Each pie graph 
corresponds to one subject. The pink slices represent the proportion of OTUs in the tissue 
samples that are similar to those found in the PBS controls. The blue slices represent the 
OTUs unique to the tissue samples. 
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Figure 5-2. Examining the relatedness of bacterial profiles in tissue samples to that 
of the environmental controls   
Dendogram of Euclidian distances were constructed from centered log-ratio transformed 
data to compare bacterial profiles between tissue samples, PBS controls, skin swabs and 
the no template PCR control. Two distinct branches are evident, separated by a red line.  
One branch consists of tissue samples (right of red line) and the other mainly of 
environmental controls (left of the red line). Those samples that fell within the 
environmental control branch (left) were removed from further analysis. “HC”- PBS 
control during surgery of healthy patients; “BTC”= PBS control during surgery of tumour 
patients; neg= PCR no template control; skin= skin swab of either healthy patients (“H) 
or tumour patients (“BT”) 
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Figure 5-3.  Breast tissue microbiota identified by 16S rRNA gene amplicon 
sequencing. 
(A) The relative abundances of bacterial genera in different breast tissue samples were 
visualized by bar plots. Each bar represents a subject and each colored box a bacterial 
taxon. The height of a coloured box represents the relative abundance of that organism 
within the sample. Taxa present in less than 2% abundance in a given sample are 
displayed in the “Remaining fraction” at the top of the graph (gray boxes). As shown by 
the bar plots, a variety of bacteria were detected in breast tissue. The legend is read from 
bottom to top, with the bottom organism on the legend corresponding to the bottom 
colored box on the bar plot. (B) Box plots of the six phyla identified in breast tissue. The 
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of 
the samples lie. The black line inside the box represents the median. The whiskers 
represent the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile 
and the highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with 
open circles 
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A comparison of normal adjacent tissue from women with breast cancer with that of 
tissue from healthy women showed distinctly different bacterial profiles on weighted 
UniFrac PCoA plots (Figure 5-4A). Unsupervised K-means clustering of the clr 
transformed dataset indicated two clusters and the PCA plot in Figure 5-4B shows clear 
separation between the healthy and cancer groups. Differences between the groups were 
also confirmed using the Microbiome Regression-based Kernel Association Test 
(MiRKAT) (Table 5-1). 
 
Table 5-1. Summary of p-values generated by MIRKAT 
p-values displayed represent the min, max, average and median values generated from 
128 Dirichlet Monte-Carlo instances 
 
 Bray-Curtis Weighted 
UniFrac 
Unweighted 
UniFrac 
GUniFrac 
α=0.5 
Optimal 
Min 4.58E-05 2.64E-06 4.12E-06 2.64E-06 0 
Max 0.000129826 1.04E-05 0.004191322 1.15E-05 0 
Average 7.87E-05 4.52E-06 0.000395004 5.33E-06 0 
Median 7.70E-05 4.24E-06 2.05E-04 4.87E-06 0 
 
ALDEx2, which allows for the direct comparison of bacterial taxa between groups 
showed significantly higher compositional abundances of Prevotella, Lactococcus, 
Streptococcus Corynebacterium and Micrococcus in healthy patients and Bacillus, 
Staphylococcus, Enterobacteriaceae (unclassified), Comamondaceae (unclassified) and 
Bacteroidetes (unclassified) in cancer patients (Figure 5-5)(Dataset 5-2). 
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Figure 5-4.  Comparison of bacterial profiles between breast cancer patients and 
healthy controls 
(A) Weighted UniFrac principal coordinate (PCoA) plot and (B) K-means clusterplot of 
centered log-ratio transformed data.  Each breast tissue sample, represented by a coloured 
point is plotted on a three-dimensional, 3-axis plane representing 79% of the variation 
observed between all samples (A) or 44.85% of the variation on a 2-axis plane (B).  
Samples (points) that cluster together are similar in biota composition and abundance.  
The distinct separation between the two groups indicates that bacterial profiles differ 
between women with and without cancer.  The PERMANOVA test performed on the 
weighted UniFrac distances showed that the observed differences were statistically 
significant (10000 permutations; pseudo F-statistic=14.4; p-value <0.01). 
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Figure 5-5. Differences in relative abundances of taxa exist between healthy and 
cancer patients 
Summary of taxa that were statistically significantly different between the two groups as 
determined by ALDEx2. The top panel shows the bacteria that were higher in healthy 
patients compared to those with cancer (i.e. normal adjacent tissue) and the bottom panel 
shows the bacteria that were higher in cancer patients compared to healthy controls. The 
box signifies the 75% (upper) and 25% (lower) quartiles and thus shows where 50% of 
the samples lie. The black line inside the box represents the median. The whiskers 
represent the lowest datum still within 1.5 interquartile range (IQR) of the lower quartile 
and the highest datum still within 1.5 IQR of the upper quartile. Outliers are shown with 
open circles.  
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To assess whether bacteria surrounding the tumour microenvironment might be 
associated with the severity of cancer, we compared bacterial profiles in normal adjacent 
tissue from women with various stages of breast cancer. No differences were found based 
on invasiveness or stage (data not shown). However normal adjacent tissue from women 
with benign tumours had profiles that were more similar to normal adjacent tissue of 
women with cancerous tumours rather than tissue from healthy subjects (Table 5-2). 
 
Table 5-2.  Comparison of relative abundances of bacteria in breast tissue between 
women with benign  tumours, cancerous tumours and healthy controls.  
ALDEx2 was performed to compare the relative abundances of bacteria in breast tissue 
between healthy women, and normal adjacent tissue from those with benign tumours and 
cancerous tumours. Bacterial profiles in normal adjacent tissue from women with benign 
tumours are more similar to normal adjacent tissue from women with cancerous tumours 
rather than healthy controls.   
 
Cancer vs Healthy Benign vs Healthy Benign vs Cancer  
Higher in Healthy 
Prevotella 
Lactococcus 
Corynebacterium 
Streptococcus  
Micrococcus 
 
Higher in Cancer 
Bacillus 
Staphylococcus 
Enterobacteriaceae 
Comamonadaceae 
Bacteroidetes unclassified 
Higher in Healthy  
Prevotella 
Lactococcus  
 
 
 
 
Higher in Benign 
Bacillus 
Staphylococcus 
Higher in Benign  
Micrococcus 
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We have previously published two reports showing which bacteria are present in tumour 
tissue and normal adjacent tissue of women from Ireland (Lehouritis et al., 2015; 
Urbaniak et al., 2014). In this report, we now show, using weighted UniFrac distances, 
that bacterial communities do not differ between tumour tissue and normal adjacent 
tissue, both at the population level (Figure 5-6A) and within an individual (Figure 5-
6B). Thus, when suitably-collected tumour tissue for microbiome analysis is not 
available, normal adjacent tissue may be a practical alternative. 
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Figure 5-6. Comparison of bacterial profiles between tumour tissue and normal 
adjacent tissue 
Tissue from malignant tumours and matched normal adjacent (i.e. non-malignant) tissue 
from 33 women from Cork, Ireland were collected and analyzed. (A) Weighted UniFrac 
PCoA plots to assess bacterial profiles at the population level. Lack of distinct clustering 
between tumour and normal adjacent tissue groups indicates that bacterial profiles are 
similar between the two tissue types. (B) Differences in microbial communities between 
conditions can sometimes exist within an individual, which may not be evident at the 
population level. To examine whether this was the case, weighted UniFrac distances were 
analyzed between matched tumour and normal adjacent tissue (i.e. “paired”). The smaller 
the weighted UniFrac distance is between two samples, the more related they are. As 
depicted in the boxplots, the UniFrac distances between paired samples was even smaller 
than the distances calculated between all normal adjacent tissue (NA vs NA), all tumour 
tissue (T vs T) and between normal adjacent and tumour tissue (NA vs T) showing that 
even within an individual bacterial profiles are the same between tumour and normal 
adjacent tissue. ** denotes p-value <0.01  (1- way ANOVA, followed by a student’s t-
test with the FDR multiple test correction). 
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5.3.2 Assessment of DNA damage ability of breast tissue 
isolates 
E.coli strains belonging to the B2 phylotype harbour the pks pathogenicity island, which 
encodes for machinery for the production of the genotoxin, colibactin. These pks + strains 
have been implicated in colon cancer (Arthur et al., 2012; Buc et al., 2013) via their 
ability to induce DNA double stranded breaks and chromosomal instability (Cuevas-
Ramos et al., 2010; Nougayrède et al., 2006). As shown in Figure 5-5, the family 
Enterobacteriaceae, of which E.coli is a member of, was relatively more abundant in 
cancer patients compared to healthy controls. For this reason, we wanted to examine 
whether E. coli, cultured from breast tissue of cancer patients, had the ability to induce 
DNA double stranded breaks (DSB). Cellular levels of γH2AX, a surrogate marker of 
DSB, were measured in HeLa cells after incubation with various E.coli tissue isolates. 
E.coli IHE3034, which contains the pks pathogenicity island and induces DSB 
(Nougayrède et al., 2006) was used for comparison. 
HeLa cells exposed to E.coli tissue isolates had significantly higher levels of γH2AX 
compared with untreated cells, as measured by mean fluorescent intensity (MFI) and % 
of cells that stained positive for γH2AX, with levels equivalent to that induced by E.coli 
IHE3034 (Figure 5-7). Additional isolates from breast cancer patients were also 
examined for the ability to induce DNA damage; (i) Bacillus and Staphylococcus were 
tested as these genera were more abundant in cancer patients; (ii) Micrococcus, as this 
genus was higher in healthy individuals and (iii) Propionibacterium as there were no 
differences in relative abundances between cancer patients and healthy controls. Neither 
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Bacillus, Microccoccus nor Propionibacterium isolates induced DSB, whereas 
Staphylococcus did (Figure 5-8). 
γH2AX foci can occur and be resolved very quickly in response to DNA damage, thus a 
time course was performed, with Bacillus treated cells analyzed every 15min over a 2 
hour period. No statistically significant differences at any time point were observed 
between treated and untreated cells (data not shown). 
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Figure 5-7.  DNA damage ability of E.coli breast tissue isolates from cancer patients.  
E.coli was isolated from normal adjacent tissue of 2 patients with breast cancer and tested 
for its ability to induce DNA double stranded breaks. E.coli (isolates H and E) from 
subject 41, isolate L from subject 34 and strain IHE3034 were incubated with HeLa cells 
at MOI 100 cfu bacteria per HeLa cell for 4hr and then stained for γH2AX and DAPI. (A) 
Representative immunofluorescent images of HeLa cells at 1000x magnification. (B) 
Image J was used to measure the mean fluorescent intensity (MFI) of γH2AX positive 
cells from the digitally acquired images. (C) Percent of total cells stained for γH2AX 
calculated from the immunofluorescent images.  Data displayed in the bar graphs 
represent the mean +/- SD of 3 experiments representing a total of 48 fields of view and 
approximately 300 cells for each treatment group.  ** denotes p-value <0.01 
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Figure 5-8. DNA damage ability of bacteria isolated from breast tissue of cancer 
patients 
Bacteria isolated from normal adjacent tissue of patients with breast cancer were tested 
for their ability to induce DNA double stranded breaks. Staphylococcus epidermidis, 
Micrococcus luteus, Micrococcus sp, Propionibacterium acnes and Propionibacterium 
granulosum were incubated with HeLa cells at MOI 100 cfu bacteria per HeLa cell for 
4hr or with Bacillus cereus at MOI 1 for 2hr and then stained for γH2AX and DAPI. (A) 
Image J was used to measure the mean fluorescent intensity (MFI) of γH2AX positive 
cells from digitally acquired immunofluorescent images. (B) Percent of total cells stained 
for γH2AX calculated from the immunofluorescent images. Data displayed in the bar 
graphs represent the mean +/- SD of 3 experiments (with the exception of 
Propionibacterium which was only done once) representing a total of 48 fields of view 
and approximately 300 cells for each treatment group.  * denotes p-value <0.05. 
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 Discussion 5.4
This study has shown that different bacterial profiles exist in “normal adjacent” breast 
tissue from women with breast cancer compared with “normal” tissue from healthy 
controls. In colorectal cancer (CRC) and oral squamous cell carcinoma (OSCC) bacterial 
profiles in the stool and saliva respectively, also differ between healthy and diseased 
patients (Mager et al., 2005; Wang et al., 2012; Weir et al., 2013) with evidence 
suggesting that changes in this community composition and function may be driving 
cancer progression at these sites (Ahn et al., 2012; Schwabe and Jobin, 2013). This raises 
the possibility that the differences observed in the breast could also play a role in breast 
cancer progression. 
Enterobacteriaceae and Staphylococcus are two taxa found in higher abundance in breast 
cancer patients compared with healthy controls. Examination of three E.coli isolates (a 
member of the Enterobacteriaceae family) and one Staphylococcus epidermidis isolate, 
cultured from normal adjacent tissue of breast cancer patients, all displayed the ability to 
induce DNA double stranded breaks (DSB). DSB are the most detrimental type of DNA 
damage and are caused by genotoxins, reactive oxygen species, and ionizing radiation 
(Lees-Miller, 2003). Non-homologous end joining, the mechanism by which DSB are 
repaired, is extremely error- prone often resulting in missing bases at the site of damage 
(Lees-Miller, 2003). Accumulation of these mis-repairs within the cell over time leads to 
genomic instability and eventually cancer (Khanna and Jackson, 2001). DSB caused by 
bacteria such as Helicobacter pylori and certain strains of E.coli have been shown to 
induce chromosomal instability with prolonged exposure (Cuevas-Ramos et al., 2010; 
Toller et al., 2011). While the same mechanisms may be involved in the in vitro assay 
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described here (or indeed breast tissue transformation), further tests would need to be 
done to verify whether chromosomal abnormalities do occur subsequent to the DNA 
damage induced by these breast isolates. In support of this hypothesis, total cell numbers 
were consistent between all treated and untreated groups, suggesting no induction of 
apoptosis. It is important to note that bacterial induced DNA damage may not be 
sufficient in itself to promote breast cancer development unless it occurs in a genetically 
susceptible host.  All genetic and 3-30% of sporadic cancer cases have mutations in DNA 
repair or DNA checkpoint machinery (Negrini et al., 2010). Thus women who have 
impaired DNA repair/checkpoints may be more susceptible to bacterial induced DNA 
damage and may be at a higher risk of developing breast cancer than women without 
these mutations, even if they have the same “detrimental” microbes in their mammary 
glands. 
Bacillus was also elevated in breast cancer patients compared with healthy controls, 
confirming our previous findings (Urbaniak et al., 2014). While Bacillus did not induce 
DSB like E.coli and S.epidermidis it could have other pro-carcinogenic effects. One study 
has shown that a Bacillus cereus strain, isolated from gingival plaque, metabolizes the 
hormone progesterone into 5 alpha-pregnane-3,20-dione (5αP) (Ojanotko-Harri et al., 
1990).  5αP is higher in breast tumours compared with healthy breast tissue (Wiebe et al., 
2000) and is believed to promote tumour development by stimulating cell proliferation  
(Wiebe, 2006; Wiebe et al., 2000). While our molecular analysis did not permit species 
level identification, all Bacillus strains cultured from our breast cancer patients were of 
the species B.cereus. 
150 
 
An epidemiological study has shown that women who drink fermented milk products 
have a reduced risk of breast cancer development, irrespective of multivariable risk 
factors (van’t Veer et al., 1989). This protection could be attributed to the health 
promoting properties of the various lactic acid bacteria (LAB) present in fermented 
products. Lactococccus and Streptococcus, two such bacteria that were higher in healthy 
women compared with breast cancer patients, exhibit anti-carcinogenic properties and 
could play a role in prevention. Natural killer (NK) cells are vital in controlling tumour 
growth with epidemiological studies showing that low NK cell activity from PBMC is 
associated with an increased incidence of breast cancer (Imai et al., 2000; Strayer et al., 
1984). Lactococcus lactis has been shown to activate murine splenic NK cells, enhancing 
cellular immunity (Kosaka et al., 2012). While no studies have yet been published 
comparing NK cell functionality in the breast between “normal” (i.e. healthy patients) 
and “normal adjacent” (breast cancer patients) tissue, it could be assumed, based on the 
PBMC data, that NK functionality is also impaired in the breast of those with cancer. 
Lactococcus sp present in the mammary glands, could be modulating cellular immunity 
by maintaining the cytotoxic activity of resident NK cells (Carrega et al., 2014) thus 
helping to prevent cancer development. Streptococcus thermophilus on the other hand, 
better than any other LAB tested, protects against DNA damage caused by reactive 
oxygen species by producing antioxidant metabolites that neutralize peroxide and 
superoxide radicals (Koller et al., 2008). 
Orally administered Lactobacillus sp, has shown to be protective in animal models of 
breast cancer (de Moreno de LeBlanc et al., 2005). While total numbers did not differ 
between healthy and diseased patients, those with breast cancer may not experience the 
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full anti-carcinogenic benefits afforded by Lactobacillus due to the decrease in 
Lactococcus and Streptococcus, as LAB have been shown to act in synergy with each 
other (Shiou et al., 2013). 
Prevotella, which was more abundant in healthy women compared with breast cancer 
patients, produces the short chain fatty acid (SCFA), propionate. Propionate, like other 
SCFA, has many beneficial health effects in the gut, one of them being the ability to 
regulate colorectal tumour growth (Hosseini et al., 2011). In both animal and human 
studies, higher levels of Prevotella were observed in the stool of healthy subjects 
compared to those with CRC (Weir et al., 2013; Zackular et al., 2013).  However in the 
oral cavity, patients with OSCC have higher levels of Prevotella compared with healthy 
controls and when Prevotella presence was used as a diagnostic tool, the authors could 
predict 80% of the cancer cases (Mager et al., 2005). The conflicting association of 
Prevotella in CRC and OSCC could be due to the fact that metabolites function 
differently at different body sites. While SCFA are anti-inflammatory in the colon and 
associated with health (Louis et al., 2014), in the vagina, they are pro-inflammatory and 
associated with bacterial vaginosis (Aldunate et al., 2015). What role Prevotella and/or 
propionate may be playing in breast health (or disease) remains to be determined. 
While we have reported differential abundances of certain organisms between health and 
diseased states, in reality, it is probably not a single organism driving disease progression 
or protection but rather an interplay of poly-microbial interactions. To get a better 
understanding of the microbial influence on breast cancer, the functionality of these 
microbes should be investigated. Further studies examining bacterial metabolites and 
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bacterial-induced host metabolites would provide vital information on the role of bacteria 
in breast health. 
 Conclusion 5.5
This is the first report, to our knowledge to show that bacterial profiles differ in breast 
tissue between healthy subjects and normal adjacent tissue of breast cancer patients. 
Some of the bacteria that were relatively more abundant in breast cancer patients had the 
ability to induce DNA double stranded breaks. Further studies need to be done to 
examine whether this DNA damage can lead to chromosomal aberrations and whether the 
differences in the bacterial profiles are a cause or a consequence of the disease. This 
study raises important questions as to the role of the breast microbiota in breast cancer 
development or prevention and whether bacteria could be harnessed for interventions to 
help prevent disease onset. 
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Chapter 6  
6 Draft genome sequence of a Bacillus cereus strain 
isolated from non-malignant breast tissue from a 
woman with breast cancer 
 Genome announcement  6.1
Bacillus cereus was the predominant organism cultured from the breast of cancer patients 
that we studied (normal adjacent tissue), with it being present in more than half of the 
samples tested. No isolates were cultured from healthy controls (women undergoing 
breast reductions or enhancements). 16S rRNA gene targeted sequencing of the V6 
hypervariable region showed higher relative abundances of Bacillus sp in breast cancer 
patients compared to healthy controls (Chapter 5). Previously, B. cereus, isolated from 
gingival pockets of a patient with periodontitis, has shown the ability to metabolize 
progesterone into metabolites that increase the risk of breast cancer development 
(Ojanotko-Harri et al., 1990; Wiebe, 2006). Various species of Bacillus (though not B. 
cereus) are dominant in pulmonary tissue from lung cancer patients (Apostolou et al., 
2011). To get a better understanding of what B. cereus could be doing in the breast and 
whether it could have a role in breast cancer development or progression, we sequenced 
the genome of a B. cereus isolate, designated CU-1, cultured from a 70 year- old woman 
with stage 1 invasive breast cancer. 
Genomic DNA was isolated using the PureLink Genomic DNA Mini Kit (Invitrogen). 
Libraries were then made using the Nextera XT DNA Library Preparation Kit (Illumina) 
and paired end sequenced (2x150bp) on the Illumina MiSeq platform (London Regional 
Genomic Center, London, Canada). Reads were assembled into contigs using Velvet 
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(version 1.2.10) set at the optimal kmer size of 31. 1467 contigs >100bp were generated, 
with 17x read coverage within contigs and an N50 of 17818bp. Gene calling of the 
assembled genome was carried out with RAST. A genome comparison between our 
breast tissue isolate and other fully sequenced B. cereus genomes, deposited in NCBI, 
was performed using JSpecies (version 1.2.1), an in silico alternative to DNA-DNA 
hybridization. 
The B. cereus CU-1 strain has a genome size of 5.5 Mb, typical of other B. cereus strains.  
RAST analysis revealed 5536 coding sequences, with 41% assigned to a functional 
subsystem (Figure 6-1).   
 
 
Figure 6-1. Schematic of protein functional groups 
5536 coding sequences of B. cereus CU-1 were annotated with RAST and assigned to 
different functional groups (i.e. “subsystems’). Of the 5536 coding sequences, 41% 
belonged to a subsystem. 
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JSpecies comparisons showed that CU-1 was similar to other B.cereus strains, being the 
most similar to B.cereus ATCC14579 (Table 6-1). Interestingly, our strain and not any of 
the others in Table 6-1, has the Lde efflux pump, which is associated with 
fluoroquinolone resistance. Since fluoroquinolones are synthetic antibiotics, this lends 
weight to the idea of CU-1 being associated with the human body over a period of time. 
 
Table 6-1. JSpecies analysis comparing B. cereus CU-1 to other B. cereus isolates 
with fully sequenced genomes. 
A comparison was also performed with a different species from the same genera. The 
tetra regression coefficient is an indication of how similar two strains are, with values 
closer to “1” representing more similarity 
Name Tetra regression Description  
B.cereus ATCC14579 0.99934 Avirulent strain type strain 
B.cereus B4264 0.99908 Isolated from male patient with fatal 
pneumonia  
B.cereus F837/76 0.99845 Isolated from prostate wound 
B.cereus ATCC10987 0.99844 Dairy isolate, avirulent strain  
B.cereus  03BB102 0.99841 Isolated from blood from a male welder 
with fatal pneumonia  
B.cereus E33L 0.9984 Isolated from a swab of a zebra carcass 
in Namibia 
B.cereus NC7401 0.99834 Produces high levels of the emetic toxin 
cereulide, isolated from symptomatic 
patient  
B.subtilis subspecies 
subtilis str.168 
0.72452 Strain 168 was isolated after B. subtilis 
Marburg was mutagenized with X-rays 
by two Yale University botanists. 
Nearly all B.subtilis strains used in 
academia are derivatives of strain 168.  
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The genome was examined for genes involved in estrogen or progesterone metabolism, 
as hormone regulation plays a key role in many types of breast cancer. However none of 
these were present in our strain. Other genes were identified that could play a role in 
breast cancer development or prevention (Table 6-2) but future in vitro studies would 
need to confirm their functionality.  
Overall, although the fully closed genome of CU-1 was not mapped, the analysis shows a 
genome with the genetic tools for virulence and regulation of cancer development. The 
well known pathogenicity of this species and the lack of obvious infection in this patient 
raises an interesting question regarding the activity of CU-1 within the breast and a 
possible role of the breast tissue environment in down regulating or inhibiting the 
expression of these virulence genes.  
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Table 6-2. Potential proteins involved in cancer development or protection. 
Analysis of the 5536 coding sequences revealed proteins that could contribute to health 
and disease. The ones with a possible connection with breast cancer progression or 
prevention are shown in this table 
Protein Description 
Toxins: Hemolysin BL, Non- hemolytic 
enterotoxin, Cytotoxin K 
Known to cause disease in humans. Have 
the potential to induce DNA damage  
Chitin binding protein and chitinase 
 
Chitin is the second most abundant 
polysaccharide in nature next to cellulose. 
Chitinases are found in a variety of 
prokaryotes even though they do no 
produce endogenous chitin. It is believed 
that chitin binding protein and chitinases 
act as virulence factors in some pathogens 
by modulating adhesion and/or invasion 
into host cells. Increased serum levels of 
chitinase correlate with disease severity, 
poorer prognosis, and shorter survival in 
many human cancers such as breast, colon, 
prostate, ovaries, brain, thyroid, lung, and 
liver. 
Azurin 
 
Azurin released from Pseudomonas 
aeruginosa blocks breast cancer cell 
proliferation and induces apoptosis through 
the mitochondrial pathway both in vitro 
and in vivo. Azurin is being considered as a 
potential chemotherapeutic treatment for 
breast cancer. 
Bacillolysin 
 
Bacillolysin is an enzyme found in many 
Bacillus species. It has been shown that 
bacillolysin from B. megaterium has the 
ability to convert plasminogen to 
angiostatin-like fragments. Angiostatin 
inhibits proliferation of vascular 
endothelial cells, which is a fundamental 
process in angiogenesis. Angiostatin has 
been shown to suppress both in situ and 
metastatic tumour growth in animal 
models. 
S layer 
 
S-layers from Bacillaceae function as 
adhesion sites for cell associated exo- 
enzymes. Strains containing S-layers are 
resistant to polymorphonulcear leukocytes 
in the absence of opsonins. 
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Chapter 7  
7 Discussion 
 Verification of a breast tissue microbiome 7.1
The tissue microbiota data presented in Chapters 4 and 5 challenge the assumption that 
breast tissue is sterile unless under active infection. While HTS has allowed scientists to 
unravel the diversity and functionality of microbial communities across the body, 
concerns have been raised that sites once thought of as sterile but now purported to have 
a “microbiome” are really just contaminated DNA, sequenced from reagents and 
laboratory equipment (Salter et al., 2014). I dispute this suggestion for the work reported 
herein. In these studies, numerous aliquots of PBS (“environmental” controls) were 
processed in parallel with the tissue samples. Most of the tissue samples had microbial 
profiles that were different from the controls. Those with similarities to the controls and 
any OTUs associated with them were removed from the dataset before further 
characterization of the microbiota. In addition, the contamination predictor tool, 
“SourceTracker”, showed that even before implementation of the above, 90% of the 
microbial reads were derived from the human specimens and not from the environment. 
Even with these quality control measures in place, some people will still be wary of 
sequencing results. However, the ability to culture live bacteria from tissue (and not from 
any of our environmental controls) further suggests that organisms are present within the 
breast. These results are consistent with a study published in 1988 from the University of 
Michigan in which bilateral breast tissue from 30 women undergoing either breast 
reductions or enhancements were analyzed by culture (Thornton et al., 1988). The most 
abundant organisms identified were coagulase-negative staphylococci, 
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Propionibacterium acnes, Corynebacterium and Lactobacillus. To a lesser extent, 
Bacillus, alpha- and beta-streptococci, Clostridium, Peptococcus, Micrococcus, 
Enterococcus and gram-negative rods were also cultured. After a 12-month follow-up, 
only 2 of the 30 women developed infections, suggesting to the authors that the bacteria 
that had been isolated were not contaminants from surgical equipment. All of the 
organisms detected by Thornton and colleagues were also identified in our studies by 
either culture or HTS. In short, it may be difficult to overcome skepticism. In dealing 
with a non-sterile environment of a surgical suite and human body, it may never be 
possible to prove conclusively that an isolate was not from the air or other sources. The 
low numbers of bacteria compared to other body sites also make it hard to prepare 
histological sections that show the organisms within tissues. 
7.1.1 Why do these bacteria not induce infections or 
inflammation 
Similar to the Thornton study, Bacillus and Propionibacterium (acnes and granulosum) 
were isolated from our tissue specimens. Whole genome sequencing performed on one 
Bacillus cereus tissue isolate revealed the presence of genes that encode for the toxins 
hemolysin BL, non-hemolytic enterotoxin and cytotoxin K, which are believed to 
contribute to enteritis caused by this species (Fagerlund et al., 2008). P. acnes and P. 
granulosum, which are harmless constituents of the skin microbiota, are associated with 
catheter and prosthetic joint infections. Propionibacterium avidum, another skin 
commensal, has been implicated in breast abscesses after breast reduction mammoplasty 
(Kritikos et al., 2015; Levin et al., 2008).  Overall, between 75-2000 cfu/ml were cultured 
from homogenized tissue (~190-5000 cfu/gram of tissue), and qPCR performed on tissue 
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samples collected from the Irish cohort showed an average of 5x105 16S rRNA gene 
copies per gram of tissue. In blood, numbers as low as 10 cfu/ml can induce an 
inflammatory response with sometimes fatal outcomes (Potgieter et al., 2015). This 
therefore begs the question as to why these organisms did not cause infections or induce 
pro-inflammatory responses?  
One possibility is that these bacteria have adapted to survive in the breast without being 
detected and attacked by the immune system. While B. cereus has the genes that encode 
for virulent enterotoxins, they may not be expressed within the mammary environment. 
While it is hard to ascertain what these factors could be, as many act in concert with each 
other, it has been shown that enterotoxin production is regulated by energy availability, 
growth rate, cell numbers, aeration and pH (Ceuppens et al., 2011). For example, the 
enterotoxin genes are under the control of the quorum sensing regulator, phospholipase C 
regulator (PlcR), hence enterotoxins are produced during stationary phase (Ceuppens et 
al., 2011). Thus, the density of cells within the breast may be below the threshold needed 
to activate PlcR. Furthermore, lactose has been shown to inhibit enterotoxin production, 
even in the absence of growth impairment (Rowan and Anderson, 1997).   
It is important to note that the bacteria identified in tissue were mostly at the genus, and 
in some cases species, level. Bacterial strains vary greatly in their properties even within 
a species. A notable example is E.coli: strain Nissle 1917 is considered a probiotic while 
O157:H7 is a deadly gastrointestinal pathogen. Thus, the strains in the breast may be less 
virulent then other strains of the same species known to cause infections and/or induce 
pro-inflammatory responses.  
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Another potential reason for the lack of infection and inflammation is the presence of 
mechanisms within the mammary gland, similar to those in the GIT, that ensure 
homeostasis. Two of them, compartmentalization and immune hyporesponsiveness, are 
discussed below.  
7.1.1.1 Compartmentalization 
It had long been a subject of debate as to why healthy individuals do not mount an overt 
pro-inflammatory response against their gut commensals even though they share the 
same molecular patterns as pathogens, which do trigger an inflammatory cascade. It was 
not until a paper published in 2000 that we began to appreciate the importance of host-
microbe compartmentalization in maintaining homeostasis (Macpherson et al. 2000). In 
this paper, it was shown that specific pathogen free mice lacked serum IgG antibodies 
specific against Enterobacter cloacae, the dominant aerobe in the gut of these mice. 
Upon systemic intravenous administration of 106 cfu of live bacteria, a strong IgG 
response against E. cloacae was mounted. This showed that the non-responsiveness 
observed in the serum of un-manipulated mice was due to ignorance rather than 
tolerance. 
The single layer of epithelial cells lining the lumen of the gut creates a physical barrier 
between the luminal contents and the “inside” of the body and plays an essential role in 
compartmentalization (Peterson and Artis, 2014). When this barrier is disrupted, 
microbial translocation occurs resulting in an inflammatory response (Adams et al., 2008; 
Dubinsky et al., 2006; Fava and Danese, 2011; Pastor Rojo et al., 2007). In a similar 
fashion, the ducts and the lobules of the mammary glands are made up of a lumen, 
surrounded by epithelial cells that form a stratified cuboidal epithelium (Chapter 1). 
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While this is different than the simple columnar epithelium of the GIT and has more of a 
role in secretion and absorption, it still provides a protective physical barrier against 
environmental agents. During lactation, milk and the bacteria present in it, are 
sequestered within the lumen of these ducts and lobules, which could explain the lack of 
infection and inflammation while the mother is breast-feeding. Even though our tissue 
samples were collected from non-gravid/non-lactating women, some of whom never had 
children, there is still an extensive ductal system in the “resting” state and in nulliparous 
women (Chapter 1). Thus, there is the possibility that the bacteria detected in our tissue 
samples (composed of a collection of ducts surrounded by adipose tissue) are 
compartmentalized within the lumen of these ducts and are not found within the 
surrounding adipose rich stroma. Case reports of breast infections caused by S. aureus 
and P. avidum report liponecrosis and adipose edema, with the ability to culture 
organisms from these areas (Jari et al.; Kritikos et al., 2015; Levin et al., 2008). These 
observations, to some degree, would support the idea that infections occur when bacteria 
penetrate into the stroma. To determine whether bacteria were localized within the ducts, 
histological sections were stained with methylene blue or probed with an antibody against 
peptidoglycan (Appendix 8.3). Unfortunately the methods used did not allow us to 
determine where these bacteria localized. Scanning electron microscopy could be 
informative, but with so few organisms present, it could take many samples to find the 
organisms.  
7.1.1.2 Immune hyporesponsiveness  
Another mechanism that could help maintain homeostasis, regardless of where the 
bacteria are localized, could be an altered state of immune regulation. Immune 
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hyporesponsiveness in the GIT is one way in which the host can co-exist with the trillions 
of bacteria that reside there (Maynard et al., 2012). For example, intestinal macrophages 
are phenotypically and functionally different than those derived from sterile sites, like the 
blood. Upon exposure to either Gram negative or Gram positive organisms these 
intestinal macrophages produce less inflammatory cytokines compared to blood 
monocytes (Smythies et al., 2005). Although there is no data for human breast 
macrophages, bovine mammary macrophages are also less responsive against pathogens 
than blood monocytes and are also less effective at priming antigen-specific 
inflammatory T cells (Politis et al., 1991, 1992), collectively protecting the host against 
immune related tissue pathology (Günther et al., 2012).  
 Factors contributing to the microbial differences 7.2
between breast cancer patients and healthy controls 
Bacterial profiles were shown in Chapter 5 to differ between breast tissue from women 
who are healthy and normal adjacent tissue from those with breast cancer. We 
hypothesized that these differences could be contributing to disease development since 
women with cancer had higher relative abundances of bacteria that induce host DNA 
damage and lower relative abundances of bacteria that can inhibit tumour growth 
(properties that have been shown by others). 
There is the possibility, however, that these differences are a consequence rather than a 
cause of the disease. It is well established that the tumour mass creates an environment 
vastly different than the surrounding tissue. Metabolism differs so much so that metabolic 
readouts can be used as biomarkers for tumour detection (Balog et al., 2013; Bathen et 
al., 2013; Budczies et al., 2012). However, despite these metabolic differences, which 
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could impart a selective advantage for one organism(s) over another, our microbiota 
analysis of tumour tissue vs normal adjacent tissue showed no differences in bacterial 
profiles. Since normal adjacent tissue is more similar to healthy tissue (i.e. from women 
without disease) than to tumour tissue, I am inclined to believe that the differences 
observed between healthy and normal adjacent tissue were present before the 
development of the tumour.  However, this is not to say that host metabolites have no role 
in shaping the breast microbiome. Perhaps due to genetics or lifestyle factors (diet, stress, 
smoking etc) women who develop breast cancer have different metabolic profiles than 
those who do not, which consequently influence the bacterial patterns in the breast. For 
example, in our healthy cohort, higher relative abundances of Prevotella were observed, 
and this genus has the ability to uptake and metabolize estradiol, which in turn enhances 
bacterial growth (Kornman and Loesche, 1982). Studies in pre- and post-menopausal 
women have shown that estradiol levels are lower in normal adjacent tissue of breast 
cancer patients than tissue from healthy controls (Geisler, 2003; Savolainen-Peltonen et 
al., 2014). Perhaps due to these low levels of estrogen in breast cancer patients, 
Prevotella strains do not have the optimal energy requirements for growth, which could 
explain the lower levels of Prevotella observed in breast cancer patients compared to 
healthy controls.  
A metabolomics analysis is currently being performed on tissue samples and hopefully 
will provide information on how the host can shape this tissue microbiome, and also on 
the metabolic activity of the microbes (i.e. bacterial metabolites) and how they interact 
with the host (i.e. bacterial induced host metabolites). It may even shed light on how 
these breast tissue bacteria might contribute to, or help prevent, breast cancer 
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development. Our preliminary analysis does show that there are higher levels of ceramide 
in healthy tissue compared to normal adjacent tissue from breast cancer patients.  
Ceramide is a pro-apoptotic signaling molecule that controls aberrant cell growth and 
there is the possibility that probiotics, like L. rhamnosus GR-1, can breakdown 
lactosylceramide (found in high abundances in milk), into ceramide (Appendix 8.4), 
possibly protecting against breast cancer development in lactating women. Other strains, 
found within tissue, could also have similar properties.   
It appears that the breast microbiome can be influenced by bacterial composition at distal 
sites. Women with celiac disease, who are known to have altered gut microbial 
communities, have different microbial profiles in their milk compared to healthy mothers 
(Olivares et al., 2015). Thus, there is the possibility that the differences in bacterial 
communities observed between healthy and breast cancer patients could be a reflection of 
differences in the GIT. Indeed, the gut microbiota of post-menopausal women with breast 
cancer is different than that of disease free subjects (Goedert et al., 2015). A possible way 
to test this concept would be to examine the gut microbiota of women prescribed 
antibiotics or who have had radical changes in diet and then determine whether these 
changes alter the breast microbiota, possibly through collection of nipple aspirate fluid. If 
true, this would have important implications, and may provide a means to manipulate the 
breast microbiota in order to mitigate disease and promote health.  
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 The influence of the breast tissue microbiome on the 7.3
response to chemotherapy 
7.3.1 The ability of bacteria to bio-transform drugs 
In Chapter 5, I present a rationale for how some bacteria could promote breast cancer 
development and how others could help prevent it. But the breast microbiota could have a 
significant impact on women’s health irrespective of its role in breast cancer 
development, by its ability to modulate the efficacy of chemotherapeutics. As shown in 
Chapter 2, chemotherapy drastically changed microbial profiles in human milk as early as 
Week 2 after the start of treatment. To test the reverse, E.coli, the most relatively 
abundant organism within breast tumours, was used as a model to test the impact of 
bacteria on cancer treatment. It was found that E. coli had the ability to bio-transform a 
variety of drugs used to treat various cancers, leading to decreased efficacy in vitro in 
half of the drugs tested (Lehouritis et al., 2015) (Table 7-1). This was further elucidated 
in vivo, as gemcitabine was less effective at controlling established tumours that had been 
intra-tumourally injected with E.coli compared to PBS. The bio-modulation that occurred 
in gemcitabine, after incubation with pure bacterial cultures, is consistent with possible 
acetylation. Xenobiotics are metabolized in two distinct phases, the 2nd of which includes 
acetylation (Omiecinski et al., 2011). Byproducts of acetylation are typically more 
hydrophilic than the parent compound and therefore more readily excreted from the cell 
(Omiecinski et al., 2011). Certain strains of E.coli have been shown to possess N-
acetyltransferases, the enzymes responsible for acetylation (Chaslus-Dancla et al., 1986; 
White-Ziegler et al., 2002). So, a possible mechanism explaining our results could be that 
N-acetlytransferases from E.coli, acetylate gemcitabine, which decreases drug efficacy by 
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either (i) promoting faster removal of the drug from the tumour once it has entered or (ii) 
inhibiting drug uptake, preventing the drug from entering the tumour in the first place.  
 
Table 7-1.  Effects of bacteria on chemotherapeutic drug cytotoxicity in vitro 
E.coli Nissle 1917, grown to log phase, was incubated for 2 hours with each of the drugs 
listed below. After incubation, the drug solution was filter sterilized to remove bacteria 
and then added to plates containing the 4T1 mouse mammary carcinoma cell line. Drug 
cytotoxicity was measured using the Cell Titre 96 Aqueous One solution Cell 
Proliferation Assay (Promega).  
 
Drug Efficacy  
Gemcitabine decreased 
Doxorubicin decreased 
Daunorubicin decreased 
Mitoxantrone decreased 
Idarubicin decreased 
Capecitabine no change 
5-fluorouracil no change 
Vinblastine no change 
Irinotecan no change 
Estramustine no change 
fludarabine increased 
Tegafur increased 
 
7.3.2 The ability of bacteria to modulate the immune system 
which indirectly effects drug therapy 
In addition to the direct effects that bacteria can have on drug efficacy, they can also have 
indirect effects. Common drugs administered to women to treat breast cancer include 
doxorubicin (or epirubicin), paclitaxel, gemcitabine and 5-flurouracil (5-FU). While their 
primary mode of action is disruption of DNA synthesis or microtubule formation, their 
efficacy may also depend on the engagement of the immune system. For example, 5-FU 
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and gemcitabine have been shown to sensitize tumours to CD8+ T cell and NK cell 
mediated cytotoxicity and to reduce the levels of myeloid derived suppressor cells, 
thereby restoring CD8+ T cell and NK cell functionality (Ghiringhelli and Apetoh, 2015; 
Weir et al., 2011). Both paclitaxel and doxorubicin upregulate the cation-independent 
mannose-6-phosphate receptor on the surface of tumor cells, thereby increasing the 
efficiency of granzyme B mediated killing by cytotoxic T lymphocytes (CTL) and NK 
cells (Ramakrishnan et al., 2010). Doxorubicin has also been shown to mediate tumour 
infiltration of a subset of dendritic cells that are highly efficient at presenting tumour 
antigens to CTLs (Ma et al., 2013). This interaction between the immune system and 
chemotherapeutics for optimal tumour killing is further highlighted by the fact that (i) 
synergy has been observed in mouse models of solid tumours between chemotherapy and 
immunotherapy (Nowak et al., 2003); (ii) immune-deficient mice do not respond as well 
to certain chemotherapeutics compared to their immune-competent counterparts (Casares 
et al., 2005; Tesniere et al., 2010) and (iii) patients with genetic immune defects are less 
responsive to chemotherapy (Ghiringhelli et al., 2009; Tesniere et al., 2010). Therefore if 
a patient does not have a proper functioning immune system, then the engagement of the 
immune system by chemotherapeutics will not be fully exploited. This could partly 
explain why drug therapy is so variable between patients even within the same subtype 
and stage.  
One of the most well studied and established factors that modulate the immune system is 
our microbiota (Hooper et al., 2012; Macpherson and Harris, 2004). The importance of 
the microbiota in cancer treatment was recently unraveled by two groups who showed 
that chemotherapy was not as effective in germ-free and antibiotic treated mice because 
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of inefficient priming of immune cells (Iida et al., 2013; Viaud et al., 2013). In the Viaud 
study, Lactobacillus johnsonii and Enterococcus hirae could reverse these drug defects, 
while E. coli could not. E. coli was the most abundant organism observed in our breast 
tumour specimens while Lactobacillus presence was negligible. Thus, antimicrobial or 
probiotic therapy to try and alter the breast microbiota might be worth considering in 
order to improve drug efficacy. However, what these strategies may entail would have to 
be considered in the context of the drug and the immune response elicited as opposite 
bacterial effects were observed in the Iida study- Lactobacillus (L. murinum, L. 
intestinalis and L. fermentum) presence was negatively correlated with efficacy while 
E.coli showed a positive correlation.  
 Future directions 7.4
A common thread throughout this thesis had been the idea that one’s microbiota can 
modulate health and disease. While it is informative to study bacterial composition and 
function once disease has developed, there are merits to examining how factors that shape 
one’s microbiome during infancy, such as breast feeding, can influence disease risk later 
in life.   
In the milk study presented in Chapter 3, we showed that bacterial communities are 
highly variable amongst healthy women. One mother (Subject 32) had a milk microbiota 
composed of 72% Enterobacteriaceae and no Bifidobacterium nor Lactobacillus while in 
another mother (Subject 6), who gave birth vaginally and at term like subject 32, 
Enterobacteriaceae made up only 0.8% of her microbiota with Bifidobacterium (24.5%) 
and Lactobacillus (8%) dominating. The latter are generally associated with health 
whereas Enterobacteriaceae are more associated with disease at various body sites. An 
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important question that therefore arises from these results is whether there is a milk 
microbiota that is “healthier” than another or whether each unique microbiota is adapted 
for a particular host and is the best profile for that individual and her offspring.  
To help address this idea, we had intended on administering human milk from subject 6 
(high Bifidobacterium/Lactobacillus, low Enterobacteriaceae) to neonatal germ free 
mice and compare the outcome with milk from Subject 32 (low 
Bifidobacterium/Lactobacillus, high Enterobacteriaceae) in terms of immune 
development and function over time. A collaboration was established with Dr. Sven 
Petterrson of the Karolinska Institute and the studies were planned for his research site in 
Singapore. However, too few animals were available to provide us with enough 
meaningful data, so we did not go ahead with the study. Nevertheless, this remains a 
worthwhile experiment and if differences were to exist, animal models of breast cancer 
could help elucidate whether the different immune effects induced by different milk 
microbial communities would put the offspring at a higher risk of breast cancer 
development. 
 Concluding remarks 7.5
The studies conducted on the breast tissue and the breast milk microbiotas presented in 
this thesis raise important questions as to what bacterial profiles are considered “healthy” 
and what factors influence their composition. Longitudinal studies following lactating 
women over a span of a few months or even years would give us a better appreciation of 
the factors that shape the milk microbiota (i.e. diet, antibiotics, stress, probiotic intake) 
and how quickly the microbiota can rebound from these changes. If further studies show 
that milk and tissue microbial communities are similar, human milk could provide a non-
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invasive way in which to study factors that shape the tissue microbiota. Future studies 
that monitor healthy subjects (from either those from whom we collect milk or tissue) for 
breast cancer development could provide more insight into the organisms that may drive 
disease progression. Once diagnosed with cancer, antimicrobial or probiotic therapy 
might be worth considering to try and alter the breast microbiota in order to improve the 
efficacy of chemotherapy. Overall, the results presented in this thesis represent a new line 
of thought that had not been considered before. Hopefully, the data will stimulate new 
areas of research that helps prevent breast cancer development or improves treatment 
strategies.  
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8 Appendix 
 Optimization of DNA extraction methods for breast milk 8.1
and breast tissue 
8.1.1 Breast milk 
Two different DNA extraction protocols were compared to determine which one would 
generate higher yields of bacterial DNA. The methods followed were by Hunt; 
“Characterization of the diversity and temporal stability of bacterial communities in 
human milk” (Hunt et al., 2011) and Martin; “Cultivation-independent assessment of the 
bacterial diversity of breast milk among healthy women” (Martín et al., 2007). A 
schematic of each method is presented in Figure 8-1. Some modifications to the above 
protocols were also compared. For Hunt’s protocol, 1ml and 2ml of milk were also tested 
as well as 0.5ml, 1ml and 2ml of milk that had been centrifuged at 20,000 x g for 10min 
(as per the Martin protocol). For the Martin protocol, DNA was also extracted from 2ml 
of milk pellet. 
Three different breast milk samples were tested with the above methods. After extraction, 
the DNA was amplified using HDA primers, which amplify the V2-V3 hypervariable 
region of the 16S rRNA gene (Table 8-1). The PCR was carried out in a 50µl reaction 
containing 10µl of DNA template (or nuclease free water as a negative control), 2.5mM 
MgCl2, 0.64mM of each primer, 5µl of 10X PCR Buffer (Invitrogen), 0.21mM dNTPs, 
0.05U Taq Polymerase (Invitrogen) and 0.15µg/µl of bovine serum albumin. Thermal 
cycling was carried out in an Eppendorf Mastercyler using a step-down approach with an 
initial denaturation of 94oC for 2min followed by 9 cycles of 94oC for 45s, 61oC for 45s, 
72oC for 45s and then another 14 cycles of 94oC for 45s, 61oC for 45s,72oC for 45s. This 
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was followed by an elongation step at 72oC for 2 min. After PCR, samples were run on a 
1.5% TAE agarose gel for 1hr at 120V, stained with 0.5µg/ml ethidium bromide for 
20min and then viewed under UV light in an AlphaImager (Alpha Innotech Corporation). 
8.1.2 Breast tissue 
65µl, 100µl, 200µl and 400µl of homogenized tissue [0.4g/ml], representing 26mg, 
40mg, 80mg and 160mg respectively were used for extractions following the protocols 
outlined by Hunt and Martin (Figure 8-1), with the exception of Martin’s initial 
centrifugation step. These weights were chosen based on the recommendations outlined 
in the QIAamp DNA Mini Kit (max 25mg for tissue) and the QIAamp DNA stool Mini 
Kit (180-220mg of stool). In addition to the above protocols, a method used to detect 
bacteria in colonic mucosa of patients with IBD was also tested (Sproule-Willoughby et 
al., 2010) (Figure 8-2). Three different tissue samples were extracted with these 3 
methods and amplified as per the milk samples.  
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Figure 8-1. Schematic of DNA extraction protocol for bacterial detection in breast 
milk 
These published methods were also used for bacterial detection in breast tissue.  
 
 
0.5ml milk 
500µg lysozyme, 50µg 
mutanolysin, 4µg lysostaphin 
Bead beading: 
30s, 4800rpm x3 
37oC, 1hr 
20µl proteinase K 
200µl Buffer AL 
56oC, 30min;  95oC, 15min 
200µl ethanol 
100µl 3M sodium 
acetate  
DNA eluted in 120µl 
Buffer AE 
Hunt protocol 
1ml milk, centrifuged at 20,000 x g 
for 10min  
1.4ml Buffer ASL 
added to pellet 
Bead beading: 
30s at 4800rpm 
15µl proteinase K 
200µl Buffer AL   
200µl ethanol 
DNA eluted in 120µl 
Buffer AE  
Martin protocol 
Samples added to 
Qiagen columns and 
washed as per kit 
instructions 
Samples added to 
Qiagen columns and 
washed as per kit 
instructions 
70oC, 10min 
95oC, 5min 
Based on QIAamp DNA Mini Kit Based on QIAamp DNA Stool Mini Kit 
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Figure 8-2. Schematic of DNA extraction for bacterial detection in breast tissue 
This protocol was also compared to the ones presented in Figure 8-1. 1lysozyme 
solution= 20mg/ml lysozyme (Sigma) in 20mM Tris-HCl pH 8.0, 2mM EDTA and 1.2% 
Triton X-100. 
80µl tissue 
200µl lysozyme 
solution1 
Bead beading: 
30s, 4800rpm x3 
37oC, 30min 
 200µl Buffer AL 
56oC, 30min; 95oC, 10min 
200µl ethanol 
DNA eluted in 60µl Buffer AE 
Sproule-Willoughby protocol 
Samples added to 
Qiagen column and 
washed as per kit 
instructions 
Based on QIAamp DNA Mini Kit 
200µl Buffer ATL 
20µl proteinase K 
70oC, 10min 
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8.1.3 Chosen method for extractions 
Based on band intensities of the amplicons after running the PCR on the gel, the Martin 
protocol using 2ml of milk and 400µl of tissue produced the strongest band, indicative of 
a higher yield.  No bands were detected in the no-template negative control.  
Numerous studies comparing various DNA extraction methods have shown that bead 
beading gives a better representation of bacterial diversity in mixed samples (Yuan et al., 
2012). Bead beading can, however, shear DNA, causing lower DNA yields after 
amplification (Lever et al., 2015). To assess whether the bead beading time could be 
increased without losing DNA integrity, 30s of bead beading (Martin protocol) was 
compared to 60s, repeated twice. Since longer bead beading did not appear to change 
amplicon yields, this adjustment was made to the Martin protocol and used for both milk 
and tissue extractions.  
 Denaturing gradient gel electrophoresis   8.2
DNA extracted from breast tissue was analyzed by DGGE before being sent for HTS, to 
get an idea of how diverse the bacterial communities were in the samples. The U968f-
GC/L1401r primer pair, which amplifies the V6-V8 region of the 16S rRNA gene, was 
used (Table 8-1). The PCR was carried out in a 50µl reaction containing 10µl of DNA 
template (or nuclease free water as a negative control), 3.0mM MgCl2, 0.2mM of each 
primer, 5µl of 10X PCR Buffer (Invitrogen), 0.2mM dNTPs, 0.05U Taq Polymerase 
(Invitrogen) and 0.15µg/µl of bovine serum albumin. Thermal cycling was carried out in 
an Eppendorf Mastercyler under the following conditions: Initial denaturation at 95oC for 
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2min followed by 35 cycles of 95oC for 30s, annealing at 56oC for 40s, elongation at 
72oC for 60s and then a final elongation step of 72oC for 5min.   
Following amplification the products were then run on a 30-70% denaturing gradient gel. 
Preparation of gradients and gel electrophoresis were carried out using the D-code 
Universal Detection system (Bio-rad) following the manufacturers protocol. A 30% and 
70% denaturing solution were made up using the recipe outlined in Table 8-2. 50 µl of 
TEMED [N,N,N′,N′-tetramethylethylenediamine; Sigma] and 90 µl of 10% ammonium 
persulphate (Bio-Rad) were added to each solution to promote polymerizatiom. Gels 
were allowed to polymerize overnight. Either 20µl (Figure 8-3A) or 75µl (Figure 8-3B) 
of PCR product were mixed with 2× loading buffer (0.25ml of bromophenol blue [2%, 
Sigma], 0.25ml of xylene cyanol [2%, Sigma], 7ml of glycerol, and 2.5ml of ddH2O) and 
loaded into the wells. Gels were run at 130 V in 1× TAE at a constant temperature of 
60oC until the second dye front (xylene cyanol) approached the end of the gel. After 
electrophoresis, gels were removed, allowed to cool before the removal of the glass-plate 
sandwich, stained for 20 min in 5µg/ml ethidium bromide, and destained for 10 min in 1× 
TAE. Gels were viewed under UV light in an AlphaImager (Alpha Innotech 
Corporation). 
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Table 8-1.  Primers used in the studies discussed in the appendix 
Bolded sequence refers to the GC clamp. The qPCR primers target genes from 
L.rhamnosus GR-1. pfk= 6 phosphofruktokinase.  1(Burton and Reid, 2002), 2 (Martín et 
al., 2007). 
Gene Primer sequence  Target 
HDA-1 
HDA-2 
5’ ACTCCTACGGGAGGCAGCAG  3’ 
5’ GTATTACCGCGGCTGCTGGCA 3’ 
V2-V3 region 16S 
rRNA gene1 
U968F-GC 
 
L1401r 
5’CGCCCGGGGCGCGCCCCGGGCGGGGCA
CGGGGGGAACGCGAAGAACCTTAC 3’ 
5’CGGTGTGTACAAGACCC 3’  
V6-V8 region 16S 
rRNA gene2 
(DGGE) 
orf_2365-F 
orf_2365-R 
5’ CTTTGGAACATTGCCTTGGA 3’                       
5’ TCTTGCGTGTAGTTGGTGGA 3’ 
glucosylceramidase 
(qPCR) 
orf_1121-F 
orf_1121-R 
5’ CTAAATGAACAAGGCAATCCAA 3’              
5’ TCCAAGACTGCGAACAAGG 3’ 
beta-galactosidase 
(qPCR) 
orf_817-F 
orf_817-R 
5’ CATTATCCCCGAACACGA 3’ 
5’ GAAATCACCATAGGCAGCAA 3’ 
pfk (qPCR-
housekeeping 
gene) 
 
 
Table 8-2.  Recipe for making denaturing polyacrylamide gel solutions 
  30%  70% 
40% acrylamide/bis-
acrylamide solution (Bio-rad) 
5ml 5ml 
50X TAE 0.5ml 0.5ml 
Urea 3.15g 7.35g 
Formamide 3ml 7ml 
ddH2O 16.5ml 12.5ml 
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Figure 8-3.  Denaturing gradient gel electrophoresis analysis on breast tissue 
DNA was extracted from normal-adjacent tissue from 9 women with tumours and the 
corresponding PBS environmental controls. DNA was also extracted from 9 healthy 
tissue samples from women who were disease free. The 16S rRNA gene was amplified 
using primers that span the V6-V8 hypervariable regions (U968/L1401). The PCR 
products were then run on a 30-70% denaturing gradient gel and stained with ethidium 
bromide. (A) DGGE gel with 20µl of PCR product loaded into the wells. “N” = normal 
adjacent tissue and “E”= PBS environmental controls. (B) DGGE gel with 75µl of PCR 
product loaded into the wells.  With the exception of two faint bands in 17E, no bands 
were detected in any of the other environmental controls 
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 Histology 8.3
Histology was performed on the breast tissue samples to determine where bacteria 
localize within the mammary glands. Upon collection, a small piece of fresh tissue was 
placed in a cryomold filled with OCT (Tissue-Tek), snap frozen in liquid nitrogen and 
then stored at -80oC.  Frozen tissue samples were cut into 5µm sections using a Leica CM 
1850 cryostat set at an internal temperature of -30oC. Sections were captured onto 
SuperfrostTM Plus microscope slides (FischerBrand), dried overnight at room temperature 
and then stored at -80oC until use.  
8.3.1 Simple stain 
Frozen slides were taken out of the -80oC freezer, allowed to warm up to room 
temperature, and then heat fixed by passing through the flame of a Bunsen burner.  Slides 
were then covered with 1% methylene blue stain for 1min and excess stain washed off 
with ddH2O. Slides were then viewed with a Zeiss AxioSkop microscope using both the 
40X and 100X objectives, under oil immersion. As a positive control, an overnight 
culture of Lactobacillus rhamnosus GR-1 was thinly spread over the slides before being 
heat fixed.  
Unless distinct and large numbers of bacteria are present, as with the positive control, a 
simple stain is not helpful in detecting bacteria in breast tissue (Figure 8-4). However, 
this simple stain did show that we had good quality slides with breast architecture intact. 
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Figure 8-4. Methylene blue stain of breast tissue cryosections 
Cryosections of 5µm breast tissue samples were stained with 1% methylene blue solution 
for 1 min and viewed under oil immersion at 400X magnification. (A) Image of normal 
adjacent breast tissue from a woman with stage 1 invasive breast cancer. Image is 
representative of 3 different clinical samples. (B) Image of tissue section with an 
overnight culture of Lactobacillus rhamnosus GR-1 spread across the top, to act as a 
positive control.  
A
B 
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8.3.2 Immunohistochemistry 
We next tried to detect bacteria using an antibody specific for peptidoglycan, a molecule 
present in all bacterial cell walls. This antibody was used by a group at McMaster 
University to detect bacteria present in the human brain (Branton et al., 2013).  First, in 
order to determine the versatility of the antibody in detecting different bacteria, 
immunohistochemistry was performed on pure cultures of Bacillus cereus, 
Staphylococcus epidermidis and L. rhamnosus GR-1.  
Overnight cultures of each organism were placed on two microscope slides, left to dry 
and then heat fixed. Endogenous peroxidases were inhibited by covering the slide with a 
0.3% H2O2 solution for 20min, which was then washed with TBS for 5min. One slide 
received acid treatment and the other did not. According to the manufacturer, pre-
treatment with a strong acid for Gram-positive bacteria (or a detergent, for Gram-
negative bacteria), may be needed to expose the epitopes. For those receiving acid, 
25mM of HCl was added to the slides for 5min and then washed 3x with TBS. Slides 
were then blocked with 5% goat serum for 1 hour. Afterwards, a 1/100 dilution of the 
primary antibody (mouse anti-bacterial peptidoglycan monoclonal antibody, EMD 
Millipore) was added to the slides and incubated overnight at 4oC. After washing, the 
slides were incubated at a 1/500 dilution for 45min with the secondary antibody (HRP 
conjugated goat anti-mouse IgG (H+L), Jackson Laboratories). The slides were then 
developed in the dark with AEC (3-amino-9-ethylcarbazole) stain  (Table 8-3) for 30min 
and the reaction stopped with ddH2O. Slides were viewed with a Zeiss AxioSkop 
microscope under oil immersion with the 100X objective. 
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The antibody only bound to Staphylococcus (Figure 8-5) and neither Lactobacillus nor 
Bacillus, regardless of acid treatment. While different acid concentrations could have 
been tested, addition of 10mM or 25mM of HCl to the tissue slides ruined the 
architecture of the breast. Due to the amount of time and money needed for optimization 
and the fact that this was a minor side project, we decided not to pursue this idea further.  
Table 8-3. Recipe for AEC stain for immunohistochemistry  
AEC stain  *Acetate buffer (100ml) 
16mg AEC powder (Sigma) 
4ml DMF 
56ml acetate buffer* 
40µl 30% H2O2 
 
Dissolve DMF and AEC together, then add 
acetate buffer, filter into designated bottle, 
add in H2O2 
1.36g sodium acetate trihydrate 
0.6ml acetic acid 
make up to 70ml with ddH2O 
adjust pH to 5.2 
top up to 100ml 
 
 
Figure 8-5.  Immuno-staining of breast tissue cryosections. 
An overnight culture of Staphylococcus was immunolabeled with anti-peptidoglycan 
antibody and developed with AEC. Cultures were treated either with 25mM HCl or 
without (image displayed). Positive staining was observed with and without acid 
treatment.   
20  antibody alone 
Mouse anti-bacterial peptidoglycan monoclonal  antibody  
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 Examining the ability of the probiotic Lactobacillus 8.4
rhamnosus GR-1 to break down lactosylceramide into 
ceramide   
8.4.1 Background 
Lactosylceramide is a lipid molecule ubiquitous on all eukaryotic cells and is a major 
component in human and bovine milk (Newburg and Chaturvedi, 1992). Surprisingly, 
considering the health benefits of milk, lactosylceramide has properties that could 
promote cancer development, such as the ability to stimulate reactive oxygen species 
from various types of cells (Arai et al., 1998), the ability to promote VEGF (vascular 
endothelial growth factor) induced angiogenesis (Kolmakova et al., 2009) and the ability 
to upregulate the expression of PECAM-1 (platelet/endothelial cell adhesion molecule) 
(Gong et al., 2004), which is associated with a poor prognosis in breast cancer patients 
(Martin et al., 2005). Lactosylceramide, however, can be broken down into ceramide, a 
pro-apoptotic signaling molecule that suppresses tumour growth (Obeid et al., 1993; 
Ogretmen and Hannun, 2004). Increased ceramide levels also make multi drug resistant 
tumours sensitive to therapy (Liu et al., 2004, 2001). Certain strains of probiotic bacteria 
have been shown to possess the ability to increase endogenous ceramide levels on tumour 
cells, leading to cellular death (Angulo et al., 2011; Di Marzio et al., 2001).  
Lactosylceramide is first broken down into glucosylceramide by beta-galactosidase (EC 
3.2.1.23), with this intermediate then broken down to ceramide by glucosylceramidase 
(EC 3.2.1.45). An RNA-seq experiment performed by a former graduate student in the 
lab, examining the effects of different growth conditions on Lactobacillus rhamnosus 
GR-1, revealed higher abundance of mRNA transcripts for glucosylceramidase when 
GR-1 was grown to stationary phase in milk compared to broth.  
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Considering the importance of ceramide in breast cancer risk reduction, I wanted to 
explore whether GR-1 did have the ability to break down lactosylceramide to ceramide 
and whether the ceramide generated could inhibit breast cancer cell proliferation in vitro. 
First, a quantitative real-time PCR (qPCR) experiment was performed to confirm the 
RNA-seq results and to determine at what growth phase these enzymes were most active.  
The methods for RNA extraction, primer design and qPCR are outlined below.    
8.4.2 RNA isolation from bacterial cultures grown in milk or 
broth 
A fresh overnight culture of L.rhamnosus GR-1 was prepared in 12ml de Man-Rogosa-
Sharpe (MRS) media (Difico Laboratories). The culture was diluted in a 96-well plate 
and scanned using a Multiskan Ascent (Thermo Scientific) to select a dilution with an 
absorbance of approximately 1.09 at 600nm. A culture of this dilution was made from the 
fresh overnight culture in sterile PBS. Next 3.3ml of the diluted culture was transferred 
into 2 sterile culture tubes and centrifuged for 4 minutes at 12000 x g. The supernatant 
was discarded, the pellet washed twice with sterile PBS, and then re-pelleted for 4 
minutes at 12000 x g. Following the washes, the pellet from one tube was resuspended in 
3.3ml skim milk that had been pre-warmed to 37oC and the other in 3.3ml MRS. Milk 
was prepared by suspending skim milk powder (Sigma) in deionized water to a 
concentration of 10% w/v followed by a 5 minute autoclave cycle at 121oC. Next, 2.5ml 
of the milk or MRS suspension was added to 47.5ml pre-warmed skim milk or 47.5ml 
MRS respectively in a 50ml conical tube, mixed and loosely capped. Immediately, the 
culture was placed in the interchange of an anaerobic chamber and following de-
oxygenation, placed into the chamber’s incubator at 37oC.  Milk cultures were grown for 
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10 or 22 hours, corresponding to mid-log and stationary phases of growth respectively.  
MRS cultures were grown for either 5 or 14 hours, corresponding to mid-log and 
stationary phases of growth respectively. 
8.4.2.1 RNA stabilization 
Upon completion of the incubation period, 20ml of milk or MRS culture was 
immediately added to 40ml of Bacterial RNAprotect (Qiagen) containing 50mg/ml 
Rifampicin (Sigma) inside the anaerobic chamber. This mixture was thoroughly vortexed 
and incubated at room temperature for 10min to allow for full RNA stabilization and then 
removed from the chamber. Next, the cultures were centrifuged at 6000 x g at 4oC for 
20min. The supernatant was then discarded and the pellet immediately frozen in liquid 
nitrogen and stored at -80oC until extraction. 
8.4.2.2 Optimized L.rhamnosus GR-1 RNA extraction 
The frozen pellet was immediately suspended and vortexed in 20ml of lysis solution 
made from 20ml DEPC treated water; 20mg/ml lysozyme (Sigma), 50U/ml mutanolysin 
(Sigma) and 100 µg/ml rifampicin (Sigma). The lysis mixture was then incubated at 37oC 
for 45min with vortexing every 5min. After the incubation period, the mixture was 
centrifuged at 6000 x g for 20min at 4oC. The supernatant was discarded and the pellet 
suspended in 20ml TRIzol reagent (Invitrogen) and vortexed for 2min. The sample was 
then passed through an RNase-free 21 gauge needle and syringe to aid in homogenization 
of the pellet followed by incubation at room temperature for 10min. It was then 
centrifuged at 12000 x g for 10min to remove excess contaminant proteins and the 
supernatant then transferred to a fresh tube. Next, 4ml chloroform was added and the 
sample mixed for 15s by vortexing, incubated at room temperature for 5min and then 
198 
 
centrifuged at 12000 x g for 20min. Next 10ml of the upper aqueous phase was 
transferred into 500µl aliquots into fresh RNase-free microcentrifuge tubes. RNA was 
precipitated with the addition of 5µg nuclease-free glycogen (Ambion), 50µl 3M sodium 
acetate and 550µl isopropanol, inverted 40 times and allowed to precipitate at room 
temperature for 10min. RNA was then pelleted by centrifugation at 12000 x g for 20min 
at 4oC. The resulting pellet was rinsed twice by adding 70% ethanol (non-denatured) 
followed by vortexing and centrifugation at 12000 x g for 5min. The pellet was then air 
dried for 10min on ice and resuspended in 100µl RNase-free water (Qiagen). Samples 
were stored at -80oC until further analysis.  
8.4.2.3 Total RNA cleanup and DNA digest 
RNA cleanup was carried out using the RNeasy mini-columns (Qiagen) according to the 
manufacturer’s instructions. The optimal on-column DNA digest was applied using 
RNase-free DNaseI (Qiagen). Clean, DNA-free, total RNA was eluted from the column 
with 2 aliquots of 50µl RNase-free water. The RNA was then concentrated via ethanol 
precipitation using 5µg glycogen, 2.5 volumes of 100% ethanol and 0.1 volumes of 3M 
sodium acetate, incubated overnight at -80oC and centrifuged at 12000 x g for 30min.  
After discarding the supernatant, the pellet was rinsed twice with 75% ethanol, air dried 
and then resuspended in 15µl RNase-free water.  
8.4.2.4 Analysis of RNA quality 
RNA quality was analyzed by loading 1µl total RNA solution on a 1% agarose gel made 
with tris-borate (TBE) buffer. Gels were run at 6V/cm for 1 hour, stained with 0.5µg/ml 
ethidium bromide in TBE buffer for 20min and then viewed under UV light in an 
199 
 
AlphaImager (Alpha Innotech Corporation). Quality was determined by the presence of 
crisp rRNA bands. High quality samples were then analyzed using a nanodrop (Thermo 
Scientific) to ensure a 260nm/280nm ratio between 1.8-2.0 and a 260nm/230nm ratio 
above 1.4.  Samples meeting these criteria were then used for qPCR. 
8.4.3 qPCR primer design 
Primers were designed against beta-galactosidase (EC 3.2.1.23), glucosylceramidase (EC 
3.2.1.45) and the housekeeping gene 6-phosphofruktokinase (pfk) using the GR-1 
genome sequence generated in our lab. Primer3plus (http://biotools.umassmed.edu/cgi-
bin/primer3plus/primer3plus.cgi) was used to design the primers, taking into account the 
following considerations:   
• avoid repeats of G or C longer than 3 bases 
• have G and C on the ends of the primers as this helps in specificity  
• length of primer should be between 18-22 nucleotides long 
• avoid nucleotide runs of more than 4bp (so 4 or more of the same nucleotide 
beside each other) 
• GC content should be between 50-60% 
• primer annealing temperature should be between 55-60C 
• melting temperature of primers should not differ by more than 2C 
• the amplicon should have a GC content of 40-60%  
• amplicon length for qPCR should be approximately 100bp 
Once adequate primers were chosen, the primer sequences were inputted into Beacon 
Designer (www.premierbiosoft.com/molecular_beacons/index.html) to verify that the 
primer pairs would not form hairpins or cross-dimerize.  mfold 
(http://unafold.rna.albany.edu/?q=mfold)  was used to make sure that the chosen 
amplicon would not form secondary structures above the annealing temperature.  Finally 
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blastn (http://blast.ncbi.nlm.nih.gov) was used to verify the specificity of the primers and 
to ensure that it would only bind the gene of interest.  The primer sequences used are 
summarized in Table 8-1.  
8.4.4 Quantitative real time PCR 
Synthesis of cDNA from the RNA isolated above was performed using random hexamers 
and SuperScript® II Reverse Transcriptase (Invitrogen) according to the manufacturer’s 
instructions. Amplification of cDNA by qPCR was performed using the iQ™ SYBR® 
Green Supermix (Bio-Rad) using 10µl iQ SyberGreen, 1µl of forward pimer (10µM), 1µl 
of reverse primer (10µM), 1µl of cDNA (or DNA standard) and 7µl of ddH20. Reactions 
were run in a Rotor-Gene 6000 thermocycler (Corbett) under the following program: an 
initial melting ramp from 72°C to 95°C, followed by 35 cycles of 95°C for 45s, 60°C for 
45s, and 72°C for 60s, ending with a hold at 95°C for 5 min. Data was analyzed using the 
Rotor-Gene 6000 series software (version 1.7; Corbett). A series of standards was created 
to quantify gene concentrations during data analysis. Total DNA was isolated from an 
overnight culture of GR-1 using InstaGene matrix (Bio-Rad). PCR was carried out in 50-
µl reaction mixtures consisting of the following components: 1× PCR buffer (Invitrogen), 
2.5mM MgCl2 (Invitrogen), 0.2mM dNTP mix, 0.5µM each primer pair used for qPCR 
(Table 8-1), 0.05U Taq polymerase (Invitrogen), 2µl template, and ddH2O to reach 50µl. 
Amplification was performed in a Mastercycler (Eppendorf) using the following 
program: 95°C for 1 min, followed by 30 cycles of 95°C for 45 s, 60°C for 45 s, and 
72°C for 60s with a final elongation step of 72°C for 2 min. Products were viewed via 
electrophoresis on a 1% agarose gel using 1× TBE, stained with ethidium bromide, and 
viewed under UV light in an AlphaImager (Alpha Innotech Corporation). The 
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concentration of DNA in each sample was determined using a nanodrop, and a series of 
standards with concentrations ranging from 5,000 pg/µl to 5 × 10−3 pg/µl were made. 
These standards were used as templates in the qPCR reactions to construct standard 
curves with known concentrations of DNA. Genes of interest were normalized to the 
housekeeping gene 6-phosphofructokinase (pfk) (EC 2.7.1.11) before determining the 
relative fold change compared to log phase growth in broth. 
The qPCR confirmed the results of the RNA-seq experiment in that glucosylceramidase 
mRNA transcripts are more abundant at stationary phase when GR-1 is grown in milk 
compared to broth. Transcripts were also more abundant at log phase when grown in in 
milk compared to broth. Beta-galactosidase mRNA transcripts were also significantly 
higher when grown in milk compared to broth at log phase but not so when grown to 
stationary phase.  These results are displayed in Figure 8-6. 
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Figure 8-6. qPCR results showing the relative fold change of the genes involved in 
the breakdown of lactosylceramide to ceramide 
Concentrations of each gene were determined using a standard curve and then normalized 
to the house keeping gene, pfk. Abundances are displayed as fold changes compared to 
log phase growth in broth (“log_broth”). Log phase= 5hr broth and 10 hour milk and 
stationary phase=14 hour broth and 22hr milk. For all variables with the same letter (“a”, 
“b”, “c”, “d”, “e”, “f”, “h”) the difference between the means is statistically significant 
following the Bonferroni multiple test correction (p<0.05). Bars represent the mean +/- 
standard deviation of 3 separate experiments.  
 
8.4.5 Verifying the in vitro ability of GR-1 to degrade 
lactosylceramide 
As qPCR confirmed that the genes involved in lactosylceramide breakdown to ceramide 
were upregulated when grown in milk compared to broth, the next step was to show that 
GR-1 did have the ability to breakdown lactosylceramide. To test this, GR-1 was grown 
to log and stationary phase of growth in nutrient broth supplemented with 17µM of 
purified lactosylceramide (Matreya LLC), the concentration present in bovine milk 
(Newburg and Chaturvedi, 1992).  
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To test the amount of lactosylceramide remaining over time, an ELISA was performed 
using an antibody specific against lactosylceramide. While HPLC is the common method 
to detect sphingolipids, I opted to try an ELISA. Unfortunately, the antibody purchased 
did not recognize sphingolipids and this method had to be abandoned. In the future, 
HPLC or LC-MS could be used to measure both lactosylceramide breakdown and the 
production of ceramide by GR-1. Bacterial supernatants containing ceramide could then 
be used in in vitro experiments to test the ability of the ceramide generated to inhibit 
breast cancer cell proliferation.      
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